Molecular Mechanisms of Aortic Aneurysms by Burger, J. (Joyce)
Molecular Mechanisms of Aortic Aneurysms





Joyce Burger en Kirsten Peerdeman, Atelier Indrukwekkend, Delft
Inside:
Bregje Jaspers, ProefschriftOntwerp.nl, Nijmegen 
Print 
ProefschriftMaken | www.proefschriftmaken.nl
Financial support for printing this thesis by Stichting Lijf en Leven and the Dutch Heart Foundation 
is gratefully acknowledged.
© Joyce Burger, 2020 
All rights are reserved. No part of this book may be reproduced, distributed, stored in a retrieval 
system, or transmitted in any form or by any means, without prior written permission of the author.
Molecular Mechanisms of Aortic Aneurysms
Moleculaire mechanisme van aorta aneurysmata
Proefschrift 
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
Prof.dr. R.C.M.E. Engels
en volgens het besluit van het College voor Promoties. 
De openbare verdediging zal plaatsvinden op 




Prof. dr. R. Kanaar 
Prof. dr. R.M.W. Hofstra 
Overige leden
Prof. dr. H.J.M. Verhagen
Prof. dr. D.F.E. Huylebroeck
Prof. dr. B. Callewaert
Copromotoren
Dr. J. Essers 
Dr. I. van der Pluijm 





Chapter 1 General introduction
Chapter 2  Molecular phenotyping and quantitative assessment of 
the effects of pathogenic variants in the aneurysm genes 
ACTA2, MYH11, SMAD3 and FBN1 
Chapter 3  SLC2A10 knockout mice deficient in ascorbic acid synthesis 
recapitulate aspects of arterial tortuosity syndrome and 
display mitochondrial respiration defects 
Chapter 4  Fibulin-4 deficiency differentially affects cytoskeleton 
structure and dynamics as well as TGFβ signaling 
Chapter 5  Decreased mitochondrial respiration in aneurysmal aortas of 
Fibulin-4 mice is linked to PGC1A regulation  
Chapter 5  Gene expression profiling in syndromic and non-syndromic 
heritable thoracic aortic disease: further evidence on the role 





























STRUCTURE OF THE AORTIC WALL
The aorta is the largest artery in the human body and facilitates oxygenated blood flow from the 
pumping heart to the rest of the body. The aorta is built to resist high pressure and propagate blood 
flow, especially in the ascending aorta and aortic arch. Elasticity and rigidness are provided by the 
three layers that make up the aorta; the intima, the media and the adventitia (Fig. 1). The intimal 
layer (intima) consists of a single layer of endothelial cells that are lined along the inside of the artery 
and its connective tissue. This layer also contains an internal elastic membrane that separates the 
intimal layer from the medial layer (media). The medial layer is built up of vascular smooth muscle 
cells surrounded by extracellular matrix and a defined number of elastin layers. The media is often 
called the muscular layer of the artery as it provides the aorta the ability to contract and relax, thereby 
regulating blood pressure. While the elastin layers present in the media appear as single layers in 
histological cross-sections of the aorta, they are composed of continuous elastin sheets that are 
circumferentially oriented in the medial layer of the artery and separated by the vascular smooth 
muscle cells. The adventitial layer (adventitia) mainly consists of fibroblasts and collagen giving the 
aorta strength and stability. The adventitia also harbors the vasa vasorum; small blood vessels that 
supply nutrients to the adventitia and the outer region of the medial layer. These small blood vessels 






Vascular smooth muscle cells
External elastic membrane
Internal elastic membrane
Figure 1. Schematic overview of the aortic wall layers
Cross-section of the aortic wall displaying the tunica intima, tunica media and tunica externa and an overview 
of their main components.
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The aorta can be divided into different regions: the thoracic part, which originates from the heart, 
and the abdominal part, which starts below the diaphragm. The thoracic aorta can be further 
subdivided into the ascending aorta, the arch and the descending aorta. The abdominal aorta 
can be subdivided into a suprarenal region, above the renal artery, and the infrarenal region, 














Figure 2. Schematic overview of the aortic regions
The aorta can be divided into a thoracic part and an abdominal part, these are anatomically separated 
by the diaphragm. The thoracic aorta can be subdivided into the ascending aorta, the aortic arch and the 
descending aorta. The abdominal aorta can be further divided into the suprarenal abdominal aorta and the 




VASCULAR PATHOLOGIES OF THE AORTA
Genetic variants and/or cardiovascular risk factors, such as high blood pressure, smoking, 
obesity and advanced age, can cause a variety of pathologies of the aorta, including aortic 
aneurysms. The aortic wall becomes thinner when aneurysms occur, which can lead to 
dissections or a complete rupture of the aorta. Dissections can be divided into different types 
depending on the location of the tear. During an aortic dissection the intima is often injured which 
results in accumulation of blood between the intima and media of the aorta. The most common 
symptom of an aortic dissection is sudden pain on the chest and/or back, depending on the 
location of the dissection. An aortic dissection can be defined as acute (within two weeks of 
onset of pain), subacute (two-six weeks after onset) or as chronic (more than six weeks after the 
onset). Classification of aortic dissections occurs via two systems, the DeBakey and the Stanford 
systems (Fig. 3). The DeBakey system classifies into three types (I, II and III) according to the 
first entry site and extent of the dissection in the aorta. Type I has an initial entry in the ascending 
aorta and the dissection continues into the descending aorta. In type II, the dissection originates 
and is confined to the ascending aorta. Type III has an initial entry in the descending aorta and 
can propagate to the ascending aorta (IIIa) or further into the descending aorta (IIIb) [1, 2]. The 
Stanford system classifies the region of the aorta that is affected by the dissection, the ascending 
aorta (type A) or the descending aorta (type B) [2, 3]. The Stanford system is a simplification 
of the DeBakey system and is based on the clinical course and prognosis of patients who had 
dissections involving the ascending aorta as opposed to those in whom the disease did not 
extend proximal to the left subclavian artery [3, 4]. Symptoms of a full wall rupture also include 
acute chest and/or back pain. A full wall rupture results in severe hypotension which can lead to 
a deep coma or death [2].
Aortic aneurysms can occur in different regions along the aorta, abdominal aortic aneurysms 
(AAA) below the diaphragm and thoracic aortic aneurysms (TAA) above the diaphragm. The 
TAA group can be further subdivided into ascending TAA (directly subsequent to the heart), 
aortic arch TAA and descending TAA (subsequent to the aortic arch) [5-7]. If an AAA is localized 
above the kidneys it is referred to as an suprarenal AAA, below the kidneys it is referred to as a 
infrarenal AAA. When an aneurysm encompasses the thoracic and abdominal region, crossing 
through the diaphragm, it is called a thoracoabdominal aneurysm. Figure 4 shows a schematic 
overview of the locations of these different aneurysms. 
During development the aorta originates from distinct embryological origins: the endoderm, 
the mesoderm and the ectoderm. The ectoderm is the exterior layer and is responsible for the 
formation of the neural tube and gives rise to neural crest cells in close proximity of the neural 
tube. Neural crest cells are a temporary cell type and give rise to e.g., melanocytes, bone, 












Figure 3. DeBakey and Stanford classification of aortic dissections
Aortic dissections can be classified according to the Debakey or the Stanford classification. The DeBakey 
system classifies into three types of dissections according to the first entry site of the dissection. Type I has 
an initial entry in the ascending aorta and continues into the descending aorta. Type II initially enters the 
ascending aorta and remains there. Type III has an initial entry in the descending aorta and propagates into 
the ascending aorta of further into the descending aorta. The Stanford system only classifies by the affected 
region of aorta, the ascending aorta (Type A) or the descending aorta (Type B).
the formation of cardiac and skeletal muscle tissue, connective tissue, adipose tissue and the 
circulatory system. The embryonic mesoderm can be subdivided into chordamesoderm or axial 
mesoderm (prechordal plate and notochord), initially unsegmented paraxial mesoderm that 
becomes segmented, intermediate and lateral plate mesoderm (with two leaflets, the splanchnic 
and the somatic leaflet). In amniotes (birds, mammals) the extra-embryonal mesoderm that is 
embryonic by origin forms the allantois and participates in formation of yolk sac and amnion 
[9, 10]. The vascular smooth muscle cells (VSMCs) of the ascending aorta and the aortic arch 
originate from the neural crest, while the VSMCs of the descending aorta arise from the somites. 
The VSMCs of the abdominal aorta as well as a small region around the diaphragm, derive from 
the splanchnic mesoderm (Fig. 4).
Apart from embryological origin, the regions of the aorta have different physical properties and 
compositions. One of these properties is the distensibility, or elasticity, of the aorta. The aorta 
needs to be able to stretch to resist the pressure of the blood flow from the heart, therefore 
the distensibility is of great importance. The distensibility of the thoracic aorta is far greater 




surrounded by the extracellular matrix (ECM) they produce. The ECM is composed of elastin and 
collagen among others. Elastin, together with the microfibrils, forms the elastic laminae that are 
circumferentially oriented in the medial layer and are responsible for the elasticity of the aorta. 
Collagen provides the aorta with rigidity to withstand the pulses of the blood flow. The ratio of 
elastin to collagen is approximately 2:1 in the thoracic aorta, while it is 1:2 in the abdominal aorta. 
Analysis of the aorta has also revealed an increased presence of elastic laminae in the thoracic 
aorta compared to the abdominal aorta [11]. These differences in aortic composition can, in part, 
explain the difference in distensibility of the aortic regions. These differences in embryonic origin 
and aortic composition could explain the differences in susceptibility to aneurysm formation 

















Figure 4. Locations of aorta aneurysms and embryological origins of aortic regions
A) Schematic overview of aorta aneurysms and their location. B) Representation of the difference in 
embryological origin of the thoracic and abdominal aorta.
The incidence of detected thoracic aortic aneurysms was estimated to be between 5.6 and 
10.4 cases per 100,000 per year [13, 14]. However, studies likely underestimate the incidence 
of asymptomatic thoracic aortic aneurysms in the population since the diameter at risk is often 
defined as >5.0 cm, thereby excluding aneurysms with a diameter below this cut-off [15, 16]. 
For abdominal aortic aneurysms the incidence of newly detected AAA is between 3.5 and 6.5 
per 1,000 per year [17-20]. 
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The annual risk of rupture of a thoracic aortic aneurysm is less than 2% for aneurysms with a 
diameter between 4.0 and 4.9 cm, but almost 7% for aneurysms with a diameter of more than 6.0 
cm [21]. The annual risk of rupture for abdominal aortic aneurysms is approximately 1% when 
the diameter is 4.0 to 4.9 cm. When the diameter exceeds 7 cm the annual risk of rupture ranges 
from 30 to 50% [22, 23]. 
Since aortic aneurysms are often asymptomatic and thereby discovered by coincidence, the 
mortality rate of aortic aneurysms is high. Results from a study performed from 1984 to 1993 that 
included unoperated aortic aneurysm patients revealed a 5-year survival of approximately 40% for 
TAA and 20% for AAA [24, 25]. Another study performed between 1985 and 1996 reports a 5-year 
survival of 64% for TAA patients [25, 26]. In this study half of the patients underwent surgery for 
their TAA, which could explain the higher survival rates. To lower this mortality, aortic aneurysms 
are traditionally treated with surgery to either replace the aneurysm by a surgical graft (open 
aneurysm repair) or to place a stent in the aorta that spans over the aneurysm (endovascular 
aneurysm repair, EVAR). During an open aneurysm repair the thorax or the abdomen has to be 
opened to place a graft in the healthy aorta and remove the excess tissue of the aneurysm. The 
first open abdominal aortic aneurysm repair was performed in France in 1951 [23, 27]. Since 
then the procedure has been optimized and elective open aortic aneurysm repairs are very 
effective in preventing deaths related to aortic dissections. The perioperative mortality, mortality 
related to surgery and recovery, of open elective repair varies in literature from 1% in centers of 
excellence to approximately 8% in population studies [23, 28]. The first EVAR procedure was 
performed in Buenos Aires in 1990 and was soon embraced as a less invasive alternative for 
open elective repair. Apart from being less invasive, the EVAR procedure is associated with a 
decreased perioperative mortality, approximately 0,5 to 1% compared to open elective repair 
[29-31]. The 4-year overall survival does not significantly differ between EVAR and open elective 
surgery [30, 32]. Although the EVAR procedure is often favorable compared to the open elective 
repair, not all abdominal aortic aneurysms are suitable for an EVAR procedure [23]. Therefore, 
the open elective repair remains an important procedure for the repair of aortic aneurysms.
GENETICS OF AORTIC ANEURYSMS
Thoracic aortic aneurysms
Thoracic aortic aneurysms (TAA) comprises hereditary TAA and sporadic aneurysms, e.g. without 
family history. In total, approximately 25% of the TAA is suspected to have a genetic component 
as an underlying cause. Of these 25%, approximately one fifth of TAAs are associated with a 
known genetic disorder, while the rest of patients with a TAA have a positive family history of 




referred as a mutation if the variant is known or predicted to be pathogenic, if the effects are 
unknown it will be referred to as a variant. 
When TAA patients additionally present with syndromic features there is a higher chance of 
finding a genetic cause [36, 37]. Syndromic features can include, for instance, distinct facial 
features, tall stature or hypermobility of the joints. Well-known TAA syndromes are Marfan, 
Loeys-Dietz and Ehlers-Danlos syndrome. Marfan syndrome (MFS) was originally described in 
1896 by Dr. Antoine Marfan, a French pediatrician. Characteristic features of Marfan patients are 
increased height, disproportionally long limbs and digits as well as other skeletal deformations. 
Other clinical features include aortic root aneurysms, ocular defects (in particular ectopia lentis 
and severe myopia) and hypermobility of the joints. In 1991 the FBN1 gene, encoding for the 
ECM protein fibrillin-1, was identified via genetic linkage analysis as the causative gene for Marfan 
syndrome [38]. Loeys-Dietz syndrome (LDS) is a genetic disorder characterized by widespread 
vascular disease not limited to the aortic root. Other hallmarks of the disease include patent 
ductus arteriosus, skeletal malformations, craniofacial features such as bifide uvula, cutaneous 
findings and joint hypermobility. LDS is caused by a disease-causing mutation in one of six genes 
involved in the TGFβ pathway (TGFBR1/2, SMAD2/3, TGFB2/3), which is important for proper 
growth and development of the body’s connective tissue [39-42]. Ehlers-Danlos syndrome 
(EDS) is a group of rare inherited disorders that affect connective tissues. Symptoms include 
joint hypermobility, skin hyperextensibility, atrophic scaring, bruisability and aortic aneurysms. 
To date 19 genes are identified to cause 13 subtypes of EDS, of which mutations in the collagen 
genes COL5A1 and COL5A2 cause classical EDS [43-45]. Mutations in COL3A1 lead to vascular 
EDS [43, 46].
Cutis laxa encompasses a heterogeneous group of connective tissue disorders typified by loose 
and/or wrinkled skin. Although not all mutations that cause cutis laxa are associated with aortic 
aneurysms, mutations in ELN and EFEMP2 do lead to aneurysm formation in cutis laxa patients. 
Zhang et al. identified heterozygous mutations in the ELN gene in patients with autosomal 
dominant cutis laxa [47]. In 2006 the first homozygous missense mutation in the EFEMP2 gene 
(Fibulin-4) was identified in a patient with autosomal recessive cutis laxa [48].
Disease-causing mutations in the genes ACTA2, MYH11, MYLK and PRKG1 lead to non-
syndromic familial aortic aneurysms. These patients present with aortic aneurysms, but without 
other clinical features that are normally associated with syndromes such as Marfan and Loeys-
Dietz. Via linkage analysis Guo et al. (2007) identified heterozygous missense mutations in the 
ACTA2 gene in 15 families, five of which carried the same mutation although these families were 
unrelated [49]. Analysis of co-segregation and specific gene mutation screening by Zhu et al. 
revealed two different heterozygous mutations in MYH11 [50]. In 2010 heterozygous disease-
causing mutation in the MYLK gene were identified in families with TAAs and dissections by 
18
CHAPTER 1
segregation analysis [51]. Segregation analysis of four unrelated families with TAAs identified a 
heterozygous missense mutation in PRKG1 by Guo et al. [52]. 
Abdominal aortic aneurysms
Abdominal aortic aneurysms (AAA) are often associated with common cardiovascular risks 
such as increased age, chronic inflammation, atherosclerosis and smoking [53]. It is therefore 
frequently thought that AAA is caused by an unhealthy lifestyle. Although this might be true for 
a part of AAA patients, there is also a genetic component in AAA. In the 1970s Clifton reported 
a case study of three brothers who all had a ruptured AAA [54]. There was no history of trauma, 
or signs of post-stenotic dilatation, sepsis or syphilis in any of the three brothers that could be 
responsible for the aneurysm formation [55-58]. The author therefore suggested a hereditary 
factor in these patients. The risk of AAA was increased in relatives of AAA patients compared 
to the general population [59]. In addition, the age onset of AAA formation in a relatives of AAA 
patients was also decreased [59]. Due to the association of AAA formation and atherosclerosis, 
a study was conducted to identify the atherosclerotic burden of patients with familial AAA and of 
patients with sporadic AAA [60]. Analysis of the carotid intima-media thickness (CIMT) revealed 
a lower atherosclerotic burden, reflected by a lower CIMT, in patients with familial AAA compared 
to patients with sporadic AAA. Familial AAA patients further presented less hypertension, 
diabetes mellitus and were less likely to smoke. This underlines the idea of a hereditary factor in 
AAA as opposed to common cardiovascular risk being the only cause for AAA.
Since the hereditary component in AAA is becoming more apparent, studies are conducted to 
identify possible causative genes for AAA. This identification is currently performed via different 
methods: family-based linkage, analysis of known TAA genes in the AAA population and 
genome-wide association studies (GWAS) [61, 62]. 
The most extensive family-based linkage analysis of familial AAA was performed by Shibamura 
et al. [63]. In this study 119 families were analyzed and two loci, 4q31 and 19q13, were shown 
to be in linkage with AAA, but only when sex and number of affected individuals were included 
as covariates. Due to the large size of the regions it was difficult to identify causative genes, 
however, they do harbor potential genes of interest. Endothelin receptor type A (EDNRA) in 4q31 
and several kallikrein (KLK) genes in 19q13 were suggested as potential causative genes since 
their expression is altered in AAA tissue [64, 65].
Analysis of known TAA genes in 155 AAA patients revealed variants in some known TAA genes 
[62]. The found variants in AAA patients were classified according to (likely) benign, unknown 
significance (VUS) or (likely) pathogenic. VUS was defined as “Intronic, silent or missense 
variants that affect splicing, in-frame deletions/insertions, missense variants for which more than 




and a pathogenic effect cannot be excluded. In 99 familial AAA patients one pathogenic and 
segregating COL3A1 mutation, one likely pathogenic and segregating MYH11 mutation and 15 
VUS were found. In 56 sporadic AAA cases one pathogenic TGFBR2 mutation was found and 
seven VUS [62].
Currently the largest GWAS analysis of 4,972 cases and 99,858 controls was performed by a 
multinational consortium and is a meta-analysis of 6 GWAS studies from 5 countries (United 
States, United Kingdom, the Netherlands, Iceland and New Zealand). The outcome was further 
validated in eight independent cohorts [66]. Unfortunately, family history was not collected for 
these GWAS studies and therefore familial and sporadic AAA cannot be differentiated. The meta-
analysis revealed ten genetic loci that were associated with AAA and of these nine loci remained 
below the genome-wide level of significance when validated in the independent cohorts. The loci 
and the nearest gene(s) mapped are summarized in Table 1 [61, 66].
Table 1. Genetic loci associated with AAA
Identification method Locus (Nearest associated) Gene(s)
Family-based linkage analysis 4q31 EDNRA
19q13 Several KLK genes
Analysis of known TAA in AAA patients COL3A1
MYH11
TGFBR2












Mouse models for aortic aneurysms
To study the progression and molecular mechanisms of aortic aneurysms, mouse models are 
used to mimic human aortic aneurysms. Mouse models can be generated by genetic modification 
or induced chemically.
 I. Genetic mouse models
The effect of a genetic mutation can be difficult to analyze when the number of patients or the 
patient material is limited, therefore mouse models are often generated to investigate this. Inbred 
mice are genetically homogeneous and there is very little variation or heterogeneity within a pure 
inbred strain. This provides the opportunity to investigate the pathogenesis and outcome of 
specific gene associated diseases. The described genetic mouse models for aortic aneurysms 
are summarized in table 2.
For Marfan syndrome a number of mouse models with variable disease severities have been 
created. The Fbn1mgN allele results in no Fbn1 expression, Fbn1mgΔ leads to severely decreased 
expression of Fbn1 (approximately 10-fold) while  Fbn1GT-8 and Fbn1mgR have a 4- to 5-fold reduced 
Fbn1 expression. The Fbn1C1039G allele results in a missense mutation with normal expression 
of Fbn1 but leads to reduced fibrillin-1 fiber formation. Homozygous Fbn1mgΔ, Fbn1C1039G, 
Fbn1mgN, and Fbn1GT-8 mice all die at an early postnatal age due to cardiovascular events, while 
homozygous Fbn1mgR mice with reduced expression of normal fibrillin-1 have a milder phenotype 
and die around 4 months due to aortic dissection [67-71]. 
Tgfbr1 and Tgfbr2 germline (conventional, total knock-out) and conditional (mostly cell-type 
specific) knock-out mice have been generated for LDS. The germline knock-out models show 
severe defects in the vascular development of the yolk sac and die during this phase of embryonic 
development [72, 73]. Conditional knock-outs in endothelial cells, VSMCs and neural crest cells, 
respectively, resulted in specific cardiovascular and craniofacial abnormalities. However, not all 
symptoms of human LDS are mimicked in these mice [74-76]. LDS type 3 conventional knock-
out Smad3-/- mice present with aneurysm formation, fragmentation of the elastic laminae and 
immune infiltration in the aorta [77, 78]. 
Mutations in ACTA2 and MYH11 in humans result in familial TAA, however, Acta2 null and Myh11 
null mice do not present with aneurysms. Nevertheless, Acta2 null mice develop abnormal 
vascular contractility, tone and blood flow and Myh11 null mice show delayed closure of the 
ductus arteriosus [79, 80].
Cutis laxa type 1b is characterized by aneurysm formation and non-elastic, loose skin and is 
caused by mutations in the EFEMP2 gene. Several different Fibulin-4 (mouse EFEMP2) mouse 




10% of the mice survive until postnatal day 1 [81]. Arteries of Fibulin-4-/- mice show tortuosity, 
aneurysm formation and ruptures. Since complete absence of fibulin-4 is embryonically lethal, 
a VSMC specific knock-out model was generated [82-84]. Fibulin-4f/-/SM22Cre+ mice only 
lack fibulin-4 in VSMCs of the aorta, resulting in aneurysm formation in the ascending aorta. 
Furthermore, Fibulin-4f/-/SM22Cre+ aortas show severe fragmentation of the elastic laminae, 
however, the elastin layer adjacent to the endothelial cells appears to remain intact. In the 
hypomorphic Fibulin-4R/R mouse model the R stands for reduced fibulin-4 expression, as these 
mice have 25% of fibulin-4 expression compared to its wild-type littermate. Fibulin-4R/R mice 
show aneurysm formation along the entire aorta. Other characteristics of the aortic phenotype 
include fragmentation of the elastic laminae, increased TGFβ signaling and increase deposition 
of extracellular matrix [85, 86]. Fibulin-4E57K/E57K mice have a patient specific mutation that causes 
reduced ECM assembly and reduced binding to LTBP1s and LOX-propeptide [87, 88]. Like 
Fibulin-4R/R mice, Fibulin-4E57K/E57K show aneurysm formation and fragmentation of the elastic 
laminae. Disease-causing mutations in LOX result in cutis laxa and research shows that Lox-
/- mice die soon after or just before birth due to large aortic aneurysms. This indicates the 
importance of LOX in proper ECM formation and elastic fiber assembly [89, 90].
Table 2. Genetic mouse models for aortic aneurysms






Fbn1 Fbn1mgN No Fbn1 expression Die at early 
postnatal age due to 
cardiovascular events
[71]
Fbn1mgΔ 10-fold reduced Fbn1 
expression
Die at early 
postnatal age due to 
cardiovascular events
[67]
Fbn1GT-8 4- to 5-fold reduced 
Fbn1 expression
Die at early 
postnatal age due to 
cardiovascular events
[70]
Fbn1mgR 4- to 5-fold reduced 
Fbn1 expression
Die around 4 
months due to aortic 
dissection
[68]
Fbn1C1039G Missense mutation, 
normal expression
Die at early 







Tgfbr1 Tgfbr1 knock-out No Tgfbr1 expression Embryonic lethality 
due to severe 








No Tgbr1 expression 






Tgfbr2 Tgfbr2 knock-out No Tgfbr2 expression Embryonic lethality 
due to severe 








No Tgfbr2 expression 






Smad3 Smad3-/- No Smad3 
expression
Aneurysm formation, 
fragmentation of the 
elastic laminae and 
immune infiltration in 
the aorta
[77, 78]
Familial TAA Acta2 Acta2 null No Acta2 expression Abnormal vascular 
contractility, tone and 
blood flow
[79]





Fibulin-4 Fibulin-4-/- No Fibulin-4 
expression
Embryonic lethality 










fragmentation of the 
elastic laminae
[82-84]




fragmentation of the 
elastic laminae
[85, 86]





of the elastic laminae 
and reduced binding 
of fibulin-4 to LTBP1 
and LOX-propeptide
[87, 88]
Lox Lox-/- No Lox expression Embryonic lethality 







 II. Chemically induced mouse models
Since the knowledge on causative genes for AAA is still limited, there are no genetically generated 
AAA mouse models that develop abdominal aortic aneurysms without further (chemical, 
enzymatic) challenge (summary in table 3). 
Chemical induction as such challenge can be performed in several ways, which often rely on the 
fragmentation of the elastic laminae. Exposure of the adventitial intraluminal space to elastase 
results in extensive destruction of the elastic laminae and infiltration of inflammatory cells in 
the adventitia [91]. Another methods relies on exposure to calcium chloride, which results in 
structural degradation of the medial layer and infiltration of the immune system. Both methods 
are known to cause typical AAA in mice [91].
Other chemical induction protocols can result in both TAA and AAA in mice. Administration 
of β-aminopropionitrile monofumarate (BAPN) could lead to the inhibition of LOX activity and 
can thereby induce medial degradation. In combination with induced hypertension, BAPN 
administration can cause TAA as well as AAA, but these aneurysms are often only observed 
by chance [92]. Treatment with angiotensin II in mice with an ApoE-/- or LDLR-/- background also 
result in TAA and AAA [93-95].
Table 3. Chemically induced mouse models.
Treatment Outcome TAA/AAA development
Elastase Extensive destruction of the elastic 
laminae and infiltration of inflammatory 
cells
AAA
Calcium chloride Structural degradation of the medial 





Inhibition of LOX activity and can 
thereby induce medial degradation
TAA/AAA
Angiotensin II (in ApoE-/- or  
LDLR-/- background)
Medial disruption and results in luminal 
dilation
TAA/AAA
GENES, CELLULAR LOCATION AND MOLECULAR FUNCTION
Gene mutations that lead to aortic aneurysms result in alteration of the function of its associated 
protein or its abundance. These affected proteins are located in different cellular compartments 
and can be distinguished on the basis of their location or molecular function within the vascular 
smooth muscle cell. They can be divided into proteins for 1) proper functioning of the extracellular 
matrix (FBN1, COL3A1, COL5A1/2, EFEMP2 and ELN), 2) functioning of the TGFβ signaling 
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pathway (TGFBR1/2, SMAD2/3 and TGFB2/3) and 3) cytoskeleton organization (ACTA2, MYH11, 
MYLK and PRKG1). Although these proteins are located in different cellular compartments, they 
are all interconnected at the molecular level (Fig. 5). The ECM is connected to the cytoskeleton 
via integrins and focal adhesions. TGFβ that activates the TGFβ signaling pathway is stored in 
the ECM and activation of TGFβ signaling can result in upregulation of cytoskeleton proteins. 
Since the molecular processes are all connected, a disease-causing mutation in one molecular 
pathway can result in dysregulation at multiple molecular levels. The molecular function of the 

















































Figure 5. Cross talk between cellular components
The cellular components that are involved in aneurysm formation (ECM, TGFβ signaling and the cytoskeleton) 
all appear to be individually affected during aneurysm formation. However, these components are all 
interconnected with each other as is depicted in this figure. The ECM is build up out of collagen and elastin, 
among others, and serves as a base to which cells can adhere. A cell is bound to the ECM via its integrins 
and the cytoskeleton of the cell is connected to these integrins via the focal adhesions for stability. Focal 
adhesions are a cluster of linker proteins that include talin, vinculin, FAK and paxillin. The cytoskeleton is an 
important structural component of the cell and consists of multiple fibers with different functions and provides 
attachment of organelles, such as the mitochondria. The actin cytoskeleton is formed by F-actin fibers that 
consist of G-actin monomers and these fibers are continuously polymerized and depolymerized. Apart from 
providing attachment for cells, the ECM is needed for storage of cytokines, such as TGFβ. Inactive or latent 
TGFβ is stored in the ECM until activation of the TGFβ pathway is needed. When TGFβ is activated it can 
bind to the TGFβ receptors and thereby activate a number of processes. Transcription of TGFβ target genes 
is induced by the phosphorylation of Smad2/Smad3 and Smad4 after which they translocate to the nucleus 
and induce transcription. Cellular adhesion is influenced by TGFβ signaling via Rac/Cdc42, PAK and Par6/




actin (de)polymerization via RhoA, ROCK and by the phosphorylation status of cofilin. This illustrates that 
these different cellular components are all connected and that a mutation in one of the genes in this network 
can result in dysregulation at multiple levels. 
Extracellular matrix aberrations in aortic aneurysms
The ECM is a non-cellular three-dimensional structure that is present between cells and organs. 
The ECM is important for the adhesion of cells to a basal membrane, but is ultimately responsible 
for cell signaling since growth factors are deposited and released from intrinsic components of 
the ECM. The ECM consists of a mixture of elastin, collagen, fibrillin, fibulin, laminin, fibronectin, 
microfibril-associated glycoproteins and proteoglycans [96, 97]. Although these proteins are all 
present in the ECM, their composition varies between different tissues and even within one tissue 
the composition can vary, as is shown in figure 6. For instance, the three aortic layers consist 
of different collagen types (collagen VIII, XV and XVIII in the intima vs collagen I, III and V in the 
media and adventitia) or the ratio between two collagen types is different (I>III in the media, 
while III>I in the adventitia). 
Elastic bers
Endothelium

























Figure 6. Representation of the aortic wall and the ECM components per layer
Overview of the ECM components that are present in each aortic wall layer.
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ECM proteins are structurally dependent on each other and form structures together, such as 
fibrillin that covers the elastin core [98]. Mutations in major ECM components, such as elastin 
or fibrillin, lead to disorganization and weakening of the ECM, which can lead to aneurysm 
formation. Additionally, mutations in proteins that are essential for ECM assembly, such as LOX 
or fibulin-4, can lead to an unstructured ECM resulting in aneurysm formation.
 III. Elastin 
Elastin is a major component of the ECM in the medial layers of the aorta. Elastin layers are 
circumferentially oriented in the aortic media, providing elasticity and strength. Elastic fibers are 
formed out of microfibrils and the crosslinked elastin precursor protein, tropoelastin [99-101]. 
Tropoelastin contains lysine residues that serve to crosslink the precursor into a functional elastin 
polymer [97]. This crosslinking is mediated by the enzyme lysyl oxidase, which is recruited by 
fibulin-4 [99, 102]. If the elastin fibers are not properly formed, they will have a fragmented 
appearance and will not provide the elasticity and strength needed in the aorta [102]. Disease-
causing mutations in the elastin assembly genes as well as mutations in the tropoelastin gene 
itself lead to weakening of the aorta and eventually causing aneurysm formation [102].
Fibulin-4 (EFEMP2) is part of the fibulin family that consists of seven members. Fibulins are ECM 
proteins that commonly contain multiple calcium binding EGF-like repeats and a motif in the 
C-terminus very similar to fibrillin proteins. Fibulin-4 strongly co-localizes with elastic fibers in the 
aortic wall. Alterations in the fibulin-4 protein lead to decreased secretion of fibulin-4 into the ECM 
or decreased binding to proteins such as lysyl oxidase, thereby preventing proper recruitment to 
the elastic fibers. These mutations in fibulin-4 lead to cutis laxa in patients [88, 96, 97].
Lysyl oxidase is essential for the crosslinking of tropoelastin, thereby maturing it to elastic fibers. 
The lysyl oxidase family consists of five members that are genetically very distinct from each 
other, but are all copper binding proteins. LOX, the first identified lysyl oxidase, is involved in 
crosslinking of elastic fibers. The function of the other lysyl oxidase family members is currently 
unknown. The amine oxidase activity of LOX catalyzes the formation of lysine-derived (and 
hydroxylysine-derived crosslinks in collagens) crosslinks in elastin [96]. 
 I.V. Collagen
Apart from elasticity the aorta is also in need of rigidity to withstand the blood pressure after 
each heartbeat. Collagen deposition in the ECM can provide this strength to the aorta. Currently 
28 types of collagen are identified of which type I, II, III, IV and V are the most prominent in the 
human body [103, 104]. Collagen is assembled from three alpha chains that are super-coiled 
and form a right-handed structure, also called procollagen. Procollagen peptidase then removes 




is then assembled into a collagen fibril, which can be combined with other collagen fibrils to form 
a collagen fiber [103, 105, 106].
Improper formation of these collagen fibers by mutations in the collagen protein itself or the 
enzymes that are associated with its assembly, will lead to a disorganized ECM and can result in 
aneurysms by weakening of the aorta. Disease-causing mutations in collagen type I (COL1A1, 
COL1A2), III (COL3A1) and V (COL5A1, COL5A2) are known to cause Ehlers-Danlos syndrome. 
Collagen assembly enzymes that are known to cause aneurysms are: ADAMTS2 and PLOD1 
[107, 108].
 V. Fibrillin
Another major component of the elastic fiber is fibrillin. The glycoprotein fibrillin is secreted 
into the ECM by fibroblasts and forms a microfibril network with fibril diameters of 10 to 12 
nm. Fibrillin is important for elastin assembly as the microfibrils cover the elastic core [109]. 
Furthermore, these microfibrils are important for the interaction with the latent TGFβ-binding 
proteins that retain inactive TGFβ in the ECM [109, 110]. Other proteins that are associated 
with microfibrils are microfibril-associated glycoproteins (MAGPs). These MAGPs interact with 
fibrillin to influence microfibril function. These MAGPS can further interact with TGFβ ligands 
and can induce TGFβ signaling by preventing the binding of latent TGFβ to fibrillin-1 as well as 
actively releasing latent TGFβ from fibrillin-1 [111]. Fibrillin monomers are assembled by a N- to 
C-terminal self-interaction leading to a beads-on-a-string appearance after assembly. 
The presence of fibronectin is essential for the formation of fibrillin-1 into microfibrils [112]. 
Fibronectin is secreted from the cell as a soluble dimer, that is converted into larger insoluble 
fibrils in the ECM. Mutations in Fibrillin-1 affect elastin assembly, but also TGFβ activity. Disease-
causing mutations in the FBN1 gene (coding for the fibrillin-1 protein) clinically present as Marfan 
syndrome [113].
Cytoskeleton aberrations in aortic aneurysms
In a large group of patients with familial TAA, mutations have been identified in genes associated 
with contraction and the cytoskeleton. Cytoskeleton proteins are intracellular proteins that form 
the skeleton of the cell. These proteins are important for the shape of the cells, their ability to move, 
their contractile capacity, and they also facilitate intracellular transport along their fibers [114]. 
Components of the cytoskeleton can be subdivided into three types of filaments; microfilaments, 
microtubules and intermediate filaments. The combination of these three filament types makes 
up the cellular cytoskeleton [114, 115]. A subset of the cytoskeleton responsible for contraction 
is called the contractile apparatus. During contraction myosin can pull on the microfilaments 
(actin). Mutations in the cytoskeleton lead to problems with contractility and movement. Loss 
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of proper contractility can cause aneurysms, since the cell cannot properly react to forces from 
outside of the cell.
 I. Actin
The microfilaments are the thinnest fibers present in the cytoskeleton, approximately 6 nm 
in diameter. Microfilaments are alternatively called actin fibers since they are built up of actin 
monomers. These actin monomers (globular actin or G-actin) are linked together to form the 
actin filament (filamentous actin or F-actin) upon hydrolysis of ATP. Each microfilament is made 
up out of two helical actin filaments and consists of a positive and a negative end. Polymerization 
of actin monomers happens at the positive side (barbed end) of the actin filament, while 
breakdown or depolymerization occurs at the negatively charged end (pointed end) [116-118].
Polymerization and depolymerization of actin fibers is tightly regulated by a number of proteins. 
Polymerization of actin monomers is facilitated by formins, profilin and the arp2/3 complex. 
Formins promote the elongation of actin fibers by removing capping proteins from the positive 
end, allowing attachment of new monomers. Profilin is an actin binding protein that catalyzes 
the exchange of ADP to ATP on the actin monomers, thereby making the monomers suitable for 
attachment to the actin filament at the positive end. The arp2/3 complex promotes side-branching 
by attaching itself to the main actin fiber as a new nucleation point [116, 119]. Depolymerization 
of actin fibers is performed by actin depolymerizing factor (ADF) and cofilin. By binding to the 
actin fiber, ADF and cofilin cause twisting of the fiber, resulting in structural weakening that leads 
to fiber decomposition. This process of polymerization/depolymerization is also known as actin 
filament treadmilling [116, 118-120].
During cellular contraction, actin filaments form the base network on which myosin filaments 
can pull to induce contraction. Organization of actin filaments into bundles makes a contraction 
more efficient. One of the main actin filament crosslinking proteins is α-actinin, an antiparallel 
homodimer that has actin binding sites at each end. Due to its structure α-actinin leaves space 
for interaction between actin and myosin [121, 122]. Typically, actin filaments are attached to a 
load near their barbed end, while during a contraction myosin moves towards the barbed end 
and can pull on the actin filament. In smooth muscle cells the barbed ends of actin filaments are 
embedded in dense bodies [122]. Mutations in the ACTA2 gene are known to lead to familial 
TAA.
 II. Myosin
Myosin is one of the proteins present in the contractile apparatus of VSMCs, that slides over the 
thin actin filament thereby creating contraction. Myosin consists of a head and a tail region; the 
head contains an actin binding site while the tail region can form a coil with another myosin tail. 




form the thick myosin filament that is found in the contractile apparatus. The myosin molecule 
is also referred to as the heavy chain. The myosin light chain is located at the neck of the 
myosin molecule, and can be further subdivided into the essential and the regulatory light chain 
[118]. To start a cellular contraction a calcium influx is needed, which can either come from 
the extracellular space or from the sarcoplasmic reticulum. Calcium then binds to calmodulin, 
making it possible for calmodulin to phosphorylate the myosin light chain kinase (MYLK). After 
this activation, MYLK can phosphorylate the myosin light chain, thereby allowing cross-bridging 
of the myosin head and the actin fibers. Release from contraction can be induced by removal 
of the phosphate group from the myosin light chain by a myosin light chain phosphatase [123, 
124]. Mutations in the myosin heavy chain (MYH11) are found in families with hereditary TAA. 
Myosin light chain kinase (MYLK) mutations also lead to hereditary TAA.
Deregulation of TGFβ signaling in aortic aneurysms
Mutations in components of the TGFβ pathway are associated with aortic aneurysm formation. 
Mutations in TGFβ1, TGFβR1, TGFβR2 and SMAD3 lead to the inability to activate the TGFβ 
signaling pathway or to transfer the signal to downstream effectors and are known to cause 
aneurysms [125-128].
TGFβ cytokines belong to the TGFβ family that in humans are encoded by 33 genes. These family 
members can be subdivided into two functional groups; 1) the TGF-like groups that, for instance, 
include TGFβs, Activins and Nodal, and 2) the BMP-like groups that include BMPs, growth and 
differentiation factors (GDFs). The TGFβ family is involved in a wide range of fundamental cell 
processes such as proliferation and differentiation, survival versus death as well as adhesion, 
migration and cytoskeleton dynamics [129].
TGFβ has three highly homologous isoforms, TGFβ1, TGFβ2 and TGFβ3, and these isoforms are 
synthesized as a precursor protein called pro-TGFβ (Fig. 7A). The precursor protein is cleaved 
by proprotein convertases (e.g. the Furin family) resulting in a mature homodimeric ligand and 
secreted from cells in a large complex that includes the cleaved proregion of the TGFβ precursor, 
also referred to as the latency associated peptide (LAP). This large complex is often called the 
small latent complex (SLC). The SLC is bound intracellularly, in the secretory pathway, by latent 
TGFβ binding proteins (LTBPs) to form the large latent complex (LLC) that is secreted and bound 
to the ECM via the N-terminal domain of LTBP [127, 129-133]. The C-terminal domain of LTBP is 
bound to the microfibrils via binding to the N-terminal domain of fibrillin-1. By storing TGFβ in the 
ECM, the activity of TGFβ can also be locally controlled [134]. Activation of TGFβ occurs via a 
multilevel process (Fig. 7B); first the LLC has to be removed from the matrix which can be done 
via proteolytic enzymes such as elastases. Second, the SLC has to be cleaved which is achieved 
by proteases like MMPs. Lastly LAP has to be removed from mature TGFβ by proteases such as 




























Figure 7. Storage and activation of TGFβ
A) Storage of TGFβ in the ECM. TGFβ is produced as a precursor protein (pre-pro-TGFβ) and is cleaved by 
proprotein convertases. The mature homodimeric ligand is then secreted from the cells in a large complex 
with the cleaved pro region of TGFβ also referred to as the latency associated protein (LAP), together they 
form the small latent complex (SLC). The SLC is bound to the latent TGFβ binding protein (LTBP) to form the 
large latent complex (LLC). The LLC is secreted and binds to the ECM via its N-terminal, while the C-terminal 
binds to the fi brillin-1 microfi brils. B) Activation of TGFβ in the ECM. Proteolytic enzymes remove the LLC 
from the ECM after which proteases remove the LTBP from the SLC. The LAP is then removed by proteases 




varies between cell types and the context of the activation [129, 135-138]. This intricate way of 
storing and activation of TGFβ regulates the bioavailability of TGFβ and thereby controls many 
essential processes.
When activated, the TGFβ signaling pathway can be divided into two parts; the canonical and the 
non-canonical pathway. The non-canonical pathway signals via ERK1/2, JNK/p38, RhoA and Akt, 
among others [139] (Fig. 5). The canonical pathway is often associated with aneurysm formation 
and makes use of TGFβ and receptor-activated phosphor-Smad2/3 for its signaling [127, 140]. 
The canonical TGFβ pathway is activated by binding of TGFβ to a TGFβ receptor 2 dimer (Fig. 
8). A TGFβ receptor 1 dimer is then recruited to form a heterotetramer of TGFβ receptors. 
Binding of the TGFβR2 to the TGFβR1 enables TGFβR1 phosphorylation by TGFβR2, thereby 
activating the TGFβR1 in its juxtamembrane GS-rich segment (also named type 1 box). Smad2/3 
proteins, which are auto-inhibited, are recruited to the TGFβR1 and are then phosphorylated. 
Phosphorylated Smad2/3 forms a complex with Smad4, which accumulates in the nucleus. 
Here the Smad2/3-Smad4 complex, via weak DNA binding, often with co-operation of Smad-
interacting transcription factors, initiates transcription of downstream effector molecules such as 
matrix metalloproteases (MMPs), connective tissue growth factor (CTGF) and PAI-1 [126, 127, 
140]. A negative feedback loop in the TGFβ signaling pathway is activated after transcriptional 
activation of the SMAD7 gene. Smad7 inhibits TGFβ signaling by blocking Smad2 to Smad4 
binding, and also by forming a stable complex with the TGFβR1 and preventing phosphorylation 
of Smad2 [127, 140, 141]. 
IMMUNE RESPONSE AND AORTIC ANEURYSMS
Next to genetic causes of aneurysm formation many non-genetic factors also contribute to 
aneurysm formation, an important one being the immune system. Influx of immune cells is 
thought to happen after an initial injury of the aorta, such as degradation of elastin fibers or loss 
of VSMCs. Animal studies in which aneurysms were induced with elastase showed that immune 
infiltration was present prior to aneurysm formation one week after elastase treatment [142, 143]. 
These studies further show that after the initial injury with elastase, reactive isotopes of the ECM 
were unmasked and immunoglobins with reactivity to microfibrils were identified. This increase 
in influx of immune cells and increased reactivity to the ECM leads to further attraction of the 
immune system and a snowball effect of aortic damage.
Most often AAA is thought to be associated with chronic inflammation and an increased immune 
response [53]. However, an increased immune response can also be found in TAA. Smad3-/- 
mice show an influx of CD3+ T cells and macrophages in their aorta [78]. Although less research 
was performed on the involvement of the immune system in human TAA, studies have shown that 
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half of the patients with a TAA or dissection under study have increased IFNγ expression [144]. 
































Figure 8. Activation of the TGFβ signaling pathway
Schematic overview of the TGF signaling pathway. TGFβ binds to a TGFβR2 dimer, a TGFβR1 dimer is then 
recruited to form a heterotetramer of TGFβ receptors. Binding of the TGFβR2 to the TGFβR1 enables TGFβR1 
to be phosphorylated by the TGFβR2. Smad2/3 proteins are recruited to the TGFR1 and are phosphorylated. 
Phosphorylated Smad2/3 forms a complex with Smad4 to enter the nucleus, where they initiate transcription 
of TGFβ target genes, such as matrix metalloproteases (MMPs), connective tissue growth factor (CTGF) and 
PAI-1. The transcribed Smad7 serves as a negative feedback loop by preventing Smad2 to Smad4 binding 




Chronic infections of the aorta by microorganisms can also result in aneurysm formation by 
infiltration of the immune system. Inflammatory aneurysms were first mentioned in 1972 by 
Walker et al. and are caused by a viral or bacterial infection of the aorta. Inflammatory aneurysms 
are associated with thickening of the aortic wall and eventually dilation of the lumen, leading 
to aneurysm formation [145, 146]. Some human leukocyte antigen (HLA) classes are more 
predominant in AAA patients suggesting that AAA could also have an autoimmunity origin [147]. 
Furthermore, immunoglobins have been identified in AAA patients that showed reactivity to 
elastin and collagen [148].
MOLECULAR PHENOTYPING OF AORTIC ANEURYSM GENES
Although much research has been performed on potentially causative genes for aneurysm 
formation in relation to hereditability of aneurysms, nowadays many so-called variants of 
uncertain significance (VUS) are identified in the clinic. These VUS’s are variants that are not 
directly identifiable as benign or pathogenic. VUS are defined as “intronic, silent or missense 
variants that affect splicing, in-frame deletions/insertions, or as missense variants for which more 
than two in silico protein predictions are damaging” [62]. The problem with these VUS’s is that 
identification of potential pathogenicity cannot be based solely on the prediction models alone 
and would need additional testing and analysis to determine their effect. Furthermore, novel 
candidate genes for aneurysm formation are identified by new techniques such as whole exome 
and whole genome sequencing (WES/WGS). In silico analysis of these variants does not always 
lead to a conclusive result on the pathogenicity. One approach to analyze the consequence of a 
given variant would be an analysis using a cellular tests (functional test) that reports on a specific 
function of the gene of interest. Using this molecular phenotyping of aneurysm genes, VUS’s can 
be compared to known ‘aneurysm’ genes to determine which molecular pathways they might 
be linked to. For example, in the past, identification of disease-causing mutations of ACTA2 was 
performed by immunofluorescent staining of smooth muscle actin (SMA) in control VSMCs and 
VSMCs from TAA patients [49]. TAA patients with an ACTA2 mutation showed less distinct SMA 
fibers in their cytoskeleton compared to control VSMCs.
As previously explained, disease-causing mutations in aortic aneurysm genes affect different 
cellular compartments: ECM, cytoskeleton and TGFβ signaling. Often aortic aneurysm genes 
are characterized by analysis of aortic material of patients. However, these results do not prove 
a causative link between a found mutation and aneurysm formation as the effects cannot be 
directly linked to the mutation. Inducing a patient mutation in a control cell line and analyzing 
the effects would be the ultimate proof for causality. However, specific functional assays on 
the function of aortic aneurysm genes in patient cells could also provide information on the 
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pathogenicity. To determine if specific functional analyses are more often used for one of these 
subgroups, we examined which assays are currently in use for which genes and subgroups. 
Extracellular matrix
Fibrillin-1 (FBN1), fibulin-4 (EFEMP2) and tropoelastin (ELN) are important factors in the assembly 
and structural integrity of the ECM. Mutations in these genes lead to aneurysm formation and are 
often related to more complex clinical syndromes. FBN1 mutations lead to Marfan syndrome, 
while EFEMP2 and ELN mutations lead to cutis laxa. Aortas of Marfan and cutis laxa patients 
show improperly formed ECM. Aortas of patients with EFEMP2 and ELN mutations often show 
fragmentation of the elastic laminae [149-151]. Loss of VSMCs was identified in the aortic wall 
of a population of Marfan patients which was accompanied by loss of SMA and SM22 protein 
[152]. FBN1 mutations (p.P1225L, p.M1576T, p.G2003R) showed activation of the TGFβ pathway 
which was demonstrated using western blotting to detect increased phosphorylation of Smad2 
[153]. Stability of mutated fibrillin-1 proteins was analyzed with a proteolytic assay by Kirschner 
et al., which showed increased susceptibility to degradation of mutated fibrillin-1 protein [154]. 
Studies were performed to determine the binding of fibulin-4 to LOX in the presence of different 
EFEMP2 mutations [88]. Results showed that some EFEMP2 (p.E57K, p.E126K, p.A397T) 
mutations resulted in reduced binding of fibulin-4 to LOX, while other mutated fibulin-4 proteins 
(p.C267Y, p.R279C) were not secreted, thereby preventing binding to LOX.
Cytoskeleton
Smooth muscle actin (ACTA2), myosin heavy chain 11 (MYH11) and myosin light chain kinase 
(MYLK) are important factors for the cytoskeleton and contractility of VSMCs. Disease-causing 
mutations in these proteins lead to aneurysm formation by dysregulation of VSMC contractility 
and are associated with hereditary aortic aneurysms. Mutations in ACTA2 often lead to 
decreased SMA protein levels and this reduction was shown to reduce the force output of ACTA2 
mutated VSMCs via a one-bead laser trap experiment [52, 155, 156]. Analysis of aortic tissue 
of ACTA2 and MYLK patients showed increased activation of the TGFβ signaling pathway via 
phosphorylation of Smad2 [157]. Similar to ECM mutations, fragmentation of the elastic laminae 
was found in aortic sections of MYH11 and MYLK patients [50, 51].
Polymerization of mutant SMA molecules in yeast cells was performed by Malloy et al. to determine 
if ACTA2 mutations affected the assembly of the cytoskeleton [158]. The most prevalent ACTA2 
mutation (R256H) showed a longer actin assembly time and less polymerization compared 
to control yeast cells, indicating that the polymerization is affected by ACTA2 mutations. The 
cytoskeleton is also affected by MYH11 mutations as MYH11R247C/R247C, leading to decreased 
ATPase activity, VSMCs showed less polymerized actin and less actin in general [159]. These 
cytoskeleton aberrations also translated to decreased attachment of the MYH11R247C/R247C VSMCs 




[159]. Kinase activity of mutant MYLK was investigated by Wang et al. and lower maximum 
kinase activity was shown for the two tested MYLK mutations leading to lowered contraction [51].
TGFβ signaling pathway
Disease-causing mutations in the TGFβ signaling components TGFβ2, TGFBR1, TGFBR2 and 
SMAD3 lead to LDS, characterized by aneurysm formation, joint hypermobility and skeletal 
malformation amongst others. Fragmentation of the elastic laminae is found in aortic sections 
of TGFβ2 and TGFβR1 patients as well as in aortas of Smad3-/- mice [39, 77, 78, 160]. Electron 
microscopic analyses further revealed absence of elastic fiber association with VSMCs in TGFβR1 
patients [39]. Reduced presence of the cytoskeleton protein SMA was found in aortic sections 
of TGFβ2 and TGFβR2 patients compared to healthy controls [42, 161]. Smad3-/- mouse aortas 
also revealed alterations to the cytoskeleton by a decrease in α-actin protein levels [77, 78]. 
TGFβ2, TGFβR1 and SMAD3 patients were shown to have increased phosphorylation of Smad2, 
which suggest increased activation of the TGFβ pathway [40, 41, 160, 162]. Activation of the 
TGFβ signaling pathways was confirmed in TGFβ2+/- mice and CTGF and collagen, downstream 
targets of the TGFβ signaling pathway, are increased in TGFβ2 patients [42, 160]. Boileau et 
al. further showed decreased protein levels of TGFβ2 in TGFβ2 patients, while TGFβ2 gene 
expression was increased. This suggests that the TGFβ2 protein is less stable upon mutation 
[160]. 
SCOPE OF THIS THESIS: MOLECULAR MECHANISMS OF AORTIC 
ANEURYSMS 
Since characterization of aneurysm genes is mainly focused on analysis of the TGFβ signaling 
pathway and cytoskeleton proteins, it is important to identify the behavior of known aneurysm 
genes and controls in cellular functional assays that report on TGFβ signaling and cytoskeleton 
function. The read-outs of these functional assays can then be applied to identify the effects of 
VUS to determine their pathogenicity or to link newly discovered genes to molecular pathways 
that affect aneurysm formation. In chapter 2 of this thesis we characterized fibroblast cell 
lines derived from control and aneurysm patients bearing ACTA2, MYH11, SMAD3 and FBN1 
mutations. We analyzed the transdifferentiation of control and patient fibroblasts to VSMC-
like cells. Subsequently we determined TGFβ responsiveness over time in these cells and 
analyzed functional parameters like cell migration and contractility. Chapter 3 describes the 
characterization of a new mouse model for arterial tortuosity syndrome (ATS). Homozygous 
mutations in SLC2A10 lead to ATS in humans and a knock-out model has been developed to 
better characterize the role of SLC2A10. Since SLC2A10 (also referred to as GLUT10) has been 
suggested to work as a vitamin C transporter, the vitamin C transporter in mice, GULO, was also 
knocked-out. Aortas were analyzed on a macroscopic and microscopic level. Isolated aortic 
VSMCs were analyzed for mitochondrial function, ECM aberrations and TGFβ signaling.
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To fully understand aneurysm formation and to identify possible therapeutic targets we must 
understand the molecular mechanisms that underlie aneurysm formation. Analyzing aneurysmal 
mouse models is an effective method to further identify processes that are involved in aneurysm 
formation. In this thesis we investigated Fibulin-4 mouse models to detect affected processes 
at the cellular level. Since aneurysm patients often show increased TGFβ signaling it was long 
thought that this led to aneurysm formation. However, current research indicates that increased 
TGFβ signaling can be protective of aneurysmal disease in the initial stages but proved to be 
detrimental during later disease stages [163, 164]. This illustrates the need for research to 
elucidate the molecular mechanisms of aneurysm formation further. 
Additionally, we want to identify other molecular mechanisms that are involved in aneurysm 
formation. In chapter 4 of this thesis we show that total absence and reduced presence of 
fibulin-4 has different effects on cytoskeleton structure and dynamics as well as on TGFβ signaling. 
Chapter 5 demonstrates that reduced levels of fibulin-4 in the Fibulin-4R/R mouse model lead to 
dysregulation of metabolism and altered mitochondrial respiration. Finally, chapter 6 shows 
that mitochondrial dysfunction is also found in aortic tissue of Marfan syndrome patients and 
non-syndromic heritable thoracic aortic disease patients. This was identified by performing RNA 
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Aortic aneurysm (AA) is a pathological dilatation of the aortic wall. The natural course of the 
disease is to grow and rupture; ruptured AA are associated with a mortality of 80% due to life 
threatening internal bleeding. Certain patients develop an aneurysm due to genetic mutations 
that can be associated with malfunctioning of vascular smooth muscle cells (VSMC). A number 
of genes associated with AA development has been identified, primarily encoding proteins that 
are involved in TGFβ signaling, contractile machinery and proper organization of the extracellular 
matrix (ECM). However, only a small portion of variants in these genes lead to a pathogenic 
effect which results in AA formation.
Our goal was to identify functional assays to investigate the effects of (pathogenic) variants 
in aneurysm genes associated with thoracic and abdominal AA. Since VSMC can only be 
obtained during invasive surgery, we used a TGFβ induced transdifferentiation protocol 
previously developed by our group. We performed growth factor-induced transdifferentiation 
of skin fibroblasts of controls and patients with a mutation in genes encoding for components 
of cytoskeleton contractility (ACTA2, MYH11), TGFβ signaling (SMAD3) and a dominant 
negative (DN) and missense variants (HI) in the extracellular matrix (FBN1). We analyzed the 
transdifferentiation potential, structural integrity of the cytoskeleton, TGFβ signaling profile as 
well as migration velocity and maximum contraction. 
TGFβ-induced transdifferentiation was strongly reduced in the SMAD3 and FBN1 DN cells. Both 
ACTA2 and FBN1 DN patient cells showed a decrease in Smad2 phosphorylation. Migration 
velocity was impaired for ACTA2 and MYH11 patient cells. Furthermore, ACTA2 cells showed 
reduced contractility. 
In conclusion, we find that transdifferentiation potential measured as the amount of SMA 
production is a distinctive readout as cells with a pathogenic SMAD3 of FBN1 DN variant can be 
identified by their inability to express SMA after TGFβ stimulation. Assays based on functionality, 
e.g. migration or contractility, could distinguish cells with pathogenic variants in ACTA2 and 
MYH11 from controls. Therefore, we conclude that functional assays are a valuable tool for 
classifying VUS in aneurysm related genes
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INTRODUCTION
Aortic aneurysms are pathological dilatations of the aorta that are life-threatening in case of 
rupture. Aortic aneurysms can occur in the thoracic as well as abdominal aorta and both show 
a clear genetic predisposition [1, 2]. Aortic aneurysms may arise from a variety of pathogenic 
gene variants encoding structural components of ECM, cytoskeletal/smooth muscle contraction 
proteins, and proteins associated with the TGFβ pathway. Pathogenic variants in the cytoskeleton/
contractile genes may lead to altered contractility of vascular smooth muscle cells (VSMCs), 
caused by structural defects or imbalance of regulatory proteins. Known affected proteins in this 
group are α-smooth muscle actin (ACTA2), myosin heavy chain 11 (MYH11), myosin light chain 
kinase (MYLK) and cGMP-dependent protein kinase 1 alpha isozyme (PRKG1) [3-6]. The TGFβ 
signaling system consists of extrinsic ligands and cell-intrinsic effector proteins, including Smads 
and Smad-interacting proteins, that determine the outcome of TGFβ signaling. Pathogenic 
variations in these proteins will lead to hampered signaling of this pathway. Mutations in TGFβ 
pathway genes known to cause aneurysms are TGFβ receptor 1 (TGFBR1), TGFBR2, TGFB2, 
TGFB3, SMAD2 and SMAD3 [7-16]. Pathogenic variants in genes encoding for components of 
the extracellular matrix (ECM)  lead to improper assembly of the ECM. This results in aneurysm 
formation due to loss of cell attachment, loss of vessel elasticity and strength, and altered 
ability to retain latent TGFβ. Proteins in this group include fibrillin-1 (FBN1), collagen type 3 α1 
(COL3A1), elastin (ELN), fibulin-4 (EFEMP2) and lysyl oxidase (LOX) [17-28].
VSMCs are embedded between elastic laminae in the medial layer of the aorta. Both the VSMCs 
and elastic laminae are important components in maintaining the elasticity and contractility of 
the aorta. During aneurysm formation of the aortic medial layer is often disintegrated which leads 
to reduced elasticity and contractility [29]. To study cell biological and molecular consequences 
of aneurysm formation, VSMCs can be isolated from aortic tissue retrieved from open surgery. 
Alternatively, dermal fibroblasts grown on a scaffold containing collagen and elastin or coverslips, 
can be transdifferentiated into VSMC-like cells within 2-weeks using 5 ng TGFβ1/ml. The induced 
VSMC-like cells are comparable to primary human aortic SMC with regard to mRNA expression 
of SMC markers ACTA2, SM22 and CNN1 [30].
The potential pathogenicity of a number of variants in aneurysm-causing genes cannot be 
classified based on existing classification systems [31-34] and remain variants of unknown 
clinical significance (VUS). To assess VUS, a set of functional assays is needed to identify the 
(pathogenic) effect of suspected causative gene variants for aortic aneurysms. The aim of this 
study is to develop these novel functional assays with robust read outs for the investigation 
of the effects of pathogenic variants in four aneurysm genes (ACTA2, MYH11, SMAD3, FBN1 
haploinsufficient and dominant negative) based on TGFβ induced transdifferentiation of skin 
fibroblasts of aneurysm patients. These functional assays could help to reclassify VUS into either 
50
CHAPTER 2
nonpathogenic or pathogenic variants. This could be a potential diagnostic tool to predict the 
effect of these variants on aneurysm formation.
MATERIALS AND METHODS
Patient cells and characteristics
Primary dermal fibroblasts of aneurysm patients from the biobanks of the departments of Clinical 
Genetics (Amsterdam University Medical Center - location VU and Erasmus University Medical 
Center) were used for all experiments. Fibroblasts were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Lonza BioWhittaker) supplemented with 10% fetal calf serum (FCS) and 1% 
penicillin/streptomycin (PS) at 37°C with 5% CO2. Human fibroblasts of healthy controls and 
aneurysm patients with heterozygous mutations in ACTA2 (cytoskeleton), MYH11 (cytoskeleton), 
SMAD3 (TGFβ signaling) and FBN1 (extracellular matrix) were used for all experiments (see 
Table 1 for patient mutations). These mutations were evaluated by the Alamut Visual, a decision-
support software for genome variant diagnostics, and predicted to be a class 5 pathogenic.
Transdifferentiation
Fibroblasts were seeded at a density of 2,5 million cells/ml, as previously described [30]. 
Fibroblasts were seeded in DMEM with 10% FCS and 1% penicillin/streptomycin at a density 
of 2,5 million cells/ml on the corners of a 1cm2 piece of matriderm (MedSkin Solutions). Two 
days after seeding, the medium was changed to DMEM supplemented with 2% heat-inactivated 
fetal calf serum, 1% PS and 5ng/ml human recombinant TGFβ1 (4342-5, Biovision). Heat-
inactivation was performed by placing the FCS in a 56°C water bath for 30 minutes and mixing 
regularly. Medium supplemented with TGFβ1 was changed every 4 days. After 14 days, the 
cells were enzymatically extracted from the matriderm with the use of a collagenase solution 
in complete medium (2000IU/ml, Worthington) at 37°C on a shaker for 3 hours. Centrifugation 
was performed to remove collagenase and cells were transferred to new flasks and cultured 
for further experiments. Passage number of ‘VSMC-like’ cells after transdifferentiation was kept 
below 5 to prevent loss of transdifferentiation markers.
RNA isolation and real-time PCR
Fibroblasts were seeded in triplicate per condition in 12-well plates at a density of 100.000 
cells/well. After two days day 0 samples were taken and medium was changed to DMEM 
supplemented with 2% heat-inactivated fetal calf serum, 1% PS and 5ng/ml human recombinant 
TGFβ1 (4342-5, Biovision) for the transdifferentiation samples. TGFβ1 supplemented medium 
was changed every 4 days and after 14 days RNA was isolated.
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RNA was isolated with the RNeasy mini kit (Qiagen). cDNA was made with iScript cDNA synthesis 
kit (Biorad) according to manufacturing protocol. q-PCR was performed with 200 nM forward 
and reverse primers and iQTM SYBR® Green Supermix (Biorad) on the CFX96 system (Biorad); 
denaturation at 95°C for 3min, 40 cycles denaturation at 95°C for 15 s, annealing/extension at 
55°C for 30 s. TBP was used as reference gene. Relative gene expression levels were determined 
with the comparative Ct (also referred to as ΔΔCt) method according to the MIQE guidelines. 
See Table 2 for primers used to detect gene of interest expression.
Table 1. Gene, cell line, pathogenic variant and additional information on the affected protein.





ACTA2 #1 c.445C>T, p.R149C Missense mutation, 
presumably affecting the 
fiber formation due to the 






MYH11 #1 c.3879+2dup, p. ? Frameshift, premature 
stop codon. Effects on 
the protein are currently 






SMAD3 #1 c.859C>T, p.R287W Missense mutation, 
potential loss of H-bridges 
at interacting site that leads 





FBN1  #1 c.2369insC, p. ? Frameshift, premature 




FBN1 #2 c.2851insG, p. ? Frameshift, premature 




FBN1 #3 c.2132G>A, 
p.C711Y
Missense mutation in the 
TGFβ binding protein-like 
domain that could affect 
binding to fibrillin-1 and 
results in a dominant 






Table 2. Primer sequences for qPCR.
Gene name Protein name RefSeq Fw and rev primer seq
TBP TATA-box binding protein NM_003194 AGTTCTGGGATTGTACCGCA
TCCTCATGATTACCGCAGCA
ACTA2 SMA NM_001141945 ACTGGGACGACATGGAAAAG
CATACATGGCTGGGACATTG
CNN1 Calponin NM_001308341 GCCCAGAAGTATGACCACCA
TGATGAAGTTGCCGATGTTC
TAGLN/SM22 SM22 NM_001001522 AAGAATGATGGGCACTACCG
AGCCCTCTCCGCTCTAACTG
Immunofluorescent staining and image quantification
Dermal fibroblasts were seeded on 18mm coverslips in 12-well plates with a density of 100,000 
cells/well in DMEM with 10% FCS and 1%PS. Two days after seeding the medium was changed 
to DMEM supplemented with 2% heat-inactivated fetal calf serum, 1% PS and 5ng/ml human 
recombinant TGFβ1 (4342-5, Biovision). TGFβ supplemented medium was changed every 4 
days and after 14 days cells were fixed with 2% paraformaldehyde in PBS for 15 minutes. After 
fixation cells were washed with PBS supplemented with 0,1% Triton X-100 and blocked with 
PBS+ (0,5% BSA and 0,15% glycine in PBS) for 30 minutes. Primary antibodies were incubated 
overnight at 4°C in PBS+; mouse monoclonal anti-smooth muscle actin (SMA) (1:1.000, ab7817, 
Abcam) and rabbit polyclonal anti-SM22 (1:400 ab14106, Abcam). Cells were washed with PBS 
supplemented with Triton-X100 and incubated shortly with PBS+ prior to incubation with the 
secondary antibody in PBS+ (1:1.000, anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 
594, Molecular Probes) for 1 hour at room temperature. Simultaneously, actin filaments were 
stained with SiR-Actin (1:1.000, Cytoskeleton). After incubation coverslips were mounted on 
glass slides with Vectashield supplemented with DAPI (H-1200, Vector laboratories) and sealed 
with nail polish. Images were recorded on a wide field epifluorescent microscope (Axio Imager 
D2, Zeiss).
Quantification of the immunofluorescent signal was performed by calculating the corrected total 
cell fluorescence (CTCF) of SMA and actin. The CTCF of actin and SMA was determined by 
setting a color threshold to select the fibers in the image with Fiji image analyzing software 
[35] and determining the integrated density of this area (intensity of the fluorescence). This 
measurement was corrected for the background fluorescence and the total area of the fibers 
and results in the CTCF. The percentage of fluorescence is then calculated by dividing the SMA 
CTCF and actin CTCF to determine what percentage of the actin cytoskeleton is positive for SMA 
compared to the total actin cytoskeleton. 
Cytoskeletal fiber organization was assessed by measuring anisotropy on microscopic images 
using FibrilTool plug-in in Fiji [36]. The anisotropy coefficient ranges from zero to one; parallel 
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lines result in an anisotropy coefficient of one, whereas nonparallel structures have an anisotropy 
coefficient close to zero. The alignment of F-actin and SMA fibers was assessed in confocal 
images of transdifferentiated cells of controls and patients with a mutation. According to the 
published protocol, X-Y fields of view were marked as regions of interest (ROI), and anisotropy 
was quantified within those regions. 
Western blotting 
VSMC-like cells were seeded at 100.000 cells/6-well and allowed to attach for 48 hours. Cells 
were scraped in PBS supplemented with protease inhibitor cocktail (1:100, 11836145001, Roche 
applied science) and phosphatase inhibitor cocktail (1:100, P0044, Sigma) and lysed in equal 
volumes of 2x Laemmli buffer (4% SDS, 20% glycerol, 120mM Tris pH 6,8) supplemented with 
protease inhibitor cocktail and phosphatase inhibitor. Lysates were cleared of large DNA by 
passing through a 25G needle and then heated to 65°C for 10 minutes. Protein concentrations 
were measured with the Lowry protein assay [37]. Equal amounts of protein were size separated 
by SDS-PAGE and separated proteins were then transferred to a PVDF membrane (1hour, 100V, 
Immobilon). Membranes were blocked for 1 hour at room temperature by either 5% BSA or 
3% milk in PBS supplemented with 0,1% Tween-20. Membranes were incubated 45 minutes at 
room temperature with primary antibody (see Table 3 for primary antibodies). Membranes were 
washed 5 times with 0,1% Tween-20 in PBS and then incubated with horseradish peroxidase-
conjugated secondary antibodies (1:2.000, Jackson ImmunoResearch) for 1 hour at room 
temperature. Bound secondary antibodies were detected with an Amersham Imager 600 (GE 
Healthcare Life Sciences) using chemiluminescence. Band intensity was quantified using Fiji 
image analyzing software [35]. 
Table 3. Primary antibodies.
Primary antibody Predicted kDa Dilution Manufacturer Catalog number 
Rabbit α-SM22 IgG 23 1:2000 Abcam Ab14106
Mouse α-SMA IgG2a 40 1:10.000 Abcam Ab7817
Rabbit α-pSmad2 IgG 55-60 1:400 Merck Millipore 04-953
Rabbit α-Smad2 IgG 60 1:1000 Cell signaling 5339S
Mouse α-β catenin IgG1 92 1:2000 BD Bioscience 610153
Stimulation with TGFβ
Stimulation with TGFβ was performed to determine the sensitivity of control and patient 
fibroblasts to TGFβ. Fibroblasts were seeded in DMEM supplemented with 10% FCS and 1% 
PS in 6-well plates to reach confluence and were allowed to attach for 24 hours. The following 
day, medium was changed to DMEM supplemented with 1% PS and fibroblasts were serum 
deprived for 24 hours prior to stimulation with human recombinant TGFβ. Protein samples were 
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collected after 0 minutes, 15 minutes, 30 minutes, 1 hour and 4 hours of stimulation with TGFβ1 
(4342-5, Biovision). Lysis of cells and western blotting was performed as previously described. 
Membranes were incubated overnight at 4°C with primary antibody (see Table 3 for primary 
antibodies).
Ring barrier migration assay
To measure the migration length and efficiency, a ring barrier migration assay was performed 
[38]. In this assay a barrier is placed in a cell culture chamber that prevents cells from entering 
the cell-free area. VSMC-like cells are seeded outside of this barrier and form a monolayer prior 
to the removal of the barrier. Upon removal of the barrier VSMC-like cells can migrate into the 
cell-free area and migration can be monitored. Migration parameters such as total and effective 
migration can be monitored. Migration velocity can be calculated based on total migration 
and the duration of the experiment. 50,000 VSMC-like cells were seeded in the outer ring of 
the set-up and were allowed to attach for 24 hours. After removing the ring barrier, cells were 
washed twice with DMEM supplemented with 1% PS (serum free) and were left in this medium 
during migration to prevent cell division. Multiple locations at the migration front were selected to 
monitor movement. Every 10 minutes pictures were taken at the selected locations for 24 hours. 
Data was analyzed with the axiovision software (version 4.5.0.0) by measuring the total migration 
length of multiple cells and calculating the migration velocity.
Measuring cell contractility
Cell contractility was measured and calculated according to previously published protocol [39]. 
VSMC-like cells were seeded in duplicate in the array at a density of 30,000 cells/well in a sterile 
96 well plate array well (96w10; Ibidi, Planegg, Germany). Cells were cultured for 48 hours prior 
to stimulation. The impedance was recorded at a frequency of 4,000 Hz.
VSMC-like cells were stimulated with 10 µg ionomycin/ml (Sigma Aldrich, Darmstadt, Germany). 
Contractile responses were measured in duplicate in each experiment. Contraction (C) of each 
well equals one minus the ratio between the resistance post- and pre-stimulation post empty well 
value subtraction, as depicted in equation 1:
C = (1 – 
(PoS[Ω ] – 290 [Ω])
(PrS[Ω ] – 290 [Ω])
 • 100
Equation 1: contractile response
The change in contraction was recorded and expressed as maximum contraction. To characterize 
the contractile output of the patients, the mean response of the control group was used as a 
reference. Contraction of the patient VSMC-like cells was compared to a range between 2xSD 
above and below the mean contractile response of the control group.
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Statistics
Number of experiment replicates and independent samples are stated in the figure legends. 
Data were corrected for outliers with the Grubbs’ test for outliers. Statistical analysis was 
performed with a non-parametric Mann-Whitney test. Significance was tested 2-tailed against the 
mean of the controls. Significance in gene expression analysis of stimulated controls was tested 
2-tailed against unstimulated controls. A p-value <0.05 was considered to indicate a significant 
difference between groups. In the figures p<0.05 is show with *, p<0.01 with **, p<0.001 with #. 
Results are expressed as mean ± SD, real-time PCR results are expressed as geometric mean 
± geometric SD. All analyses were performed using Graphpad, version 7.03.
RESULTS
Assessment of baseline measurements for control VSMC-like cells
A schematic overview of the transdifferentiation protocol is given in figure 1A. Transdifferentiation 
was initiated by replacing the culture medium from DMEM supplemented with 10% FCS and 
1% PS with DMEM supplemented with 2% heat-inactivated serum, 1% PS and 5ng/ml TGFβ1. 
According to previous protocols [30], medium was refreshed every 4 days and TGFβ stimulation 
was terminated after 14 days. Efficiency of transdifferentiation was determined by analyzing the 
RNA expression level of genes specifically expressed in vascular smooth muscle cells (VSMCs, 
Table 2). A 4.5-fold increased expression of ACTA2 was measured within 5 days after addition of 
TGFβ1 and steady-state mRNA expression levels continued to rise until the end of the experiment 
(14 days) (Fig. 1B).
We determined the induction of ACTA2 gene expression in three healthy control fibroblast cell 
lines to analyze the variability in fold change expression and determine a baseline for comparison 
with the patients. On average, a consistent 5.5-fold induction of ACTA2 gene expression was 
measured in all controls after 14 days of TGFβ stimulation (Fig 1C). CNN1 gene expression was 
2.5-3.5 fold and SM22 1.8-2.2 fold increased after 14 days of TGFβ stimulation. The expression 
of both genes showed considerably more variation compared to ACTA2 upregulation (Fig. 1D 
and E).
Subsequently we determined the transdifferentiation potential by analyzing the protein expression 
level of SMA and SM22 by immunofluorescence and western blot analysis. Supplementary figure 
1 shows a comparison of fibroblasts prior to stimulation and VSMC-like cells after stimulation with 
TGFβ for 14 days. Immunofluorescence staining after 14 days of transdifferentiation showed that 
all control fibroblast cell lines are positive for SMA which is organized in elongated cytoplasmic 
SMA fibers stretched throughout the cell. Induction of SMA shows variability between the control 
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Figure 1. Continous on the next page
57
































0 15 30 1h 4h
Control A
0 15 30 1h 4h
Control B




































































Figure 1. Assessment of baseline measurements for control VSMC-like cells
A) Time line of TGFβ induced transdifferentiation of 3 healthy control cell lines. B) Gene expression of ACTA2 
during 14 days of TGFβ stimulation. C) ACTA2 gene expression in controls after 14 days of stimulation with 
TGFβ. D) CNN1 gene expression in controls after 14 days of stimulation with TGFβ. E) SM22 gene expression 
in controls after 14 days of stimulation with TGFβ. Unstimulated samples are set to one to compare the fold 
induction and determine the variability in controls. Results are presented as geometric mean ± geometric 
SD, figures also include the geometric mean of the controls (dashed grey line) and the 2x geometric SD 
range of the controls (dotted black line). 3 samples, n=2. F) Immunofluorescent staining of SMA (green), 
SM22 (red), actin (gray) and DAPI (blue) after 14 days of transdifferentiation. Scale bar represents 100 µm. 
G) Quantification of the fluorescent signal of SMA set out against the fluorescent signal of actin. Quantified 
7 representative images per cell line. H) Quantification of SMA fiber organization in control VSMC-like cells. 
Alignment of SMA fibers was analyzed for 7 representative images per cell line. I) Quantification of actin fiber 
organization in control VSMC-like cells. Alignment of actin fibers was analyzed for 7 representative images 
per cell line. J) Western blots detecting SMA and SM22 in VSMC-like cells. β-catenin levels serve as a loading 
control. K) Quantification of SMA levels as shown in panel J. L) Quantification of SM22 levels as shown in 
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panel J. 2 independent samples, n=3. M) Western blots detecting pSmad2 and Smad2 in control fibroblasts 
upon stimulation with TGFβ (15 min, 30 min, 1 hour and 4 hours) after serum deprivation. β-catenin levels 
serve as a loading control. N) pSmad2/Smad2 ratio visualized over time in controls. O) Quantification of 
pSmad2/Smad2 ratio at 30 minutes of stimulation, n=2. Results are presented as mean ± SD. Grey dashed 
line represents mean of the controls and the black dotted line represents 2xSD range of controls.
quantify the amount of SMA fiber fluorescence intensity, we determined the ratio between SMA 
fibers to the total actin content in the cytoplasm. The transdifferentiated controls showed an 
overlay of approximately 30% of SMA fiber fluorescence with total F-actin, with the 2xSD range 
running from 9% to 51% (Fig. 1G). Anisotropy, and thereby organization, of the SMA fibers was 
quantified in control VSMC-like cells. The anisotropy coefficient ranges from zero to one; parallel 
lines result in an anisotropy coefficient of one, whereas nonparallel structures have an anisotropy 
coefficient close to zero. Control VSMC-like cells showed a mean anisotropy coefficient of 0.25, 
with a range from 0.07 to 0.43 (Fig. 1H). Analysis of actin organization showed a mean a of 0.54 
in control VSMC-like cells with a range from 0.29 to 0.79 (Fig. 1I).
Western blot analysis of SMA and SM22 expression showed the presence of both proteins in 
all controls after transdifferentiation (Fig. 1J). Quantification of SMA and SM22 protein levels 
revealed variability between the controls. The variability in relative protein expression of SMA 
in the controls ranged from 0.46 to 1.54. For SM22 the variability in relative protein expression 
ranged between 0.54 to 1.45 in the controls (Fig. 1K and L).
To determine TGFβ signaling activity the c-terminal phosphorylation of Smad2 was analyzed over 
time. The response of non-transdifferentiated control fibroblasts to TGFβ in time was determined 
as the ratio of receptor-activated (phosphorylated) Smad2 compared to total Smad2 protein 
after TGFβ stimulation (Fig. 1M and N). Overall, phosphorylated Smad2 was already detected 15 
minutes after stimulation with TGFβ. The amount of phosphorylated Smad2 reached a maximum 
level between 30 and 60 minutes, after which it decreased. As the controls almost reached their 
measured maximum at 30 minutes after TGFβ stimulation we used the expression level at this 
time point as a reference for TGFβ activation. At the 30-minute time point the mean pSmad2/
Smad2 ratio is approximately 1.1 and ranged from 0.49 to 1.72 (Fig. 1O). 
Taken together, these data show that all controls can be transdifferentiated to VSMC-like cells 
upon stimulation with TGFβ, assessed by the RNA and protein expression of SMA, SM22 and 
CNN1 as well as SMA fiber organization and pSmad2 mediated TGFβ signaling upon TGFβ 
stimulation. 
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Transdifferentiation efficiency of fibroblasts of aneurysm patients
The goal of our study is to use these parameters to determine aberrant phenotypes in aneurysmal 
patient cells. We used the mean and 2xSD range of the control cell lines to determine of patient 
cells were outside of this range they were considered significantly aberrant from controls. 
The differentiation potential of fibroblasts of aneurysmal patients was assessed by quantitative 
analysis of SMA fibers after transdifferentiation. ACTA2 #1 and MYH11 #1 VSMC-like-cells both 
showed SMA and SM22 fibers after transdifferentiation. However, MYH11 #1 VSMC-like cells 
visually showed elongated SMA fibers that stretched throughout the cell whereas ACTA2 #1 
VSMC-like cells showed disorganization of SMA fibers (Fig. 2A). Quantification of SMA fiber 
fluorescence, normalized for total F-actin, showed that both ACTA2 #1 and MYH11 #1 VSMC-
like cells have a similar SMA fluorescence as the controls, 30% and 29% respectively (Fig. 2B). 
Analysis of anisotropy confirmed decreased organization of SMA (0.099) and actin (0.32) in 
ACTA2 #1 VSMC-like cells compared to controls (Fig. 2C and D, p<0.001). MYH11 #1 VSMC-
like cells showed a similar anisotropy for SMA (0.23) and actin (0.46) as controls (Fig. 2C and D).
SMAD3 #1 fibroblasts did not appear to form SMA fibers after TGFβ stimulation, while SM22 
was present (Fig. 2A). Quantification of SMA fluorescence levels revealed that SMA fluorescence 
levels (6.5%) were significantly reduced in SMAD3 #1 VSMC-like cells (Fig. 2B, p<0.001). SMA 
fibers that were present in SMAD3 #1 VSMC-like cells after TGFβ stimulation furthermore showed 
a significantly decreased SMA anisotropy (0.12) compared to controls (Fig. 2C, p<0.01). Actin 
fiber organization (0.51) was similar to controls (Fig. 2D).
Analysis of haploinsufficient FBN1 #1 and FBN1 #2 VSMC-like cells revealed elongated SMA 
and SM22 fibers after stimulation with TGFβ (Fig. 2A). Both FBN1 #1 and FBN1 #2 VSMC-like 
cells showed similar SMA fluorescence, 22% and 26% respectively, compared to controls (Fig. 
2B). Quantification of anisotropy for SMA (0.22 and 0.30) and actin (0.52 and 0.46) in FBN1 
#1 and FBN1 #2 VSMC-like cells revealed no aberrations in the fiber organization compared 
to controls (Fig. 2C and D). In contrast, after stimulation with TGFβ dominant negative FBN1 
#3 VSMC-like cells showed a very low presence of SMA positive cells compared to controls. 
Quantification of SMA fluorescence showed a significant decrease in intensity (8.9%) compared 
to controls, suggesting reduced transdifferentiation potential (Fig. 2A and B, p<0.001). The SMA 
fibers that were present in FBN1 #3 VSMC-like cells showed no aberrations in SMA anisotropy 
(0.20) compared to controls (Fig. 2C). Actin fiber anisotropy of FBN1 #3 VSMC-like cells showed 






























Figure 2. Continuous on the next page
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Figure 2 



































































ACTA2 #1 MYH11 #1 SMAD3 #1 FBN1 #1 FBN1 #2 FBN1 #3

































































































































































































































































































Figure 2. Transdifferentiation of fibroblasts of aneurysm patients
A) Immunofluorescent staining of SMA (green), SM22 (red), F-actin (gray) and DAPI (blue) after 14 days of 
transdifferentiation. Scale bar represent 100 µm. Underlined cell lines visually showed disorganization of the 
cytoskeleton. Bold cell lines visually showed decreased presence of SMA fibers. B) Quantification of the 
fluorescent signal of SMA set out against the fluorescent signal of actin. Quantified 7 representative images 
per cell line. C) Quantification of SMA fiber organization in pathogenic variant VSMC-like cells. Alignment of 
SMA fibers was analyzed for 7 representative images per cell line. D) Quantification of actin fiber organization 
in pathogenic variant VSMC-like cells. Alignment of actin fibers was analyzed for 7 representative images per 
cell line. E) Western blots detecting SMA and SM22 in pathogenic variant VSMC-like cells. β-catenin levels 
serve as a loading control. F) Quantification of SMA levels as shown in panels E. G) Quantification of SM22 
levels as shown in panels E. 2 independent samples, n=3. Grey dashed line represents mean of the controls 
and black dotted line represents 2xSD range of controls. * p=< 0,05, ** p=<0,01, # p=<0,001.
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Besides by immunofluorescence, differentiation potential was further determined by quantitative 
western blot analysis of SMA and SM22 protein levels after stimulation with TGFβ. SMA and 
SM22 was present after transdifferentiation in both ACTA2 #1 and MYH11 #1 VSMC-like cells 
(Fig. 2E). Quantification revealed increased SMA protein levels (1.59) in ACTA2 #1 VSMC-
like cells (Fig. 2F, p<0.01), whereas SM22 protein levels (1.03) were comparable to controls 
(Fig. 2G). MYH11 #1 VSMC-like cells showed increased SMA protein levels (1.37) compared 
to controls, suggesting increased transdifferentiation potential (Fig. 2F, p<0.05). SM22 was 
significantly decreased (0.69) in MYH11 #1 VSMC-like cells compared to controls, but was also 
remained in the control range (Fig. 2G, p<0.05). 
After stimulation with TGFβ SMA remained almost absent (0.08) in SMAD3 #1 VSMC-like cells 
compared to controls and SM22 protein levels (0.51) were decreased (Fig. 2E, F and G, p<0.001). 
FBN1 #1 and FBN1 #2 VSMC-like cells showed similar SMA (0.92 and 1.47 respectively) and 
SM22 (0.94 and 0.95 respectively) protein levels to controls after transdifferentiation (Fig. 2E, F 
and G). FBN1 #3 VSMC-like cells showed decreased SMA protein levels (0.39) compared to 
controls (Fig. 2E and F, p<0.01), while having comparable SM22 protein levels (1.06) (Fig. 2E 
and G).
In conclusion, SMA and SM22 immunostaining and western blot indicate that SMAD3 #1 and 
FBN1 #3 cells have decreased transdifferentiation potential. While SMAD3 #1 and FBN1 #3 
VSMC-like cells did not show SMA fibers, ACTA2 #1 VSMC-like cells showed disorganized 
SMA fibers. This suggests that SMAD3 #1 and FBN1 #3 VSMC-like cells show reduced 
transdifferentiation after TGFβ stimulation. A summary of the data in the results section can be 
found in figure 6.
Kinetics of pSmad2 activation of fibroblasts of aneurysm patients
TGFβ signaling activity was analyzed by examining the ratio of phosphorylated Smad2 to 
total Smad2 over time as a measure of TGFβ responsiveness. ACTA2 #1 fibroblasts showed 
reduced induction of Smad2 phosphorylation after TGFβ stimulation. When quantified, ACTA2 
#1 fibroblasts showed a pSmad2/Smad2 ratio of 0.44 after 30 minutes of TGFβ stimulation 
which was below the 2xSD range of the controls (Fig. 3A and B). MYH11 #1 fibroblasts showed 
comparable phosphorylation of Smad2 to control fibroblasts (Fig. 3A). Quantification also 
indicated a normal pSmad2/Smad2 ratio of 0.98 for MYH11 #1 fibroblasts compared to controls 
(Fig. 3B). 
Phosphorylation of Smad2 was comparable to controls for SMAD3 #1 fibroblasts, the pSmad2/
Smad2 ratio at 30 minutes of 1.35 and was therefore similar to the controls (Fig. 3A and C).
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Figure 3. Continous on the next page
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Figure 3. TGFβ responsiveness over time of fibroblasts of aneurysm patients
A) Western blots detecting pSmad2 and Smad2 in TAA mutant fibroblasts upon stimulation with TGFβ (15 
min, 30 min, 1 hour and 4 hours) after serum deprivation. β-catenin levels serve as a loading control. B) 
Quantification of pSmad2/Smad2 ratio at 30 minutes of stimulation in ACTA2 and MYH11 variant fibroblasts. 
C) Quantification of pSmad2/Smad2 ratio at 30 of minutes stimulation in SMAD3 variant fibroblasts. D) 
Quantification of pSmad2/Smad2 ratio at 30 minutes of stimulation in FBN1 variant fibroblasts. 2 independent 
samples, n=2. Grey dashed line represents mean of the controls and black dotted line represents 2xSD 
range of controls.
Smad2 phosphorylation in FBN1 #1 and FBN1 #2 fibroblasts showed similar pSmad2/Smad2 
ratios, 0.72 and 1.08 respectively, compared to controls after 30 minutes of TGFβ stimulation 
(Fig. 3A and D). FBN1 #3 fibroblasts showed reduced phosphorylation of Smad2 after TGFβ 
stimulation (Fig. 3A). The pSmad2/Smad2 ratio of 0.46 for FBN1 #3 fibroblasts after 30 minutes 
of TGFβ stimulation remained below the 2xSD range of the controls (Fig. 3D).
Taken together, these data show that pSmad2 activation is highly dynamic. In non-
transdifferentiated cells we detected differences in ACTA2#1 and FBN1 #3 cells compared to 
controls although there is a large range for the readouts. A summary of the data in this results 
section can also be found in figure 6.
Migration capacity of pathogenic variant and control VSMC-like cells
The migration capacity of the induced VSMC-like cells was analyzed by performing a ring barrier 
migration assay. 
Migration velocity of ACTA2 #1 VSMC-like cells (5.0 µm/hr) was decreased compared to the 
migration velocity of controls (9.0 µm/hr) (p<0.001, Fig. 4A). Interestingly, MYH11 #1 VSMC-like 
cells also showed decreased migration velocity (3.5 µm/hr) compared to controls (9.4 µm/hr) 
(p<0.001, Fig. 4B). SMAD3 #1 VSMC-like cells displayed a comparable velocity to the control 
migration velocity (Fig. 4C). FBN1 #1, #2 and #3 VSMC-like cells all did not differ in migration 
velocity from controls (Fig. 4D and E). 
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These data indicate that both cytoskeleton mutations, ACTA2 #1 and MYH11 #1 VSMC-like 
cells, display reduced migration after transdifferentiation compared to controls. A summary of 
the data in this results section can also be found in figure 6.











































































































Figure 4. Migration potential of pathogenic variant and control VSMC-like cells
Migration velocity of pathogenic variant VSMC-like cells compared to controls. A) ACTA2, B) MYH11, C) 
SMAD3, D) FBN1 #1, and E) FBN1 #3 VSMC-like cells. n=2, # p=<0,001
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Contractility of pathogenic variant and control VSMC-like cells
Contractility was determined to analyze the effects that pathogenic variants. The maximum 
contraction of control VSMC-like cells was on average 49.7% with a 2xSD ranging from 23.3 
to 76.1% (Fig. 5A). The maximum contraction of ACTA2 #1 VSMC-like cells was 16.3% and 
thereby below the 2xSD range of the controls. MYH11 #1 VSMC-like cells showed a maximum 
contraction of 42.1% and did not differ from controls (Fig. 5B). SMAD3 #1 VSMC-like cells 
displayed a maximum contraction of 70.4% and showed a relatively high contractility, however, 
the maximum contraction did not differ from the controls (Fig. 5C). FBN1 #1 and FBN1 #2 
VSMC-like cells presented with a maximum contractility of 47.8 and 47.2% respectively and 
were thereby comparable to the controls. FBN1 #3 VSMC-like cells also did not differ from the 
controls with a maximum contraction of 46.5%. (Fig. 5D).
From these data we can conclude that ACTA2 #1 VSMC-like cells show reduced contractility 
















































































Figure 5. Contractility of patient and control VSMC-like cells
Maximum contraction of pathogenic variant VSMC-like cells compared to controls. A) Maximum contraction of 
controls VSMC-like cells. B) Maximum contraction of ACTA2 and MYH11 variant VSMC-like cells. C) Maximum 
contraction of SMAD3 variant VSMC-like cells. D) Maximum contraction of FBN1 variant VSMC-like cells. Grey 
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DISCUSSION
Variants in aneurysm-related genes are often associated with aneurysm formation. However, the 
significance of the effect of these mutations on the protein is not always clear, and thus, the clinical 
relevance is hard to assess. In this study, we used cells of aneurysm patients with six different 
pathogenic variants to evaluate the clinical relevance of novel functional assays to determine 
the pathogenic effects of variants. Such assays are certainly an unmet need in the diagnostic 
setting; since the wide implementation of next generation sequencing a growing number of 
VUS are being identified but can currently not be assessed for their potential pathogenicity. 
We measured a strong decrease in SMA staining and thereby reduced transdifferentiation 
potential in SMAD3 and FBN1 dominant negative (FBN1 #3) patients cells. ACTA2 and FBN1 
dominant negative patients also showed a decrease in pSmad2 activation. Migration velocity 
was impaired for ACTA2 and MYH11, while only ACTA2 showed reduced contractility. Our data 
suggests that TGFβ-induced transdifferentiation of fibroblasts allowed distinguishing clear 
effects from pathogenic variants in cytoskeleton, TGFβ pathway and ECM aneurysm genes for 
ACTA2, MYH11, SMAD3, FBN1 dominant negative, but not for FBN1 haploinsufficient variants. 
A limitation of our study is that only one cell line was used per mutation as proof of concept. 
In order to draw more significant conclusions on the role of mutations of these genes in AA 
formation, replication in a larger number of these and other aneurysm genes are needed. Below, 
we will discuss these results per aneurysm-causing gene analyzed. A summary of the data can 
also be found in figure 6.
ACTA2
ACTA2 #1 VSMC-like cells produced SMA protein after TGFβ stimulation and showed similar 
transdifferentiation potential as controls. However, the SMA fibers appeared fragmented and 
disorganized. Guo et al. previously showed lack of SMA fibers in VSMCs of patient with ACTA2 
variants (p.R118Q and p.T353N) [3]. Our data shows that the p.R149C variant of ACTA2 #1 
resembles other known ACTA2 pathogenic variants with its disorganized SMA fibers after 
transdifferentiation. Clinical data on ACTA2 p.R149C, p.R256H and p.T353N aortic sections 
confirmed that SMA protein is produced, but that VSMCs appear to be disorganized and lack 
structure [40]. Complications with the assembly of mutant SMA (p.R256H) is further confirmed by 
analysis of mutant ACTA2 in yeast [40]. Analysis of SMA fiber assembly by Malloy et al. showed 
decreased SMA polymerization and elongated assembly times in ACTA2 p.R256H mutant yeast 
compared to wild-type yeast. Studies on ACTA2 mutations (p.R118Q, p.R256H and p.T353N) 
show overall disorganization of SMA fibers that is caused by dysfunctional assembly of SMA. 
Our results confirmed the overall disorganization of SMA for an additional ACTA2 pathogenic 
variant (p.R149C) in VSMC-like cells.
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Additionally, ACTA2 #1 VSMC-like cells showed decreased migration and contractility. During 
migration the cytoskeleton is polymerized in the direction of movement, while depolymerization 
occurs at the rear-end of cells. Variants in proteins that constitute the cytoskeleton, such as 
ACTA2 and MYH11, can be explanatory for the observed defective migration. Literature revealed 
that ACTA2 is induced during migration as well as during metastasis, suggesting that ACTA2 is 
essential for migration [41, 42]. Decreased contractility of multiple ACTA2 pathogenic variant 
VSMCs was previously found by Lu et al. (2015) by performing a one-bead laser trap experiment 
to analyze force-output. Our data on the reduced contractility of ACTA2 #1 VSMC-like cells is in 
line with this finding and indicates the importance of ACTA2 for the contractility of VSMCs.
MYH11
MYH11 #1 VSMC-like cells showed decreased SM22 protein levels on western blot. 
Overexpression of MYH11 has been reported to induce degradation and turnover of thick 
filament associated proteins and cytoskeleton proteins like SM22 but not SMA [43]. Since MYH11 
c.3879+2dup (MYH11 #1) is a relatively unknown variant, it is unclear whether this variant could 
lead to a gain-of-function of MYH11 and thereby inducing the degradation of specific cytoskeleton 
proteins or that this pathogenic variant leads to reduced levels or function of MYH11. Our finding 
that SMA is not degraded is in line with the results of Kwartler et al. and suggests that this MYH11 
pathogenic variant could indeed induce the described unfolded protein response that induces 
degradation of specific cytoskeleton proteins.
Although the MYH11 #1 VSMC-like cells were able to transdifferentiate, migration velocity was 
decreased in MYH11 variant VSMC-like cells, similar to the ACTA2 #1 VSMC-like cells. MYH11 
pathogenic variants have been predicted to decrease SMC contractility as well as compromising 
migration, which is in line with our results [44, 45].
SMAD3
SMAD3 #1 VSMC-like cells lacked induction of SMA fibers upon TGFβ stimulation, which 
suggests reduced induction of transdifferentiation. This lack of SMA can be explained by 
disturbance in the TGFβ signaling pathway caused by the SMAD3 pathogenic variant. Induction 
of SMA by TGFβ was shown to occur via SMAD3 [46, 47], suggesting that induction will not 
occur when SMAD3 is mutated. Like SMA, SM22 is induced via activation of the TGFβ pathway, 
specifically via SMAD3 [48]. This also explains the reduced SM22 protein levels of SMAD3 
pathogenic variant VSMC-like cells.
The TGFβ signaling pathway is often considered physiologically active when Smad2 is 
phosphorylated upon TGFβ stimulation, yet, for SMAD3 variants resulting in absent or defective 
Smad3 proteins, this is not necessarily true [49]. Although, the initial response to TGFβ stimulation 
is intact in SMAD3 knock-out cells, downstream signaling is impaired due to absence of Smad3 
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protein. This hampers induction of target genes, thereby leading to impaired induction of SMA 
and SM22 and thus diminished transdifferentiation.
FBN1 
VSMC-like cells with a FBN1 dominant negative pathogenic variant (FBN1 #3) express less SMA 
protein as wells as SMA fibers after transdifferentiation. This could be caused by defective ECM 
build-up resulting from the FBN1 variant, resulting in reduced binding sites for the cytoskeleton 
via integrins. The rigidity of the ECM is also important for the development of the cytoskeleton 
as, for example, a soft matrix results in a less well-defined cytoskeleton [50-52]. The effect of a 
defective matrix on the cytoskeleton has recently also been shown in the Fibulin-4 VSMC specific 
knock-out mouse model in which absence of fibulin-4 led to absence of SMA protein and fibers 
[53].
Transdifferentiation of FBN1 dominant negative and haploinsufficient patient fibroblasts reveals 
differential results between two (predicted) types of FBN1 pathogenic variants. While the 
dominant negative FBN1 #3 VSMC-like cells show decreased induction of SMA and SM22, 
results from FBN1 #1 and #2 haploinsufficient fibroblasts appear quite similar to controls. 
Clinical data have previously also suggested differences between the FBN1 dominant negative 
and haploinsufficient variant in their responsiveness to treatment with losartan [54, 55]. Patients 
with an FBN1 haploinsufficient pathogenic variant that received treatment with losartan were 
responsive to the inhibition of aortic root dilation by losartan, whereas FBN1 dominant negative 
patients did not respond to treatment [54]. Furthermore, patients with an FBN1 haploinsufficient 
variant showed improvement in biventricular end diastolic volume and stroke volume upon 
losartan treatment. This effect was not found in FBN1 dominant negative patients that received 
losartan [55]. This indicates that mutations in one gene can lead to different outcomes and 
could result in different clinical consequences for patients. The nature of the FBN1 variants 
and their effects are in line with this as haploinsufficient variants result in half of the normal 
protein levels while dominant negative variants interfere with the normal protein and can result in 
nonfunctional protein levels. Our functional assays proved to be able to identify characteristics 
potentially distinguishing between FBN1 haploinsufficient and dominant negative mutations and 
could potentially simplify the identification of haploinsufficient and dominant negative patients. 
Especially the presence or absence of SMA and potentially the pSmad2/Smad2 ratio after TGFβ 
stimulation can distinguish FBN1 dominant negative VSMC-like cells from FBN1 haploinsufficient 
VSMC-like cells.
Conclusion
The assays we have chosen are suitable to determine the effect of the mutation on the 
functionality of the protein. We detected reduced transdifferentiation potential in SMAD3 #1 and 
FBN1 #3, defective migration in MYH11 #1 and ACTA2 #1 and defective contractility ACTA2 
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#1. Our results suggest a potential application for these novel functional assays in assessing the 
functionality of a larger number of proteins encoded by the same genes. Hopefully, this will result 
in the ability to analyze the potential pathogenic effect of VUS in aneurysm genes and thereby 
promote more accurate genetic diagnosis and family screening for aneurysms. 
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Supplemental figure 1. Comparison control fibroblasts unstimulated and stimulated for 14 days with 
TGFβ
A) Immunofluorescent staining of SMA (green), SM22 (red), actin (gray) and DAPI (blue) of a healthy control 
prior to stimulation (unstimulated) and after 14 days of TGFβ stimulation (Stimulated). Scale bar represent 
100 µm. B) Quantification of the fluorescent signal of SMA set out against the fluorescent signal of actin. C) 
Western blots detecting SMA and SM22 in a healthy control prior to stimulation (unstimulated) and after 14 
days of TGFβ stimulation (Stimulated).
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Arterial tortuosity syndrome (ATS) is a recessively inherited connective tissue disorder, mainly 
characterized by tortuosity and aneurysm formation of the major arteries. ATS is caused by 
loss-of-function mutations in SLC2A10, encoding the facilitative glucose transporter GLUT10. 
Former studies implicated GLUT10 in the transport of dehydroascorbic acid, the oxidized 
form of ascorbic acid (AA). Mouse models carrying homozygous Slc2a10 missense mutations 
did not recapitulate the human phenotype. Since mice, in contrast to humans, are able to 
intracellularly synthesize AA, we generated a novel ATS mouse model, deficient for Slc2a10 as 
well as Gulo, which encodes for L-gulonolactone oxidase, an enzyme catalyzing the final step 
in AA biosynthesis in mouse. Gulo;Slc2a10 double knock-out mice showed mild phenotypic 
anomalies, which were absent in single knock-out controls. While Gulo;Slc2a10 double knock-
out mice did not fully phenocopy human ATS, histological and immunocytochemical analysis 
revealed compromised extracellular matrix formation. Transforming growth factor beta signaling 
remained unaltered, while mitochondrial function was compromised in smooth muscle cells 
derived from Gulo;Slc2a10 double knock-out mice. Altogether, our data add evidence that ATS 
is an ascorbate compartmentalization disorder, but additional factors underlying the observed 
phenotype in humans remain to be determined. 
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INTRODUCTION
Arterial Tortuosity Syndrome (ATS, MIM#208050) is a rare autosomal recessive connective tissue 
disorder, characterized by severe patterning defects in blood vessel development. Main features 
of the disease include elongation, tortuosity, and stenosis of the large and middle-sized arteries, 
with an increased risk for aneurysm formation and ischemic events [1-3]. Patients may present 
with additional connective tissue-related features, such as cutis laxa, diaphragmatic hernias, 
joint laxity, distinctive craniofacial malformations and a marfanoid habitus. Finally, corneal 
thinning causing pellucid corneas and keratoconus were recently described [2, 4]. The disease 
has shown to be variable in terms of severity, ranging from early mortality to mild manifestations 
in adulthood [1, 2, 5, 6]. Arterial histopathology shows disorganization and fragmentation of the 
elastic fibers [1, 7-10]. Cultured fibroblasts of ATS patients showed disorganization of the actin 
cytoskeleton and multiple extracellular matrix (ECM) components, including fibronectin, fibrillin, 
type 3 and type 5 collagen, and decorin [11, 12]. 
ATS is caused by loss-of-function mutations in the SLC2A10 gene, encoding the GLUT10 
protein [3]. GLUT10 belongs to the GLUT family of facilitative transporters, consisting of 14 
transmembrane proteins, enabling the transport of monosaccharides, polyols, and other small 
carbon compounds across the membranes of eukaryotic cells [13]. GLUT members show 
specific functionalities, but some functional redundancy has been observed. Recent evidence 
identified GLUT10 as a transporter of dehydroascorbic acid (DHA), the oxidized form of ascorbic 
acid (AA), but its subcellular localization remains enigmatic and may change upon physiological 
states. GLUT10 has been shown to reside in mitochondria [14], the nuclear envelope [3], and/or 
the endoplasmic reticulum (ER) [15-17]. 
It remains to be solved how defective DHA transport results in a vasculopathy related to Loeys-
Dietz [18] or Marfan Syndrome [19, 20], respectively caused by perturbed transforming growth 
factor beta (TGFβ) pathway signaling or altered ECM proteins. In the absence of relevant vascular 
patient material, several ATS disease models have been developed. Slc2a10 knockdown in a 
morpholino-based zebrafish model showed abnormal vascular patterning and mitochondrial 
respiration [21]. Two knock-in mouse models, either carrying a homozygous likely pathogenic 
G128E or S150F missense substitution in Slc2a10 [22, 23], were previously phenotyped by two 
different research groups. While no ATS-related abnormalities could be discerned in either mutant 
by one of both groups at 3 months of age [23], the other group found elastic fiber proliferation 
in older homozygous G128E mutant mice only [22]. It is unclear whether this is related to the 
elastic fiber fragmentation seen in the vascular wall of ATS patients. Recent follow-up studies 
in this mouse model indicated altered redox homeostasis and mitochondrial dysfunction as 
pathogenic mechanisms underlying ATS [24], similar to observations in the morpholino zebrafish 
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knockdown model [21], and in ATS knockdown cell lines (rat A10, mouse 3T3-L1) [14]. Altered 
redox homeostasis contributes to the pathogenesis in other aneurysm-related diseases [25]. 
Growing evidence that GLUT10 functions as an AA transporter has led to the hypothesis 
that the innate AA synthesizing capacity of mice could rescue the phenotype. Therefore, we 
characterized a novel mouse model for ATS, with gene disruptions of both Slc2a10, the causal 
gene for ATS, and Gulo, which encodes L-gulonolactone, the enzyme catalyzing the last step in 
AA biosynthesis in mouse. 
RESULTS
Generation of the Slc2a10;Gulo double knock-out mouse model
We developed a novel mouse model for ATS in a mixed 129/SvEv-C57BL/6 genetic background 
by crossing constitutive knock-out lines for Gulo and Slc2a10, both harboring a selection cassette 
replacing multiple exons (Supplementary Figure 1A). To take into account any possible effect of a 
variable genetic background on the acquired data, all studies were performed on littermates from 
the F2 generation (Supplementary Figure 1B). RT-qPCR-based expression analysis, using primers 
targeting the sequence replaced by the selection cassette, confirmed the absence of wild type 
Slc2a10 RNA in skin and aorta obtained from Slc2a10 -/- animals (DKO and Slc2a10 KO) (Figure 1). 
Figure 1. Slc2a10 expression levels in skin and aortic tissue. 
RT-qPCR analysis identifies a near absence of Slc2a10 WT mRNA in mice homozygous for Slc2a10 
mutations (Slc2a10 KO and DKO), compared to mice harboring the Slc2a10 wild type allele (Gulo KO and 
WT). Displayed average values represent the relative expression data in skin or aorta for 3 male and 3 female 
mice. Error bars represent the SD, *: p ≤ 0.05; **: p ≤ 0.01; ***: p≤0.001.
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Double knock-out mice (DKO – Gulo tm1mae/ tm1mae;Slc2a10 -/-) were born with expected Mendelian 
frequency and had a normal lifespan to at least 9 months of age, similar to their control littermates 
(Gulo KO – Gulo tm1mae/ tm1mae;Slc2a10 +/+ , Slc2a10 KO – Gulo +/+;Slc2a10 -/- and WT – Gulo 
+/+;Slc2a10 +/+). Double knock-out mice developed normally, and showed no obvious gross 
anomalies, skeletal dysmorphisms or skin abnormalities. However, the weight of female DKO 
mice was slightly reduced, at each measurement time point (Supplementary Figure 2). 
Slc2a10;Gulo double knock-out mice do not completely copy the human ATS 
phenotype 
We carried out serial ultrasound measurements at multiple locations in the cardiovascular 
system of 10 male and 10 female mice of each selected genotype (DKO, Slc2a10 KO, Gulo KO, 
WT) at 6 weeks, 3, 6, and 9 months of age. Diameters of the ascending aorta, distal ascending 
aorta, aortic arch and descending aorta showed a subtle but statistically significant decrease 
in DKO mice compared to their wild type littermates, for a given age and sex (Figure 2). More 
distal measurements (carotid arteries) did not reveal any significant diameter alterations 
(Supplementary Figure 3). Fractional shortening and ejection fraction were comparable between 
the selected genotypes at 6 weeks and 3 months of age (Supplementary Figure 4). We did not 
detect aortic or mitral valve insufficiency using pulsed Doppler. Detailed microscopic analysis 
of the aortic tree, eye arterioles and the circle of Willis, obtained from polymer replicas of the 
cardiovascular system at 9 months of age, did not indicate any omnipresent structural anomalies 
such as tortuosity, abnormal implantation of the aortic side-branches or aneurysms. However, 
one out of three analyzed female DKO mice had a local stenosis in the vertebral artery (Figure 
3, Supplementary Figure 5). At 9 months, elastic fiber staining of aortic tissue showed mild age-
related changes, such as sporadic elastic fiber fragmentation or accumulation, in the tunica 
media of the aortic wall across all selected genotypes.
Picrosirius red polarization staining on skin tissue showed no major alterations in collagen 
deposition, but patches of increased collagen deposition could be discerned in female DKO 
mice (Figure 4, Supplementary Figure 6). 
Transmission electron microscopy (TEM) analysis of female skin samples showed a normal 
elastic fiber architecture (Supplementary Figure 7). Collagen fibril diameters were significantly 
reduced in DKO compared to WT mice (Figure 5).
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Figure 2. Serial ultrasound measurements obtained in WT, Gulo KO , Slc2a10 KO and DKO mice at 6 
weeks, 3, 6 and 9 months of age. 
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Shown data were acquired at the level of the aortic root, proximal ascending aorta, distal ascending aorta 
and aortic arch. Left and right column images represent data obtained in male (M) and female (F) animals, 
respectively. Shown p-values were obtained using a linear mixed model with covariance pattern modeling, 
without interactions. As a result, p-values should be interpreted when making the comparison for a given age 
and sex. Error bars represent 95% confidence intervals. *: p ≤ 0.05; **: p ≤ 0.01. 
Figure 3. Vascular corrosion casts of WT, Gulo KO , Slc2a10 KO and DKO female mice. 
Representative images of the aortic arch and its side branches, the circle of Willis and the eye arterioles are 
shown. A local narrowing in the vertebral artery in the circle of Willis could be observed in one DKO mouse 
(white-framed enlargement). Scale bars: 2 mm.
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Figure 4. Histological analysis of WT, Gulo KO , Slc2a10 KO and DKO female mice. 
Picrosirius red (PR) polarization staining (upper row) for collagen reveals the presence of patches with 
accumulated collagen deposition (white arrows) in the skin of DKO mice. Verhoeff-Van Gieson (VVG) elastic 
fiber staining (middle row) shows mild elastic fiber anomalies in the aortic wall of all studied mice (black 
arrows). 
Figure 5. Electron microscopic quantification of collagen diameters in WT and DKO skin samples. 
DKO mice show decreased collagen fiber diameters, compared to WT mice (measurements on EM 
micrographs of two animals per genotype). TS: transverse section, LtS: longitudinal section. Scale bar upper 
row: 1.0 µm, lower row: 0.3 µm. Error bars represent 95% confidence intervals. ***: p ≤ 0.001.
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In vitro analysis of Slc2a10;Gulo double knock-out vascular smooth muscle cells 
shows decreased ECM deposition
We examined the ECM deposition in vascular smooth muscle cells (VSMCs) of the DKO and 
WT genotypes (Figure 6). In contrast to WT VSMCs, DKO VSMCs did not show a base network 
of recognizable and organized fibronectin fibers stretching between the cells, but presented 
with a reduced intensity of fibronectin staining with a more fuzzy appearance (Figure 6A, 
Supplementary Figure 8). A similar observation was made for fibrillin-1 where stained fibers 
appeared thinner in DKO VSMCs (Figure 6B, Supplementary Figure 8). WT VSMCs showed clear 
staining of tropoelastin that appeared in a fibrillar structure (Figure 6C), next to the presence of 
a strong fiber network of both fibulin-4 (Figure 6D) and fibulin-5 (Figure 6E). In DKO VSMCs, a 
reduced staining of fibulin-4 and fibulin-5 (Figure 6D and E, Supplementary Figure 8) and an 
overlapping network of tropoelastin and fibulins (Figure 6C, Supplementary Figure 8) could be 
observed. We further assessed LTBP-4, which was present in clear fibrillar structures (Figure 6F) 
in both WT and DKO VSMCs, but appeared less intense in DKO VSMCs, organized in a more 
densely packed fibril network (Figure 6F, Supplementary Figure 8). Taken together, these data 
show that DKO VSMCs displayed decreased deposition of the various components of the ECM 
compared to WT VSMCs. 
Slc2a10;Gulo double knock-out VSMCs do not show altered activation of canonical 
TGFβ signaling 
We investigated canonical TGFβ signaling activation in VSMCs derived from WT and DKO mouse 
aortas. Under an unstimulated serum deprived condition, DKO VSMCs showed similar levels of 
Smad2 phosphorylation compared to WT VSMCs (Figure 7A and B). Following TGFβ stimulation, 
both WT and DKO VSMCs demonstrated a strong and comparable increase in phosphorylation 
of Smad2 after 15 minutes (Figure 7A). Quantification of phosphorylated Smad2 to total Smad2 
ratio revealed a further increase to its maximum at 60 minutes of stimulation after which it 
decreased (Figure 7A and B). In conclusion, our data do not support aberrations in the activation 
of the canonical TGFβ signaling pathway in DKO VSMCs compared to control VSMCs.
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Figure 6. DKO VSMCs show decreased ECM deposition. 
Immunofluorescent images show deposition of multiple ECM components after 7 days of culture. DKO 
VSMCs show less distinct ECM structures compared to WT VSMCs. Scale bars represent 100 µm.
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Figure 7. DKO VSMCs do not show altered activation of the canonical TGFβ signaling pathway. 
DKO VSMCs do not show increased phosphorylation of Smad2 without TGFβ stimulation and do not differ 
from WT VSMCs in basal conditions. Stimulation with TGFβ led to increased phosphorylation of Smad2 in 
both WT and DKO VSMCs. There was no difference in pSmad2/Smad2 ratio between the two genotypes. 
The data show 2 independent cell lines from 2 experiments. The data points represent average values of an 
independent cell line per experiment. Results are depicted as mean ± SD.
Slc2a10;Gulo double knock-out VSMCs show a reduced maximum oxygen 
consumption rate 
Since GLUT10 impairment has previously been associated with mitochondrial dysfunction in a 
Glut10 mouse model with missense mutations [24] and a slc2a10 zebrafish knockdown model 
[21], we analyzed the oxygen consumption rate (OCR) of DKO compared to WT VSMCs as a 
marker for mitochondrial function (Figure 8A). Phase I represents the basal and unstimulated 
OCR. Addition of oligomycin in phase II inhibits the ATP synthase and reduces the OCR. In 
Phase III, treatment with fluoro-carbonyl cyanide phenylhydrazone (FCCP) uncouples oxygen 
consumption from ATP production and raises OCR to its maximum. Addition of antimycin A in 
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phase IV inhibits complex III of the mitochondria and blocks mitochondrial respiration. Figure 
8B and C contain the quantification of the mean value of phase I and III per genotype. Basal 
OCR did not differ between both genotypes (Figure 8A and B). However, when VSMCs were 
treated with FCCP to reach maximum respiration, DKO VSMCs displayed decreased maximum 
respiration rates compared to WT VSMCs (Figure 8A and C).
Figure 8. DKO VSMCs show a reduced maximum OCR. 
In basal conditions, DKO and WT VSMCs do not differ in OCR, while treatment with FCCP results in a 
decreased maximum OCR of DKO VSMCs. Data represents 2 independent cell lines per genotype measured 
in 3 technical replicates. The data points represent average values of an independent cell line per experiment. 
Results are depicted as mean ± SD. ** p ≤ 0.01.
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DISCUSSION
Arterial tortuosity may occur in both innate and acquired vasculopathies, such as persistent 
hypertension and neoangiogenesis, and may associate with an increased vascular risk, 
including aneurysm formation and blood vessel rupture. Monogenic conditions may be helpful 
in delineating the underlying pathophysiology of altered vascular patterning. In this study, we 
developed and characterized a novel mouse model for ATS, since the previously reported 
mouse models for ATS failed to recapitulate the major hallmarks of the human disease [22, 23]. 
Our model addressed two concerns regarding the previous models. Firstly, we developed an 
Slc2a10 knock-out, which abolishes GLUT10 function while the previously reported missense 
mutations were only predicted to be pathogenic [22, 23]. Secondly, we impaired AA synthesis 
in our model by disrupting the Gulo gene, aiming to mimic the physiological conditions in 
human more reliably. Indeed, Gulo encodes L‐gulonolactone oxidase, an endoplasmic reticulum 
membrane-bound enzyme that catalyzes the last step in the vitamin C biosynthesis pathway 
[26]. It became mutated in many species, such as teleost fishes, guinea pigs and anthropoid 
primates, including humans, making these species unable to synthesize vitamin C and rely on 
its dietary uptake [27]. Vitamin C plays an essential role as an anti-oxidant and in collagen 
synthesis. Since recent evidence indicates that GLUT10 function may include transport of DHA 
into subcellular compartments [14, 17, 24], it could be hypothesized that murine developmental 
processes do not suffer from Slc2a10 mutations and localized vitamin C hypovitaminosis, which 
would explain the absence of a relevant phenotype in Slc2a10 mutant mice [16, 23]. 
Nevertheless, in this study, we only observed mild cardiovascular manifestations in the double 
knock-out ATS mouse model. Ultrasound-guided characterization revealed a subtle stenosis 
from the proximal ascending aorta to the descending aorta in DKO mice, but only statistically 
significant when compared with their wild type littermates. Moreover, the reduced weight in the 
double knock-out mice further questions the biological relevance of these results.
Histopathology of ATS patient vascular tissue invariably shows substantial fragmentation of the 
elastic laminae in the tunica media [1] while conversely the previously described Glut10G128E 
mouse model mainly presented with increased arterial wall thickness, most prominent at the 
age of 15 months [22, 24]. Our model only reveals mild elastic fiber anomalies in all genotypes, 
that are likely age-related changes. Nevertheless, dermal collagen histology revealed patches of 
increased collagen deposition in female DKO mice, which has also been observed in skin tissue 
of ATS patients [1], and might contribute to their ‘doughy’ skin characteristics. Ultrastructural 
analysis of skin tissue of double knock-out mice additionally revealed collagen fiber diameter 
alterations in DKO mice, but did not reveal major defective elastin deposition, which contrasts 
with TEM observations in ATS patients [1]. 
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The observed mild phenotypic abnormalities seem to be more pronounced in female mice, 
suggesting a sex discrepancy, even for nulliparous mice. Influences of sex in connective tissue 
homeostasis and disease have been previously recognized. However, most studies indicate that 
male mouse models for connective tissue disorders show more severe phenotypes than female 
mice [28-31], which contrasts with our study.
Despite the absence of a major clinical or histological phenotype, we did identify defective 
ECM deposition in cultured VSMCs of DKO mice. Ascorbic acid is a cofactor for cross-linking 
enzymes such as lysyl oxidase and lysyl oxidase-like enzymes. Hence, it is not surprising that 
elastin and collagen assembly are primarily affected. Nevertheless, our observations also 
indicate reduced deposition of the early stage fibril forming networks including the fibronectin 
and fibrillin-1 microfibrillar scaffolds. This reflects an earlier observation that in the absence of 
ascorbic acid, not only deposition of collagen, but also of fibronectin is greatly reduced [32]. 
Indeed, collagen I fibers interact preferentially with relaxed (but in a lesser extent to stretched) 
fibronectin fibers [32] and  collagen 1  increases fibronectin deposition [33]. Therefore, ECM 
assembly cannot be seen as a consequential process but rather as an interactive and growing 
mechano-sensing network of components. Similarly, fibulin-4, -5 deposition was clearly reduced, 
while LTBP4 deposition was only slightly affected. Though further experimentation is necessary, 
we hypothesize that latent TGFβ-binding proteins (LTBPs) might be upregulated due their primary 
role in elastogenesis [34]. Our results are in line with findings by Zoppi et al., who previously 
showed ECM disarray in skin fibroblasts of ATS patients [12]. In addition, a recent study revealed 
an abnormal microfibrillar scaffold and incomplete elastic core assembly in skin samples of ATS 
patients [1], that likely reflect defective ECM assembly at multiple levels, as shown in our model. 
Since defective ECM assembly is often associated with vascular phenotypes [35, 36], this might 
indicate that mice may rely on other mechanisms that overcome the deleterious defects of 
abnormal ECM assembly. 
In several aneurysm syndromes, dysregulation of the canonical TGFβ signaling pathway is at 
play in aneurysm formation [37, 38]. However, while we observed ECM abnormalities, DKO 
VSMCs do not show altered phosphorylation of Smad2 upon TGFβ stimulation over time as well 
as under basal, unstimulated, conditions. An initial report indicated a prolonged signal increase 
for downstream readouts of TGFβ signalling in arterial tissue of (one) ATS patient [3]. This finding 
remained unconfirmed on both fibroblast cultures [12], skin or artery tissue [1] in an extended 
number of patients. A role for non-canonical αvβ3 integrin-mediated TGFβ signalling in the ATS 
pathomechanisms has been suggested [12]. Our results add to the uncertainty regarding the 
role of TGFβ signalling in the pathomechanisms underlying many elastic fiber diseases, but 
cannot account for a possible contribution of spatiotemporal regulation of TGFβ signalling.
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A number of studies have pointed towards a key role for oxidative stress in ATS pathogenesis. 
For instance, GLUT10 has been identified as a mitochondrial DHA transporter, and it was shown 
that increased mitochondrial targeting of GLUT10 and associated increased mitochondrial 
DHA uptake was triggered by stress and aging conditions [14, 24]. In a morpholino slc2a10 
knockdown zebrafish model, altered OCR and differential gene expression analysis showed 
involvement in oxidative signalling [21]. In the Glut10G128E mouse model, Syu and coworkers 
similarly identified a decreased maximum OCR in early passage Glut10G128E VSMCs [24]. In 
this study, we compared basal and maximal OCR in VSMCs of double knock-out and control 
mice and identified a normal basal OCR in DKO VSMCs. However, following treatment with 
FCCP, a decreased maximum OCR could be observed in DKO VSMCs, compared to WT. Since 
basal OCR was comparable in DKO and WT VSMCs, the need for a stressor to dysregulate 
mitochondrial function in DKO VSMCs could explain the reduced maximum OCR after FCCP 
treatment. However, it has been suggested that an aberrant maximal OCR only corresponds to 
the initial symptoms of mitochondrial dysfunction caused by SLC2A10 mutations, due to reactive 
oxygen species (ROS) that trigger arterial wall remodeling. In its turn, this leads to additional 
ROS production, and disease progression promotes further decline in mitochondrial function. It 
is also plausible that mitochondrial dysfunction is a more ubiquitous phenomenon associated 
with aneurysmal disease. Van der Pluijm et al. investigated mitochondrial function in Fibulin-4R/R 
and Tgfbr-1M318R/+ mouse VSMCs and found decreased mitochondrial respiration in these mouse 
models. In addition, skin fibroblasts of aneurysmal patients with FBN1, TGFBR2 or SMAD3 
mutations revealed mitochondrial dysfunction as well [25]. 
Finally, due to the mild nature and low abundance of relevant phenotypic alterations, it could 
be argued that this novel ATS double knock-out mouse model does not appear to be a suitable 
disease model to study the pathomechanisms underlying ATS [22, 23]. While the lack of a severe 
phenotype could be attributed to the genetic background of the used mouse strains, possibly 
hindering phenotypic penetrance [39], the underlying cause could also be biological robustness. 
This is a phenomenon by which the functionality of the mutated gene is maintained by increased 
expression of related genes [40, 41], as was demonstrated earlier in a number of other mouse 
disease models [42, 43]. One mechanism of biological robustness is transcriptional adaptation 
[44, 45]. This mechanism is triggered by mRNA degradation products and is believed to act via 
sequence similarity [46, 47]. Since Slc2a10 is a member of a large family of facilitative glucose 
transporter proteins harboring a high sequence similarity, this mechanism is plausible [48]. It could 
also be argued that an extensive dose (60 mg/kg body weight) of ascorbic may have masked 
the development of a relevant phenotype, since this dose exceeds the daily recommended dose 
in human (1 mg/kg body weight) extensively. However, species differences might complicate 
the direct comparison or extrapolation of the optimal daily dose between mouse and human. A 
daily ascorbic acid dose of 1mg/kg body weight corresponds in human to plasma ascorbic acid 
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levels of 25 µM respectively. To reach comparable levels in mouse plasma, a significantly higher 
dose (80 mg/kg body weight) needs to be administered [49].
Nevertheless, the current double knock-out mouse model could be of importance in revealing 
redundant gene networks, alternative pathways or modifier genes, possibly providing clues for 
future therapies. Moreover, since isolated VSMCs of double knock-out mice mimicked cellular 
disturbances found in cell cultures of ATS patients, these VSMCs could potentially be used 
for further identification of the molecular mechanisms that underlie ATS, while analyses at the 
histological level may reveal adaptive mechanisms that contribute to the phenotypic rescue. 
In conclusion, we developed a novel mouse model for ATS, double knock-out for Gulo and 
Slc2a10. While our model does not phenocopy human ATS, it did reveal alterations at the cellular 
level including disturbed ECM assembly and altered cellular respiration. Our model confirms a 
role for ascorbate synthesis and compartmentalization in the disease mechanisms leading to 
ATS and may be helpful to identify the mechanisms underlying the phenotypic rescue in mice.
MATERIALS & METHODS 
Animals
Heterozygous knock-out mice for Slc2a10, in which a selection cassette replaces a sequence 
ranging from exon 2 to the beginning of exon 5, were purchased from Taconic Biosciences 
(cat. nr. TF2438), (Supplementary Figure 1A). The mutation resides in a mixed 129/SvEv-
C57BL/6 genetic background. Heterozygous knock-out mice for Gulo, in which a selection 
cassette replaces exons 3 and 4, were purchased from MMRRC (RRID MMRRC_000015-UCD) 
(Supplementary Figure 1A). This mouse line, residing in a mixed 129/SvEv-C57BL/6 genetic 
background as well, was previously described by Maeda and colleagues [49]. The two lines 
were crossed according to a breeding scheme depicted in Supplementary Figure 1B. To allow 
for valid data generation and to take into account any potential influence of genetic background, 
all comparisons were made between littermates from the F2 generation. Male and female mice 
of the following genotypes were studied: double knock-out (DKO – Gulo tm1mae/ tm1mae;Slc2a10 -/-), 
single knock-out (Gulo KO – Gulo tm1mae/ tm1mae;Slc2a10 +/+ and Slc2a10 KO – Gulo +/+;Slc2a10 -/-) 
and wild type (WT – Gulo +/+;Slc2a10 +/+). All procedures were conducted in compliance with the 
European Parliament Directive 2010/63/EU, and with the approval of the Ghent University ethical 
committee on animal experiments (Permit Number: ECD 13/17). All animals were fed ad libitum 
with a standard mouse breeding feed, supplemented with 300 mg/kg ascorbic acid (Ssniff® 
Spezialdiäten). The administered ascorbic acid dose is based on an average food intake of 4 g/
day, for a mouse with an average weight of 20 g. This dose translates to a daily dose of 60 mg/
kg body weight, which is comparable to the average administered ascorbic acid dose of the first 
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report on this model (110 mg/kg), by Maeda et al. [49]. Mice were maintained in a fully controlled 
animal facility (12:12 h light:dark cycle at ± 22 °C).
Genotyping
Seven-day-old mice were toe-clipped, after which genomic DNA was prepared from the tissue 
using the KAPA Express Extract DNA Extraction Kit (Kapa Biosystems, cat. nr. KK7103). For both 
Gulo and Slc2a10 the DNA was PCR-amplified using specific primers detecting the wild type and 
mutant alleles. The genotype was determined based on PCR product presence and band size 
(Supplementary Table 1). 
Quantitative real-time PCR
Skin and aortic tissue from 3 male and 3 female mice of each selected genotype were harvested 
at the age of 9 months and submerged in RNAlater™ Stabilization Solution (Thermo Fisher 
Scientific, cat. nr. AM7020) prior to the RNA extraction procedure, carried out with the RNeasy® 
Mini kit (Qiagen, cat. nr. 74106). Next, cDNA synthesis was performed using the iScript cDNA 
synthesis kit (Bio-Rad, cat. nr. 1708891). RT-qPCR reactions were carried out in quadruple on an 
LC480 machine (Roche). The reaction mix consisted of cDNA, LightCycler® 1536 DNA Probes 
Master (Roche, cat. nr. 05502381001), LightCycler® 480 High Resolution Melting Dye (Roche, 
cat. nr. 04909640001) and specific primers amplifying the Slc2a10 transcript or Expressed Repeat 
Elements (EREs) (Supplementary Table 2) [50], to which all reactions were normalized. Data 
analysis was carried out with qBase+ (Biogazelle). Values plotted correspond to the means of 
3 male and 3 female biological replicates. Error bars shown represent 95% confidence intervals. 
Data were analyzed using Welch’s ANOVA, followed by a Games-Howell post-hoc test.
In vivo imaging
Serial ultrasound imaging was performed using a dedicated ultrasound apparatus (Vevo 2100, 
VisualSonics), equipped with a high-frequency linear array transducer (MS 550D, frequency 
22–55 MHz). Imaging was carried out on mice of 6 weeks, 3, 6 and 9 months old. Ten male 
and 10 female mice of the selected genotypes were studied. The mice were anesthetized with 
1.5% isoflurane mixed with 0.5 L/min 100% O2. Body temperature was maintained at 37°C, 
by placing the mice on a heating pad. Artery and cardiac measurements were carried out in 
concordance with previously established guidelines [51]. In short, the diameter measurements 
of the aorta at the level of the aortic root, proximal ascending aorta, distal ascending aorta, 
aortic arch and descending aorta were performed, next to diameter measurements of the 
carotid arteries and cardiac assessment. Three cardiac cycles for each animal were analyzed 
(VevoLAB 1.7.0, VisualSonics). For each measurement location, a linear mixed model with 
covariance pattern modelling was fitted to account for correlated responses (diameters) within 
the same subject. Genotype, age and sex were considered as categorical explanatory variables. 
Starting from a saturated mean model with unstructured covariance matrix and using residual 
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maximum likelihood (REML), the covariance model was simplified by comparison with simpler 
structures through Akaike’s Information Criterion. The following covariance matrices that were 
as parsimonious as possible, were selected: unstructured (aortic root), autoregressive (proximal 
ascending aorta), Toeplitz (distal ascending aorta), compound symmetry (all other measurement 
locations). Afterwards, the fixed part of the model was simplified by testing simpler models using 
maximum likelihood. All final models included the main effects of genotype, age, and sex without 
interaction terms and were refitted with REML. Values plotted correspond to the means of ±10 
biological replicates. Error bars shown represent 95% confidence intervals.
Vascular corrosion casting
The vascular corrosion casting technique, based on the injection of a polymer to capture the 
3D structure of the vasculature, was performed on 3 male and 3 female mice of each selected 
genotype at the age of 9 months as previously described [23]. Briefly, 2 to 3 ml Batson’s solution 
(Polysciences, Batson’s #17 corrosion kit) was retrogradely injected in the abdominal aorta 
through a 26G catheter. After completion of the polymerization reaction, mouse bodies were 
macerated overnight in a 25% KOH solution. The resulting casts were cleaned, evaluated and 
photographed using a dissecting microscope, equipped with a 5-megapixel camera (Leica). 
Histology
From 3 male and 3 female mice of each selected genotype, skin and aorta (9-month-old 
animals) and ocular tissue (3-week-old mice) were collected for histological analysis. Samples 
were formalin-fixed and paraffin-embedded, after which 5 µm-thick paraffin sections were made. 
Sections were subjected to the standard Verhoeff-Van Gieson (VVG) and picrosirius red (PR) 
histological staining procedures, prior to visualization on a Zeiss Axio Observer Z1 microscope. 
Transmission Electron Microscopy 
Sample fixation was carried out in a 4% formaldehyde (EM grade), 2.5% glutaraldehyde (EM 
grade), 0.1M cacodylate buffer solution. Samples were  placed in a vacuum oven for 30 min and 
left rotating for 3 hours at room temperature. This solution was later replaced with fresh fixative 
and samples were left rotating over night at 4 °C. After washing, samples were post-fixed in 1% 
OsO4 with K3Fe(CN)6 in 0.1 M NaCacodylate buffer, pH 7.2. After washing in double-distilled 
H2O, samples were subsequently dehydrated through a graded ethanol series, including bulk 
staining with 2% uranyl acetate at the 50% ethanol step, followed by embedding in Spurr’s resin. 
To select the area of interest on the block and in order to have an overview of the phenotype, 
semi-thin sections were first cut at 0.5 µm and stained with toluidine blue. Ultrathin sections of 
a gold interference color were cut using an ultramicrotome (Leica EM UC6, Wetzlar, Germany), 
followed by post-staining in a Leica EM AC20 for 40 min in uranyl acetate at 20 °C and for 10 min 
in lead stain at 20 °C. Sections were collected on formvar-coated copper slot grids. Grids were 
viewed with a JEM 1400plus transmission electron microscope (JEOL, Tokyo, Japan) operating 
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at 80 kV.  Collagen diameter measurements were carried out with Fiji [52]. Error bars shown 
represent 95% confidence intervals. Data were analyzed with a two-tailed t-test. Error bars shown 
represent 95% confidence intervals.
Vascular smooth muscle cell isolation and cell culture
Mice (at an age of 25 days) were euthanized (CO2) and autopsied according to standard 
protocols. Primary VSMCs from the thoracic aorta were isolated according to the collagenase 
digestion method of Proudfoot and Shanahan [53]. Each cell line was derived from a single 
aorta. Primary VSMCs were cultured on gelatinized dishes in SmBM medium supplemented 
with the SmGM-2 kit (Lonza, cat. nr. CC-3182). Unless otherwise specified, two cell lines per 
genotype were assessed.
Immunofluorescence of extracellular matrix
ECM protein production by VSMCs was determined by immunofluorescence. VSMCs were 
seeded at 50,000 cells/well in 8-well removable chamber slides and grown for 7 days to allow 
ECM deposition. VSMCs were fixed with an ice-cold 70:30 methanol:acetone mixture for 5 
minutes and washed with PBS. Coverslips were blocked for 1 hour with PBS supplemented 
with 10% normal goat serum (Agilent, cat. nr. X0907). Primary antibodies (Supplementary Table 
3) were incubated overnight at 4°C in PBS. Coverslips were washed three times with PBS for 5 
minutes each prior to incubation with the secondary antibody for 1.5 hours at room temperature 
(Molecular Probes, anti-rabbit Alexa Fluor 594, 1:1,000). Coverslips were washed and mounted 
to glass slides with Vectashield supplemented with DAPI (Vector laboratories, cat. nr. H-1200) 
and sealed with nail polish. Images were recorded on a wide field epifluorescent microscope 
(Axio Imager D2, Zeiss). Quantification of the immunofluorescent signal was performed by 
calculating the corrected total cell fluorescence (CTCF) of the ECM components corrected for 
the number of nuclei. The CTCF was determined by setting a color threshold to select the fibers 
in the image with Fiji image analyzing software [52] and determining the integrated density of 
this area (intensity of the fluorescence). This measurement was corrected for the background 
fluorescence and the total area of the fibers and results in the CTCF. The CTCF was then divided 
by the number of nuclei that were present in the measured image. Data were corrected for 
outliers with the Grubbs’ test for outliers [54]. Statistical analysis was performed with a non-
parametric Mann-Whitney test. Significance was tested 2-tailed. Results are expressed as mean 
± SD.
TGFβ stimulation 
VSMCs were seeded in 6-well plates to reach confluence and were allowed to attach for 24 
hours. The following day, medium was changed to SmGM-2 medium without fetal calf serum 
and VSMCs were serum deprived for 24 hours prior to TGFβ stimulation. Protein samples were 
collected after 0 minutes, 15 minutes, 30 minutes, 1 hour and 4 hours of stimulation with TGFβ1 
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(Biovision, cat. nr. 4342-5). Cells were scraped in PBS supplemented with protease inhibitor 
cocktail (Roche applied science, cat. nr. 11836145001, 1:100) and phosphatase inhibitor cocktail 
(Sigma, cat. nr. P0044, 1:100) and lysed in an equal volume of 2x Laemmli buffer (4% SDS, 20% 
glycerol, 120mM Tris pH 6,8) supplemented with protease inhibitor cocktail and phosphatase 
inhibitor. Lysates were first cleared from large DNA by passing through a 25G needle and then 
heated to 65°C for 10 minutes. Protein concentrations were measured with the Lowry protein 
assay as previously described [55]. Equal amounts of protein were separated for size by SDS-
PAGE and then transferred to a PVDF membrane (1 hour, 100V, Immobilon) and blocked with 3% 
milk in PBS supplemented with 0.1% Tween-20 (1 hour, room temperature). The primary antibody 
was incubated for 45 minutes at room temperature or overnight at 4°C for phosphorylated 
Smad2 (see Supplementary Table 3 for primary antibodies). The membranes were washed 5 
times with 0.1% Tween-20 in PBS and then incubated with horseradish peroxidase-conjugated 
secondary antibodies (Jackson ImmunoResearch, 1:2,000) for 1 hour at room temperature. 
Bound secondary antibodies were detected with an Amersham Imager 600 (GE Healthcare Life 
Sciences) using chemiluminescence. Band intensity was quantified using Fiji image analyzing 
software [52]. Data were corrected for outliers with the Grubbs’ test for outliers [54]. Statistical 
analysis was performed with a non-parametric Mann-Whitney test. Significance was tested 
2-tailed. Results are expressed as mean ± SD.
Mitochondrial respiration
Oxygen consumption rate was measured using an XF-24 Extracellular Flux Analyzer (Seahorse 
Bioscience). Respiration was measured in XF assay media (non-buffered DMEM), in basal 
conditions and in response to 1 µM oligomycin (ATP synthase inhibitor), 1 µM fluoro-carbonyl 
cyanide phenylhydrazone (FCCP, uncoupler), 1 µM antimycin A (complex III inhibitor). Smooth 
muscle cells were seeded at a density of 30,000 cells/well and analyzed after 24 hours. Optimal 
cell densities were determined experimentally to ensure a proportional response to FCCP with 
cell number. For these experiments 6-8 wells were measured per time point [56, 57]. Data were 
corrected for outliers with the Grubbs’ test for outliers [54]. Statistical analysis was performed with 
a non-parametric Mann-Whitney test. Significance was tested 2-tailed. Results are expressed as 
mean ± SD.
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Supplementary figure 1. Genetics of the novel ATS mouse model, deficient for both GLUT10 and GULO. 
A) Mutation image of the mouse models employed in this study. The Slc2a10 constitutive knock-out model 
harbors a LacZ/Neo selection cassette replacing a sequence ranging from exon 2 to beginning of exon 5, 
oriented in the same transcriptional orientation than the Slc2a10 gene (indicated by a black arrow). The Gulo 
constitutive knock-out model harbors a Neo selection cassette replacing a sequence comprising exon 3 and 
4, oriented in the opposite transcriptional orientation than the Gulo gene (indicated by a black arrow). B) 
Breeding scheme executed in this study. Mice, mutant for either Slc2a10 (F0: aaBB) or Gulo (F0: AAbb) were 
crossed with each other to obtain mice heterozygous for both genes (F1). Crossing in these mice can result 
in pups with 9 different genotypes. Four genotypes were selected for further study: WT (Gulo +/+;Slc2a10 
+/+ - black), Gulo KO (Gulo tm1mae/ tm1mae;Slc2a10 +/+ - black dashed), Slc2a10 KO (Gulo +/+;Slc2a10 -/- - grey 
dashed) and DKO (Gulo tm1mae/ tm1mae;Slc2a10 -/- - grey).
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Supplementary Figure 2: Mouse body weight. 
Values plotted correspond to the means of 10 biological replicates. Error bars shown represent 95% 
confidence intervals. Data were analyzed using one-way ANOVA, followed by a Tukey post-hoc test.  *: p ≤ 
0.05, M: male, F: female
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Supplementary Figure 3. Serial ultrasound measurements obtained at 6 weeks, 3, 6 and 9 months of 
age at the descending aorta and carotids. 
Left and right column images represent data obtained in male and female animals respectively. Shown 
p-values were obtained using a linear mixed model with covariance pattern modeling, without interactions. 
As a result, p-values should be interpreted when making the comparison for a given age and sex. Error bars 
shown represent 95% confidence intervals. *: p ≤ 0.05, M: male, F: female
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Supplementary Figure 4. Cardiac parameters indicative for left ventricular function at 6 weeks and 3 
months of age. 
Error bars shown represent 95% confidence intervals. FS: fractional shortening. E/A: ratio of the early (E) to 
late (A) ventricular filling velocities. M: male, F: female
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Supplementary Figure 5. Vascular corrosion casts of WT, Gulo KO, Slc2a10 KO and DKO male mice. 
Representative images of the aortic arch and its side branches, the circle of Willis and the eye arterioles are 
shown. 
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Supplementary Figure 6. Histological analysis of WT, Gulo KO, Slc2a10 KO and DKO male mice.  
Picrosirius red (PR) polarization staining (upper row) for collagen does not reveal abnormal collagen 
deposition in the skin of Gulo tm1mae/ tm1mae;Slc2a10 -/- mice. Verhoeff-Van Gieson (VVG) elastic fiber staining 
(middle row) shows mild elastic fiber anomalies in the aortic wall of all studied mice (black arrows). 
Supplementary Figure 7. Transmission electron microscopy of elastic fibers in a skin biopsy. 
DKO mice do not show an altered elastic fiber assembly, compared to WT mice. TS: collagen transverse 
section, LtS: collagen longitudinal section, EF: elastic core, MF: microfibrils. Scale bar: 1.0 µm.  
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Supplementary Figure 8. Quantification of total cell fluorescence of the ECM components corrected for 
the number of nuclei for the graphs, displayed in Figure 6. 
Results are expressed as mean ± SD. *: p ≤ 0.05.
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Supplementary tables
Supplementary Table 1: PCR genotyping primers and products 
Slc2a10
Wild type-specific product Mutation-specific product
Forward (5’-3’) CCTTGTCGGGGGCTTCCTCATTG Forward (5’-3’) GCAGCGCATCGCCTTCTATC
Reverse (5’-3’) CACCAGCCCCAGCCCCACTACAG Reverse (5’-3’) CCTCAGAGTCTCACACTCAA
Wild-type Band 532 bp Wild-type Band none 
Mutant band  none Mutant band 325 bp
Gulo
PCR with 3 primers
Primer 1 (5’-3’) CGCGCCTTAATTAAGGATCC
Primer 2 (5’-3’) GTCGTGACAGAATGTCTTGC
Primer 3 (5’-3’) CCCAGTGACTAAGGATAAGC
Wild-type Band 343 bp
Mutant band 230 bp




ERE 1 – Rltr10b2
Forward (5’-3’) CCAATCCGGGTGTGAGACA
Reverse (5’-3’) CTGACTCGCCAGCAAGAAC





Supplementary Table 3: Antibodies 
Primary antibody Predicted kDa Dilution Manufacturer Cat. nr. 
Rabbit α-Fibronectin IgG - 1:80 Millipore AB2033
Rabbit α-mouse Fibrillin-1 - 1:1,000 Generated in Reinhardt Lab -
Rabbit α-mouse Tropo-elastin - 1:500 Generated in Reinhardt Lab -
Rabbit α-mouse Fibulin-4 - 1:500 Generated in Reinhardt Lab -
Rabbit α-mouse Fibulin-5 - 1:500 Generated in Reinhardt Lab -
Rabbit α-mouse LTBP-4 - 1:500 Generated in Reinhardt Lab -
Rabbit α-SMAD2 IgG 60 1:1000 Cell signaling 5339S
Rabbit α-pSMAD2 IgG 55-60 1:400 Merck Millipore 04-953
Mouse α-β catenin IgG1 92 1:2000 BD Bioscience 610153
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Fibulin-4 is an extracellular matrix (ECM) protein essential for elastogenesis and mutations 
in this protein lead to aneurysm formation. In this study, we isolated vascular smooth muscle 
cells (VSMCs) from mice with reduced Fibulin-4 protein expression (Fibulin-4R/R) and from 
mice with a smooth muscle cell specific deletion of the Fibulin-4 gene (Fibulin-4f/-/SM22Cre+). 
We subsequently analyzed and compared the molecular consequences of reduced Fibulin-4 
expression versus total ablation of Fibulin-4 expression with regard to effects on the SMC specific 
contractile machinery, cellular migration and TGFβ signaling. 
Analysis of the cytoskeleton showed that while Fibulin-4f/-/SM22Cre+ VSMCs lack smooth muscle 
actin (SMA) fibers, Fibulin-4R/R VSMCs were able to form SMA fibers. Furthermore, Fibulin-4f/-/
SM22Cre+ VSMCs showed a decreased pCofilin to Cofilin ratio, suggesting increased actin 
depolymerization, while Fibulin-4R/R VSMCs did not display this decrease. Yet, both Fibulin-4 
mutant VSMCs showed decreased migration. We found increased activation of TGFβ signaling 
in Fibulin-4R/R VSMCs. However, TGFβ signaling was not increased in Fibulin-4f/-/SM22Cre+ 
VSMCs. 
From these results we conclude that both reduction and absence of Fibulin-4 leads to structural 
and functional impairment of the SMA cytoskeleton. However, while reduced levels of Fibulin-4 
result in increased TGFβ activation, complete absence of Fibulin-4 does not result in increased 
TGFβ activation. Since both mouse models show thoracic aortic aneurysm formation, we 
conclude that not only hampered TGFβ signaling, but also SMA cytoskeleton dynamics play an 
important role in aortic aneurysmal disease. 
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INTRODUCTION
Aortic aneurysms are dilations of the aorta caused by a general weakening of the aortic wall. 
Patients affected by such dilations have a high risk of mortality upon rupture. Approximately 
1-2% of all deaths in the western world are caused by aortic aneurysms and dissections [1]. 
The aortic wall consists of three layers, the intima, the media and the adventitia. The medial 
layer of the aortic wall contains the elastic laminae interspaced by vascular smooth muscle 
cells (VSMCs) and is important for the elasticity and contractility of the ascending aorta. During 
aneurysm formation the medial layer of the aorta is characterized by elastin layer fragmentation, 
loss of VSMCs and deposition of excess of extracellular matrix (ECM) material. These processes 
weaken the aortic wall and increase the risk of rupture [1, 2].
Multiple genes have been identified to cause aneurysm formation when mutated. Mutations 
in the extracellular matrix protein fibrillin-1 (FBN1) lead to Marfan syndrome [3]. Mutations in 
proteins implicated in TGFβ signaling, such as TGFβ receptor 1 and 2 (TGFβR1 and TGFβR2) 
as well as SMAD3, lead to Loeys-Dietz syndrome characterized by aneurysm formation [4-8]. In 
addition, contractile or cytoskeletal protein mutations, such as α-smooth muscle actin (ACTA2) 
and myosin heavy chain 11 (MYH11) have been identified as causal genes for aneurysm 
formation [9-12]. Although these proteins are localized in different topological compartments, 
they most likely cooperate at a mechanistic molecular level and collectively play a role in 
aneurysm formation. We hypothesize that reduced presence or complete absence of the 
extracellular matrix protein Fibulin-4 could influence cytoskeleton structure and dynamics since 
cell-ECM contact is mediated by transmembrane cell adhesion receptors, such as integrins, that 
interact with extracellular matrix proteins as well as a number of cytoplasmic adaptor proteins 
that interact with the actin cytoskeleton or function in signal transduction.
Fibulin-4 is an ECM protein that is essential for elastogenesis and is responsible for the recruitment 
of lysyl oxidase [13]. Lysyl oxidase is required for proper crosslinking of the elastin precursor 
tropoelastin to form mature elastic laminae [14]. These elastic laminae are of importance for 
the elasticity of the aorta and for deposition of latent TGFβ complexes [15]. When Fibulin-4 is 
absent or unable to recruit lysyl oxidase, tropoelastin is not properly crosslinked. This leads to 
irregular elastic laminae that have a fragmented appearance [16]. EFEMP2 (Fibulin-4) mutations 
in patients lead to cutis laxa, an autosomal recessive disease that is characterized by non-elastic 
and loose skin, aneurysms and tortuosity of the large arteries [17-19]. Cutis laxa patients have 
either reduced Fibulin-4 protein levels in tissues, or reduced binding of Fibulin-4 to its targets. 
Furthermore, increased TGFβ signaling is detected in these patients [17, 20].
Different mouse models have been generated to investigate the role of Fibulin-4 in aneurysm 
formation. While complete absence of Fibulin-4 is perinatal lethal, hypomorphic mice with 4-fold 
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reduced expression levels (Fibulin-4R/R, in which ‘R’ indicates the reduced expression allele) 
are viable [21, 22]. Like cutis laxa patients, Fibulin-4R/R mice show aortic aneurysm formation, 
elastic laminae fragmentation and increased TGFβ signaling [22, 23]. In addition, VSMC-specific 
knock-out mice for Fibulin-4 (Fibulin-4f/-/SM22Cre+) also develop aneurysms exclusively in the 
ascending aorta [24]. This mouse model has previously been used to determine the role of 
Fibulin-4 in aortic development, and is instrumental to determine the role of Fibulin-4 in aneurysm 
formation and VSMC function. 
In this study we compared VSMCs isolated from aortas of Fibulin-4R/R and Fibulin-4f/-/SM22Cre+ 
mice to analyze the consequences of diminished and completely ablated Fibulin-4 expression 
on cytoskeleton dynamics, cell movement and TGFβ signaling.
MATERIALS AND METHODS
Mice 
Fibulin-4R/R and Fibulin-4f/-/SM22Cre+ were generated and described previously [22, 24]. 
Animals were housed at the Animal Resource Centre (Erasmus University Medical Centre), 
which operates in compliance with the “Animal Welfare Act” of the Dutch government, using 
the “Guide for the Care and Use of Laboratory Animals” as its standard. As required by Dutch 
law, formal permission to generate and use genetically modified animals was obtained from the 
responsible local and national authorities. An independent Animal Ethics Committee consulted 
by Erasmus Medical Center (Stichting DEC Consult) approved these studies (permit number 
140-12-05), in accordance with national and international guidelines. Animals were sacrificed 
by CO2 inhalation, unless stated otherwise. This study conforms to the guidelines from Directive 
2010/63/EU of the European Parliament on the protection of animals used for scientific purposes 
or the NIH guidelines. 
VSMC isolation and cell culture
Mice (at an age of 100 days) were euthanized and autopsied according to standard protocols. 
Primary VSMCs from the thoracic aorta were isolated according to the collagenase digestion 
method of Proudfoot and Shanahan [25]. Each cell line was derived from a single aorta. 
Fibulin-4+/+ and Fibulin-4f/+/SM22Cre+ VSMCs were used as controls, in which Fibulin-4f/+/
SM22Cre+ VSMCs also served as controls for the potential toxic effects of Cre recombinase. 
Due to differences in the genetic background of the mice (Fibulin-4+/+ and Fibulin-4R/R: C57Bl/6, 
Fibulin-4f/+/SM22Cre+ and Fibulin-4f/-/SM22Cre+: C57Bl/6 and SJL), Fibulin-4f/+/SM22Cre+ 
VSMCs will be used as a primary control for Fibulin-4f/-/SM22Cre+ VSMCs. Fibulin-4f/+/SM22Cre+ 
VSMCs show a decrease in Fibulin-4 expression compared to Fibulin-4+/+ VSMCs (Fig 1A), due 
to the deletion of one floxed allele by Cre recombinase. When experiments were performed 
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simultaneously, we depicted all four genotypes (Fibulin-4+/+, Fibulin-4R/R, Fibulin-4f/+/SM22Cre+ 
and Fibulin-4f/-/SM22Cre+) together. In the figures, Fibulin-4f/+/SM22Cre+ and Fibulin-4f/-/
SM22Cre+ VSMCs are referred to as Fibulin-4f/+ and Fibulin-4f/-, respectively. Unless otherwise 
specified two cell lines were used per genotype. Primary VSMCs were cultured on gelatinized 
dishes in Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza BioWhittaker) supplemented 
with 1% penicillin-streptomycin (PS) and 10% fetal calf serum (FCS).
RNA isolation and real-time PCR
RNA from VSMCs was isolated with the RNeasy mini kit (Qiagen). cDNA was made with iScript 
cDNA synthesis kit (Biorad) according to manufacturing protocol. Q-PCR was performed with 
200 nM forward and reverse primers and iQTM SYBR® Green Supermix (Biorad) on the CFX96 
system (Biorad); denaturation at 95°C for 3min, 40 cycles denaturation at 95°C for 15 s, annealing/
extension at 55°C for 30 s. B2M and β-actin were used as reference genes and gave similar 
expression. Data is shown with B2M as a reference gene. Relative gene expression levels were 
determined with the comparative Ct (also referred to as ΔΔCt) method according to the MIQE 
guidelines. See Table 1 for primers used. Number of replicates is specified in the figure legends.
Table 1. Primer sequences used for real-time PCR





Western blot analysis was performed to determine protein amounts in extracts of Fibulin-4f/-/
SM22Cre+ and Fibulin-4R/R VSMCs compared to their controls. Cultured VSMCs were scraped 
in PBS supplemented with protease inhibitor cocktail (1:100, 11836145001, Roche applied 
science) and phosphatase inhibitor cocktail (1:100, P0044, Sigma) and lysed in an equal 
volume of 2x Laemmli buffer (4% SDS, 20% glycerol, 120mM Tris pH 6,8) supplemented with 
protease inhibitor cocktail and phosphatase inhibitor. Lysates were first cleared from large 
DNA by passing through a 25G needle and then heated to 65°C for 10 minutes. Protein 
concentrations were measured with the Lowry protein assay as described [26]. Equal amounts 
of protein (10ug per sample) were separated for size by SDS-PAGE and then transferred to 
a PVDF membrane (1 hour, 100V, Immobilon) and blocked with either 3% milk or 5% BSA in 
PBS supplemented with 0.1% Tween-20 (1 hour, room temperature). The primary antibody was 
incubated overnight at 4°C (see Table 2 for primary antibodies). The membranes were washed 
5 times with 0.1% Tween-20 in PBS and then incubated with horseradish peroxidase-conjugated 
secondary antibodies (1:2,000, Jackson ImmunoResearch) for 1 hour at room temperature. 
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Bound secondary antibodies were detected with an Amersham Imager 600 (GE Healthcare Life 
Sciences) using chemiluminescence. Band intensity was quantified using Fiji image analyzing 
software [27]. Number of replicates is specified in the figure legends.
Table 2. Antibodies used for Western blot analysis.
Primary antibody Predicted kDa Dilution Manufacturer Catalog number 
Mouse α-β actin IgG2b 43 1:500.000 Merck Millipore MAB1501
Mouse α-SMA IgG2a 40 1:10.000 Abcam Ab7817
Rabbit α-SM22 IgG 23 1:2000 Abcam Ab14106
Rabbit α-Cofilin IgG 19 1:2000 Abcam Ab11062-50
Rabbit α-pCofilin (Ser3) IgG 19 1:1000 Cell signaling 3313S
Rabbit α-SMAD2 IgG 60 1:1000 Cell signaling 5339S
Rabbit α-pSMAD2 IgG 55-60 1:400 Merck Millipore 04-953
Mouse α-β catenin IgG1 92 1:2000 BD Bioscience 610153
Immunofluorescence
For in situ visualization of actin fibers, α-SMA and paxillin, VSMCs were seeded on 0.01% 
collagen coated coverslips and allowed to attach for 48 hours. VSMCs were fixed with 2% 
paraformaldehyde in PBS for 15 minutes. After fixation coverslips were washed with PBS with 
0.1% Trition-X100 and blocked with PBS+ (PBS supplemented with 0.15% glycine and 0.5% 
bovine serum albumin) for 30 minutes. Primary antibodies were incubated overnight at 4°C in 
PBS+, α-SMA (1:750, ab7871, Abcam) and Paxillin (1:400, ab32115, Abcam). Coverslips were 
washed with PBS with 0.1% trition-X100 and incubated shortly with PBS+ prior to incubation 
with the secondary antibody in PBS+ (1:1,000, anti-mouse Alexa Fluor 488 and anti-rabbit Alexa 
Fluor 594, Molecular Probes) at RT for 1 hour. After incubation the coverslips were mounted on 
glass slides with Vectashield supplemented with DAPI (H-1200, Vector laboratories) and sealed 
with nail polish. Images were recorded on a wide field epifluorescent microscope (Axio Imager 
D2, Zeiss).
Live cell imaging
VSMCs were seeded at a density of 10,000 cells/cm2 on a 0.01% collagen coated coverslip. 
VSMCs were allowed to attach for 48 hours prior to transfection with a Paxillin-EGFP construct 
(2 µg/6-well) using Lipofectamin 3000 (L3000-015, Thermo Fisher). Plasmid pPaxillin-EGFP 
encodes an Paxillin-EGFP fusion protein, consisting of the chicken (Gallus gallus) paxillin protein 
fused to EGFP through a 22 amino acid linker. Plasmid pPaxillin-EGFP was made by substituting 
the mTurquoise cDNA in plasmid pmTurquoise-Paxillin-22 (Addgene plasmid # 55573) for the 
EGFP cDNA from plasmid pEGFP-N1 (Clontech) as a BamH1/NotI DNA fragment. After 6 hours, 
the transfection medium was replaced with regular medium and VSMCs were allowed to recover 
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overnight. The medium was replaced with medium supplemented with 150 nM SiR-Actin (SC001, 
Cytoskeleton, Inc.) to label actin filaments. After 6 hours the VSMCs were imaged overnight with 
a confocal laser scanning microscope, Leica SP5 microscope (Leica, Mannheim). Images were 
recorded every 10 minutes at three levels of the cell (base, middle and top, 1 µm separated 
from each other). Movement of the VSMCs was quantified by Fiji image analysis software. After 
delineating the maximum projection, VSMCs were manually tracked with MTrackJ [28]. Total 
length of the path was used for comparing the mean total migration of Fibulin-4f/+, Fibulin-4f/-, 
Fibulin-4+/+ and Fibulin-4R/R VSMCs.
G-actin/F-actin in vivo assay 
The ratio between filamentous actin and monomeric actin was determined with a G-actin/F-
actin in vivo assay kit (BK037, Cytoskeleton, Inc.). Two days prior to the experiment, VSMCs 
were seeded on 0.01% collagen coated wells to reach an almost confluent density at the 
time of lysis. Manufacturer protocol was followed for the lysis and fractionation of the F- and 
G-actin, ultracentrifugation of the samples was performed at room temperature. Equal volumes 
of supernatant (G-actin) and pellet (F-actin) lysates (10 µl per sample) were run on 12% gels 
according to the above described Western blotting protocol. Analysis of the fractions was 
performed with Fiji image analysis software. Number of replicates is specified in the figure 
legends.
Immunofluorescence of extracellular matrix
ECM protein production by VSMCs was determined by immunofluorescence. VSMCs were 
seeded at 25,000 cells/well, except for Fibulin-4 staining that required a higher seeding density 
of 75,000 cells/well, in 8-well removable chamber slides and grown in DMEM supplemented 
with 10% heat-inactivated FCS and 1% PS for 7 days to allow ECM deposition. VSMCs were 
fixed with an ice-cold 70:30 methanol:acetone mixture for 5 minutes and washed with PBS. 
Coverslips were blocked for 1 hour with PBS supplemented with 10% normal goat serum (X0907, 
Agilent). Primary antibodies (Table 3) were incubated overnight at 4°C in PBS. Coverslips were 
washed three times with PBS for 5 minutes each prior to incubation with the secondary antibody 
for 1.5 hours at room temperature (1:1,000, anti-rabbit Alexa Fluor 594, Molecular Probes). 
Coverslips were washed and mounted to glass slides with Vectashield supplemented with DAPI 
(H-1200, Vector laboratories) and sealed with nail polish. Images were recorded on a wide field 
epifluorescent microscope (Axio Imager D2, Zeiss). Fibulin-4 images were recorded on a Axio 
Imager M2 epifluorescent microscope, Zeiss.
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Table 3. Antibodies used for immunofluorescent staining of the ECM.
Primary antibody Dilution Manufacturer Catalog number 
Rabbit α-Fibronectin IgG 1:80 Millipore AB2033
Rabbit α-mouse Fibrillin-1 1:1,000 Generated in Reinhardt Lab -
Rabbit α-mouse LTBP4 1:1,000 Generated in Reinhardt Lab -
TGFβ reporter assay
Downstream activation of the TGFβ pathway was determined via a CAGA-MLP-luciferase 
promoter reporter construct [29]. This construct contains palindromic repeats of the SMAD3/
SMAD4 binding site of the PAI-1 promoter and was shown to be sensitive to TGFβ [29]. VSMCs 
were seeded the day prior to transfection in gelatinized 24 well plates. Subconfluent cells were 
transfected with Lipofectamin 3000 according to the manufacturer protocol. A SV40-renilla 
construct (Addgene plasmid # 27163, [30]) was co-transfected to correct for transfection 
efficiency. After 6 hours, the transfection medium was replaced with DMEM supplemented with 
10% FCS and 1% PS. On the following day the VSMCs were serum starved for 2 hours by DMEM 
supplemented with 0.2% FCS and 1% PS. The VSMCs were then treated overnight with serum 
starvation medium supplemented with 5 ng/ml TGFβ1 (4342-5, Biovision) or 10 µM SB43542 
hydrate (S4317-5mg, Sigma) or without stimulation. VSMCs were washed with PBS, lysed and 
luciferase activity was measured with the dual-luciferase kit (E1910, Promega) with the GloMax-
multi detection system (Promega). Number of replicates is specified in the figure legends.
Statistical analysis
All experiments were performed in triplicate using three independent samples. Data were 
corrected for outliers with the Grubbs’ test for outliers. Statistical analysis was performed with 
a non-parametric Mann-Whitney test. Significance was tested 2-tailed. A p-value <0.05 was 
considered to indicate a significant difference between groups. In the figures p<0.05 is show 
with *, p<0.01 with $, p<0.001 with ‡, and p<0.0001 with #. Results are expressed as mean ± 
SD, real-time PCR results are expressed as geometric mean ± geometric SD. All analyses were 
performed using Graphpad, version 7.03.
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RESULTS
Fibulin-4 mutations affect the SMA cytoskeleton
To compare the consequences of complete Fibulin-4 deletion versus decreased expression 
of Fibulin-4, we isolated VSMCs from aortas of Fibulin-4f/-/SM22Cre+ (VSMC-specific deletion 
of the Fibulin-4 gene) and Fibulin-4R/R (reduced expression of the Fibulin-4 gene) animals and 
their respective control littermates. First, Fibulin-4 gene expression was determined in Fibulin-
4R/R, Fibulin-4f/-/SM22Cre+, Fibulin-4+/+ and Fibulin-4f/+/SM22Cre+ VSMCs. Fibulin-4 expression 
in Fibulin-4R/R VSMCs is approximately 20% of the Fibulin-4+/+ VSMCs (Fig. 1A). No Fibulin-4 
expression was detected in Fibulin-4f/-/SM22Cre+ VSMCs while Fibulin-4 gene expression was 
present in the control Fibulin-4f/+/SM22Cre+ VSMCs, but significantly reduced to about 50% 
compared to Fibulin-4+/+  (Fig. 1A). 
Previously Huang et al. have shown that VSMC-specific deletion of Fibulin-4 leads to decreased 
expression of ACTA2 in Fibulin-4f/-/SM22Cre+ aortas, indicating that absence of Fibulin-4 impairs 
differentiation and proper SMA cytoskeleton formation [24]. To further analyze these isolated 
VSMCs, cells were stained for SMA and paxillin. SMA is a marker for the contractile, non-
proliferative phenotype of adult VSMCs and paxillin is a multidomain adaptor localized at the 
interface between the plasma membrane and the actin cytoskeleton. The control VSMCs, Fibulin-
4f/+/SM22Cre+ and Fibulin-4+/+ showed numerous SMA stress fibers spanning their cytoplasm 
(Fig. 1B). The well spread controls adhered to the surface with elongated focal contacts positive 
for paxillin, positioned at the end of the individual SMA fibers (Fig. 1C, top and bottom image). 
The arrows indicate the overlay between SMA fibers and the focal adhesions in yellow. In Fibulin-
4f/-/SM22Cre+ VSMCs SMA stress fibers were not present and paxillin staining identified small 
rounded podosome-like structures instead of the elongated structures observed in control 
VSMCs. This was further confirmed in higher magnification images (Fig. 1C and D). The Fibulin-
4R/R VSMC did show SMA stress fibers, however, these fibers were not as distinct as in control 
VSMCs. Yet, paxillin did localize to the ends of SMA fibers and also formed elongated structures 
as was seen in the control VSMCs. Western blotting on whole cell lysates showed presence 
of SMA in both the Fibulin-4f/+/SM22Cre+ and the Fibulin-4+/+ control VSMCs. Compared to 
the Fibulin-4f/+/SM22Cre+ and Fibulin-4+/+ VSMCs SMA expression was significantly decreased 
in Fibulin-4f/-/SM22Cre+ (Fig. 1E and F, p<0.0001). In contrast, Fibulin-4R/R VSMCs whole cell 
lysates showed an increase in SMA protein levels compared to Fibulin-4+/+ whole cell lysates 
(Fig. 1E and F, p<0.0001). Similarly, Fibulin-4f/+/SM22Cre+ VSMCs with 50% Fibulin-4 gene 
expression showed a significant increase in SMA protein compared to Fibulin-4+/+ VSMCs (Fig. 




























































































Figure 1. Fibulin-4 is needed for SMA fi ber formation. 








 VSMCs. Data is 
shown for n=3-7 lysates in 2 independent experiments. B) Immunofl uorescent staining of SMA in green and 
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paxillin in red. Scale bar represents 50 µm. C) Close up of paxillin and SMA staining. Paxillin forms elongated 




 VSMCs (arrow indicates an 
example of overlap between SMA and paxillin). In Fibulin-4
f/-
 VSMCs paxillin did not localize to SMA fi bers 
and formed small rounded podosome-like structures (one example shown in circle). Scale bar represents 
10 µm. D) further close-up of actin fi bers and paxillin overlay in Fibulin-4
f/+ 
and podosome-like structures 
of paxillin in Fibulin-4
f/-








 VSMC protein extracts. β-catenin levels serve as a loading control. 
F) Quantifi cation of SMA levels as shown in panel E, respectively. Data is shown for n=7-8 lysates in 3 
independent experiments. Bars represent mean ± SD. Mann-Whitney test. $ p<0.01, # p<0.0001. 
These results show that complete absence of Fibulin-4 leads to loss of SMA stress fi bers, 
while reduced levels of Fibulin-4 can support SMA fi ber formation. However, this fi ber formation 
appears affected, even though the total amount of SMA protein is increased in Fibulin-4R/R
VSMCs. Furthermore, absence of Fibulin-4 in the Fibulin-4f/-/SM22Cre+ VSMCs also leads to an 
aberrant, podosome-like, appearance of the focal adhesion structures.
Actin dynamics are differentially affected by Fibulin-4 mutations
The actin cytoskeleton is a dynamic structure in which actin monomers are continuously 
polymerized and depolymerized. The lack of SMA fi bers in Fibulin-4f/-/SM22Cre+ VSMCs 
suggests less polymerization of actin monomers into actin fi bers or, alternatively, increased 
depolymerization in Fibulin-4f/-/SM22Cre+ VSMCs. Previously, alteration in actin depolymerization 
in Fibulin-4f/-/SM22Cre+ aortic tissue lysates has been linked to decrease in phosphorylated 
cofi lin to total cofi lin ratio and the restoration of cofi lin phosphorylation prevented aneurysm 
formation [31]. This shift increases activity of cofi lin leading to increased depolymerization of the 
actin fi bers. In addition, SM22, an actin crosslinking protein and VSMC differentiation marker, is 
decreased in Fibulin-4f/-/SM22Cre+ aortic tissue lysates, suggesting that the VSMCs are not fully 
differentiated into mature VSMCs when Fibulin-4 is completely absent [31-33].
To determine if actin is still polymerized in mature actin fi laments in Fibulin-4f/-/SM22Cre+
VSMCs and Fibulin-4R/R VSMCs, we performed an F-/G-actin fractionation by which the ratio of 
polymerized versus free actin monomers can be determined (Fig. 2A and B). This fractionation 
revealed a decrease in F-actin levels over G-actin levels in Fibulin-4f/-/SM22Cre+ VSMCs 
compared to control Fibulin-4f/+/SM22Cre+ VSMCs (Fig. 2B, p<0.01). No signifi cant difference 
in F-actin/G-actin fraction was found in Fibulin-4R/R VSMCs compared to Fibulin-4+/+ VSMCs 
(Fig. 2B). The F-actin/G-actin fraction of Fibulin-4f/-/SM22Cre+ VSMCs was also signifi cantly 


























































































































































































































































































































 VSMC protein extracts. B) Quantifi cation of F-actin to G-actin ratio. Data is shown for n=2 samples 









 VSMC protein extracts. D) Quantifi cation of pCofi lin/
Cofi lin ratio. Data is shown for n=4-6 samples in 3 independent experiments. E) Western blot for SM22 








 VSMC protein extracts. 
F) Quantifi cation of SM22 shown in E). Data is shown for n=4 lysates in 3 independent experiments. Bars 
represent mean ± SD. Mann-Whitney test. * p<0.05, $ p<0.01, # p<0.0001. 
The ratio of phosphorylated cofi lin to cofi lin was determined by western blot analysis to analyze the 
amount of inactive to active cofi lin, respectively. We observed a decrease in the phosphorylated 
cofi lin to cofi lin ratio in Fibulin-4f/-/SM22Cre+ VSMCs compared to Fibulin-4+/+ VSMCs (Fig. 2C 
and D, p<0,01). This shift in ratio towards more active cofi lin leads to increased depolymerization 
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of actin fi bers in Fibulin-4f/-/SM22Cre+ VSMCs. In Fibulin-4R/R VSMCs the ratio of phosphorylated 
cofi lin to cofi lin was comparable to Fibulin-4+/+ VSMCs (Fig. 2C and D). When comparing the 
ratio of phosphorylated cofi lin to cofi lin in Fibulin-4f/+/SM22Cre+ VSMCs no difference was found 
compared to Fibulin-4+/+ VSMCs (Fig. 2C and D).
Western blot analysis for SM22 protein levels was performed to assess the differentiation status 
of the VSMCs and the actin crosslinking potential in Fibulin-4f/-/SM22Cre+ and Fibulin-4R/R
VSMCs. SM22 protein levels were signifi cantly lower in Fibulin-4f/-/SM22Cre+ VSMCs compared 
to Fibulin-4f/+/SM22Cre+ VSMCs (Fig. 2F and G, p<0.0001). In Fibulin-4R/R VSMCs, SM22 protein 
levels were increased compared to Fibulin-4+/+ VSMCs (Fig. 2F and G, p<0.05). Similarly, when 
comparing Fibulin-4f/+/SM22Cre+ VSMCs to Fibulin-4+/+, SM22 protein levels were increased in 
Fibulin-4f/+/SM22Cre+ VSMCs (Fig. 2F and G, p<0.0001). Hence, reduction of Fibulin-4 leads to 
increased SM22 levels, whereas complete absence of Fibulin-4 leads to reduced SM22.
These results show that the actin dynamics are altered in both Fibulin-4f/-/SM22Cre+ VSMCs as 
well as Fibulin-4R/R VSMCs. While Fibulin-4f/-/SM22Cre+ VSMCs showed a decreased F-actin 
fraction, increased depolymerization and decreased SM22 levels, Fibulin-4R/R VSMCs showed 
no decrease in F-actin fraction and, opposite to Fibulin-4f/-/SM22Cre+ VSMCs increased SM22 
protein levels. 
Migration is disturbed by Fibulin-4 mutations
We subsequently investigated whether the changes in cytoskeletal composition and actin (de)
polymerization have implications for spontaneous cellular migration. We stained the overall actin 
cytoskeleton present in all cells (in contrast to the VSMC specifi c actin protein, SMA), by addition 
of the SiR-Actin probe, which is incorporated into the actin cytoskeleton and allows monitoring of 
cellular migration and measuring migration velocity by live cell imaging.
During cellular migration, new actin fi bers and focal adhesions are formed in the direction of 
migration, while actin fi bers are depolymerizing and focal adhesions are detaching at the back 
of the cell. Live cell imaging of VSMCs labeled with SiR-Actin and overexpression of the focal 
adhesion protein paxillin-eGFP displays this directional migration (online, Movie_1). Fig. 3A 
displays a limited set of frames from these live cell movies with the arrows indicating migration 
direction. A close up of a Fibulin-4f/+/SM22Cre+ VSMC shows the formation of new focal 
adhesions in the direction of movement and disappearance of focal adhesions at the detaching 
side of the cells. Interestingly, Fibulin-4f/-/SM22Cre+ VSMCs showed formation of new focal 
adhesions evenly distributed around the entire cell membrane and migration of individual cells 
occurs in all directions. Since this direction of migration occurred simultaneously in opposite 





































 VSMCs show less migration. 





 VSMCs. Paxillin overexpression is depicted in green and actin (SiR-Actin) is depicted in red. 









 VSMCs (online movie_3, movie_4, movie_5 and 
movie_6). Bars represent mean ± SD. Mann-Whitney test, ‡ p<0.01 # p<0.0001. 
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To obtain an overview of migration and to quantify migration velocity cells were imaged at 
lower magnification. Fibulin-4f/-/SM22Cre+ VSMCs showed a shorter path length compared 
to Fibulin-4f/+/SM22Cre+ VSMCs and thus less migration. When total migration was corrected 
for time, migration velocity was obtained. Fibulin-4f/-/SM22Cre+ VSMCs showed a decreased 
migration velocity compared to control VSMCs (Fig. 3B, p<0.001). Fibulin-4R/R VSMCs also 
showed decreased migration velocity compared to Fibulin-4+/+ VSMCs (Fig. 3B, p<0.0001). 
Unlike Fibulin-4f/-/SM22Cre+ VSMCs, directionality of movement was seen in Fibulin-4R/R VSMCs. 
Migration velocity did not differ between Fibulin-4f/+/SM22Cre+ and Fibulin-4+/+ VSMCs. Example 
movies can be found online (Movie_3 to Movie_6).
Taken together these data show that when Fibulin-4 is absent or reduced, VSMCs exhibit 
decreased migration and have a lower migration velocity compared to control cells.
Analysis of ECM production and TGFβ signaling pathway in Fibulin-4f/-/SM22Cre+ and 
Fibulin-4R/R VSMCs
Since Fibulin-4 plays an important role in ECM integrity and both Fibulin-4R/R and Fibulin-4f/-/
SM22Cre+ mutant VSMCs show decreased migration, we investigated whether this similarity in 
aberrant movement was caused by similar changes in ECM composition. Immunofluorescent 
staining of the ECM components, fibulin-4, fibronectin-1, fibrillin-1 and latent TGFβ binding 
protein 4 (LBTP4), was performed after 7 days of culture to asses ECM production in both types 
of Fibulin-4 mutant VSMCs.
Fibulin-4 is essential for elastogenesis and recruitment of lysyl oxidase. Lysyl oxidase is needed 
for crosslinking of the elastin precursor tropoelastin and the formation of mature elastic laminae. 
In contrast to Fibulin-4+/+ VSMCs, Fibulin-4R/R VSMCs do not show a clear network of fibulin-4 
fibers (Fig. 4A). Fibulin-4f/+/SM22Cre+ VSMCs do show fibulin-4 fibers, however, with less intensity 
than Fibulin-4+/+ VSMCs (Fig. 4A). In Fibulin-4f/-/SM22Cre+ VSMCs fibulin-4 fibers and protein are 
not detectable (Fig. 4A). Fibronectin serves as a base network on which other ECM proteins 
are deposited. Therefore, production of fibronectin is essential for proper ECM formation. A 
more extensive network of fibronectin fibers were apparent in Fibulin-4R/R VSMCs compared to 
Fibulin-4+/+ VSMCs, (Fig. 4B). In contrast, Fibulin-4f/-/SM22Cre+ VSMCs produced a minimal 
amount of fibronectin fibers compared to Fibulin-4f/+/SM22Cre+ and Fibulin-4+/+ VSMCs. Fibulin-
4f/+/SM22Cre+ VSMCs show a slight increase in fibronectin fibers compared to Fibulin-4+/+ 
VSMCs. Fibrillin-1 is the central component of microfibrils and is important for structural support 
in tissues and elastic fiber formation. Similarly to the fibronectin network, the fibrillin-1 fiber 
network of Fibulin-4R/R VSMCs is more extensive than of Fibulin-4+/+ VSMCs (Fig. 4C). However, 
Fibulin-4f/-/SM22Cre+ VSMCs show a less extensive fibrillin-1 fiber network compared to Fibulin-
4f/+/SM22Cre+ and Fibulin-4+/+ VSMCs. Like the fibronectin fibers, Fibulin-4f/+/SM22Cre+ VSMCs 
show a slight increase in fibrillin-1 fibers compared to Fibulin-4+/+ VSMCs (Fig. 4C). LTBP4 binds 
inactive TGFβ to the ECM where it is stored until activation occurs. LTBP4 is of importance for the 
bioavailability of TGFβ and, therefore, activation of the TGFβ signaling pathway. While LTBP4 is 
130
CHAPTER 4
detected in Fibulin-4f/-/SM22Cre+ VSMCs and fibers are formed, the number of LTBP4 fibers is far 
less compared to Fibulin-4f/+/SM22Cre+ VSMCs. Fibulin-4R/R VSMCs showed increased staining 
of LTBP4 present in an extensive ECM network compared to Fibulin-4+/+ VSMCs. Again, Fibulin-
4f/+/SM22Cre+ VSMCs show a slight increase in LTBP4 compared to Fibulin-4+/+ VSMCs (Fig. 
4D). The slight increase in ECM production by Fibulin-4f/+/SM22Cre+ VSMCs could explained 
by the reduced expression of fibulin-4. In conclusion, this suggests that a reduction in fibulin-4 
results in upregulation of ECM deposition but a complete absence of fibulin-4 abolishes the 
deposition/assembly of various ECM proteins.
The difference in ECM deposition found between Fibulin-4R/R and Fibulin-4f/-/SM22Cre+ VSMCs 
could indicate differential activities of the TGFβ pathway signaling in both mutants. Hence, we 
next performed analysis of TGFβ signaling components as well as TGFβ pathway activation. 
To determine if Fibulin-4f/-/SM22Cre+ VSMCs show increased TGFβ signaling, we performed 
western blotting to determine the phosphorylation status of SMAD2 (pSMAD2) (Fig. 4E and F). 
While SMAD2 protein levels were comparable, Fibulin-4f/-/SM22Cre+ cell lysates showed lower 
pSMAD2 protein levels compared to Fibulin-4f/+/SM22Cre+ lysates. (Fig. 4E). Fibulin-4R/R VSMC 
whole cell lysates showed higher pSMAD2 protein levels compared to Fibulin-4+/+ lysates as 
also previously observed (Fig. 4E) [23]. Quantification of the pSMAD2 and SMAD2 levels showed 
a significant decrease in pSMAD2/SMAD2 ratio in Fibulin-4f/-/SM22Cre+ VSMCs compared to 
Fibulin-4f/+/SM22Cre+ lysates (Fig. 4F, p<0.05), while Fibulin-4R/R VSMCs showed an increased 
pSMAD2/SMAD2 ratio compared to its control (Fig. 4F, p<0.05).
To examine downstream activation of the TGFβ pathway, a TGFβ reporter assay was performed. 
In this assay PAI-1 promoter activation, represented by luciferase activity, is measured. PAI-1 
can be activated by binding of the phosphorylated SMAD2/SMAD3 complex. Fibulin-4R/R VSMCs 
showed spontaneous increased TGFβ signaling pathway activation compared to Fibulin-4+/+ 
VSMCs (Fig. 4G, p<0.001). Our previous research on Fibulin-4R/R VSMCs showed that increased 
TGFβ signaling could be reduced by treatment of the cells with SB431542 hydrate, a TGFβ 
receptor blocker [23]. As visualized in Figure 4H, the intrinsic, cell autonomous TGFβ signaling 
pathway activation in Fibulin-4f/-/SM22Cre+ VSMCs was decreased compared to Fibulin-4f/+/
SM22Cre+ VSMCs (p<0.05). When TGFβ signaling was inhibited by SB431542 hydrate in Fibulin-
4f/-/SM22Cre+ VSMCs there was no significant decrease in PAI-1 promoter, while Fibulin-4R/R 
VSMCs did show such a decrease in PAI-1 promoter activation after treatment with SB431542 
hydrate (Fig. 4 I and J). 
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When stimulated with TGFβ, the TGFβ pathway can be activated in Fibulin-4f/-/SM22Cre+ VSMCs 
as well as in Fibulin-4R/R VSMCs (Fig. 4K and L, p<0.0001). Western blot analysis of protein lysates 
of VSMCs stimulated with and without TGFβ further showed increased pSMAD2 levels after 
TGFβ stimulation. Interestingly, stimulation with TGFβ increased SMA protein levels in Fibulin-4f/-/
SM22Cre+ VSMCs compared to non-stimulated Fibulin-4f/-/SM22Cre+ VSMCs. However, it did 
not increase SM22 protein levels. Fibulin-4R/R VSMCs also showed increased pSMAD2 protein 
levels upon TGFβ stimulation. A further increase of TGFβ signaling in Fibulin-4R/R VSMCs did not 
result in a large increase in SMA and SM22 protein levels.
Figure 4









































































































































































Figure 4. Continuous on the next page
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Immunofl uorescent staining of production of ECM proteins by VSMCs after 7 days in culture. Representative 
images are shown, scale bar is 100 µm. A) Immunofl uorescent staining of Fibulin-4. B) Immunofl uorescent 
staining of fi bronectin. C) Immunofl uorescent staining of fi brillin-1. D) Immunofl uorescent staining of latent 









 VSMC protein extracts. F) Quantifi cation of pSMAD2/
SMAD2 ratio. Data is shown for n=2-3 lysates in 3 independent experiments. G) Luciferase TGFβ





 VSMCs. n=3 independent experiments in triplicate. H) Luciferase TGFβ 
transcriptional based assay showing a decrease in pathway activation in Fibulin-4
f/-
 VSMCs compared to 
Fibulin-4
f/+
 VSMCs. n=3 independent experiments in triplicate.  I) and J) Luciferase TGFβ transcriptional 




VSMCs do show decreased TGFβ pathway after inhibition. Data is shown for 3 independent experiments with 
n=3-4 samples. K) Luciferase TGFβ transcriptional based assay showing increased pathway activation after 
TGFβ stimulation in Fibulin-4
R/R
 VSMCs. Data is shown for 3 independent experiments with n=4 samples. 
Western blots for pSMAD2, SMAD2, SMA, SM22 and loading control β-catenin for Fibulin-4
R/R
 VSMC protein 
extracts, with and without TGFβ stimulation. L) Luciferase TGFβ transcriptional based assay showing 
increased pathway activation after TGFβ stimulation in Fibulin-4
f/-
 VSMCs. Data is shown for 3 independent 
experiments with n=4-5 samples. Western blots for pSMAD2, SMAD2, SMA, SM22 and loading control 
β-catenin for Fibulin-4
f/-
 VSMC protein extracts, with and without TGFβ stimulation. Bars represent mean ± 




Our current data reveal that actin cytoskeleton structure and dynamics are affected in both 
Fibulin-4f/-/SM22Cre+ as well as Fibulin-4R/R VSMCs. Strikingly, we show that while TGFβ 
activation is increased in VSMCs when Fibulin-4 levels are reduced (Fibulin-4R/R), no changes in 
the activation of TGFβ signaling are observed in the absence of Fibulin-4 (Fibulin-4f/-/SM22Cre+). 
Thus, a complete absence versus reduced levels of Fibulin-4 differentially affects TGFβ signaling, 
intracellular cytoskeleton structures and consequently cell movement.
Both the Fibulin-4R/R and Fibulin-4f/-/SM22Cre+ mouse model show aortic aneurysm formation. 
Histological analysis of the aortas shows fragmentation of the elastic laminae and thickening 
of the aortic wall in both models. However, there are striking differences in the fragmentation 
of the elastic laminae differs between the two models. Although Fibulin-4f/-/SM22Cre+ aortas 
show severe fragmentation, it appears that the first elastic laminae adjacent to the endothelial 
layer remain intact [22, 24]. In Fibulin-4R/R aortas elastic laminae throughout the entire media 
are fragmented. In this respect, the affected cell populations in each model might explain this 
difference; in Fibulin-4R/R mice all cells have reduced Fibulin-4 expression, while in Fibulin-4f/-/
SM22Cre+ mice Fibulin-4 is specifically deleted in VSMCs, surrounded by wild-type endothelial 
cells and fibroblasts. Which is the reason why in this study we compared VSMCs from both 
models.
Our data showed that both Fibulin-4 models display changes in their cytoskeleton composition. 
Previous research by Huang et al. has shown that aortas of Fibulin-4 germline knock-out 
embryos (Fibulin-4GKO) contain less SMA [24]. Fibulin-4GKO VSMCs also displayed less distinct 
actin fibers upon detection with phalloidin. Gene expression of ACTA2 and SM22 is decreased in 
Fibulin-4f/-/SM22Cre+ aortas [24, 31], which is in accordance with our results of decreased SMA 
and SM22 protein levels in Fibulin-4f/-/SM22Cre+ VSMCs. Although we find decreased SM22 
protein levels in Fibulin-4f/-/SM22Cre+ VSMCs, the SM22 promoter must have been active during 
development, as the Cre expression in the VSMC specific Fibulin-4 knock out is regulated by 
the SM22 promotor. Decreased presence of SMA has previously also been found by Arnold et 
al. in a neural crest cell specific knock-out of integrin linked kinase (ILK) [34]. Wnt1cre; Ilkflox/
flox embryos present with a severe aneurysmal arterial trunk, which leads to embryonic lethality 
during late gestation. Decreased differentiation of smooth muscle tissue has been observed 
as well as disorganization of F-actin stress fibers. In addition, these embryos have decreased 
pSmad3 staining. The similarities in the Fibulin-4f/-/SM22Cre+ model and the Wnt1cre; Ilkflox/
flox model highlights a fundamental basis for the mechanistic link between the TGFβ signaling 
and proper cytoskeleton formation in aneurysmal disease. In contrast to Fibulin-4f/-/SM22Cre+ 
VSMCs, Fibulin-4R/R VSMCs show increased SMA protein levels. Research by Ramnath et al. 
has shown increased SMA mRNA in Fibulin-4R/R VSMCs [23]. Our current data now indicate that 
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this increased SMA expression is also translated into increased protein levels. From literature 
it is known that TGFβ signaling is involved in VSMC differentiation and induces expression of 
SMA and SM22 [35, 36]. The increased TGFβ signaling in Fibulin-4R/R VSMCs and aortas could 
therefore be responsible for the increased expression of SMA and SM22. 
As previously mentioned, less distinct actin fibers have been found in Fibulin-4GKO VSMCs by 
Huang et al. [24]. Yamashiro et al. investigated the actin fibers further in Fibulin-4f/-/SM22Cre+ 
aortas and have shown that the ratio of F-actin to G-actin is significantly decreased in the 
ascending aorta of Fibulin-4f/-/SM22Cre+ mice compared to their controls [31]. This decrease 
in F-actin to G-actin is in line with our results in VSMCs derived from Fibulin-4f/-/SM22Cre+ 
aortas, however, there is no significant decrease detected in Fibulin-4R/R VSMCs. The decreased 
phosphorylated cofilin to cofilin ratio we observe in the Fibulin-4f/-/SM22Cre+ VSMCs, which 
could result in increased depolymerization of actin, can explain the decrease in F-actin. The 
interaction between actin dynamics and ECM composition, as we find for Fibulin-4f/-/SM22Cre+ 
and Fibulin-4R/R VSMCs, has also been observed for different biological systems and in different 
experimental set-ups [37-39]. 
Increased activation of the TGFβ signaling pathway is often thought to be causative in aneurysm 
formation. Yet, our results do not show increased activation of the TGFβ pathway in Fibulin-4f/-/
SM22Cre+ VSMCs. Recent data suggests a dual role for TGFβ signaling in aneurysm formation; 
while increased signaling can be protective in early stages of the disease, it can be detrimental in 
later disease stages [40, 41]. This implies that disturbed TGFβ signaling is not the single culprit 
in aneurysm formation. Our data also underlines the importance of the cytoskeleton in aneurysm 
formation, since we show that Fibulin-4 defects lead to cytoskeleton alterations. While Fibulin-4R/R 
VSMCs show overproduction of the ECM, increased TGFβ signaling and increased production 
of SMA, Fibulin-4f/-/SM22Cre+ VSMCs show less ECM production, no increased TGFβ signaling 
and a lack of SMA production and SMA fiber formation. This suggests that a defect in the ECM 
protein fibulin-4 can lead to alterations of the cytoskeleton. Recent research has shown the 
importance of the VSMC cytoskeleton in combination with the ECM to contractility of the VSMCs 
and aneurysm formation. Without proper connections of the cytoskeleton to the ECM, a VSMC 
cannot generate force for its contractions. This shows that the ECM and the cytoskeleton are of 
great importance for the contractility of the aorta and may be primary drivers of thoracic aortic 
aneurysms when these are defective [42]. 
Our data show that activation of the TGFβ pathway by TGFβ stimulation is possible in Fibulin-
4f/-/SM22Cre+ VSMCs and thus receptor expression and signal transduction is still intact. We 
show that addition of exogenous TGFβ to Fibulin-4f/-/SM22Cre+ VSMCs results in increased SMA 
protein levels. This result shows the direct interconnection between TGFβ pathway signaling and 
SMA protein levels. From literature it is known that TGFβ is involved in VSMC differentiation [43-
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45]. This differentiation is directly induced by TGFβ via binding of SMAD3 to the SM22 promoter 
and induction of SMA production via RhoA [46, 47].
The difference in TGFβ pathway activation between the Fibulin-4f/-/SM22Cre+ and Fibulin-4R/R 
mouse model could be the result of the difference in ECM composition. The increased TGFβ 
levels in the Fibulin-4R/R models is thought to be due to less stable binding of the large latent 
complex (LLC) to fibrillin-1 [23]. Our data show increased ECM deposition by Fibulin-4R/R VSMCs 
and increased amounts of LTBP4, implicating higher bioavailability of TGFβ, together explaining 
the augmented TGFβ activation. Furthermore, Bultmann-Mellin et al. showed that LTBP4-L is 
needed for the deposition of Fibulin-4 in the ECM and thereby proper elastogenesis, and they 
showed a physical interaction between LTBP4 and Fibulin-4 [48, 49]. Increased TGFβ activation 
in the Fibulin-4R/R model has previously been discovered by RNA expression analysis of Fibulin-
4R/R aortas and TGFβ cytokine analysis in aortic extracts and blood of Fibulin-4R/R mice [23, 50]. 
In contrast, the less extensive ECM deposition we find in Fibulin-4f/-/SM22Cre+ VSMCs could 
lead to decreased TGFβ signaling activity since there is no properly formed ECM to bind the 
latent TGFβ. Massam-Wu et al. have shown that Fibulin-4 binds with high affinity to LTBP1, a 
key mediator in binding of latent TGFβ in the ECM by binding to LTBP4 as well as fibrillin-1 
[51]. This suggests that Fibulin-4f/-/SM22Cre+ VSMCs are unable to confine latent TGFβ in their 
matrix due to the absence of Fibulin-4. Reduced storage of TGFβ could, in part, explain the 
decreased TGFβ signaling seen in Fibulin-4f/-/SM22Cre+ VSMCs. Especially since we show that 
exogenous addition of TGFβ is able to activate the TGFβ pathway. Further research would be 
needed to determine if the decrease in TGFβ signaling in Fibulin-4f/-/SM22Cre+ VSMCs is caused 
by reduced production or secretion of TGFβ.
Since depolymerization of actin fibers is needed for retraction of the cells during migration [52, 
53], increased deposition of ECM proteins by Fibulin-4R/R VSMCs in combination with increased 
production of SMA and decreased depolymerization of the cytoskeleton could explain why Fibulin-
4R/R VSMCs show less migration compared to control VSMCs. Furthermore, the more elaborate 
ECM of Fibulin-4R/R VSMCs could lead to a stronger attachment to the culture plate, leading to 
less effective migration. The increased SMA protein levels also implicates a more contractile 
phenotype in Fibulin-4R/R VSMCs, as literature suggests less migration for this contractile VSMC 
phenotype compared to the synthetic VSMC phenotype [54]. Although Fibulin-4f/-/SM22Cre+ 
VSMCs show less deposition of ECM proteins, their migration is still less effective compared to 
Fibulin-4f/+/SM22Cre+ VSMCs. In this case, the reduced effective movement could be caused by 
the absence of SMA fibers, less differentiation of the VSMCs and decreased attachment due to 
the low ECM content. However, it remains to be determined if the absence of Fibulin-4 and lack 
of ECM production by Fibulin-4f/-/SM22Cre+ VSMCs is causative for the cytoskeleton alterations.
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Our results show that while reduction or absence of Fibulin-4 shows opposite effects in 
cytoskeleton dynamics and TGFβ signaling, both result in aneurysm formation in the mouse. 
Our data underlines the need for new possible treatments of aneurysmal disease. Currently 
most therapies are based on increased TGFβ signaling, while we show that the Fibulin-4f/-/
SM22Cre+ lack increased TGFβ signaling. Yet, Fibulin-4f/-/SM22Cre+ mice do show aneurysm 
formation. Since both Fibulin-4R/R and Fibulin-4f/-/SM22Cre+ mouse models show alterations in 
the cytoskeleton, we propose that this is an additional underlying cause of aneurysm formation, 
which would be a potential target for the development of novel therapies.
CONCLUSION
From these results we conclude that Fibulin-4 mutations lead to SMA cytoskeleton instabilities as 
well as dysregulation of the TGFβ pathway. However, reduced levels of Fibulin-4 have a strikingly 
different effect compared to the complete absence of Fibulin-4. When Fibulin-4 is absent the 
production of ECM is reduced, the TGFβ pathway is not activated and SMA is not produced. 
In contrast, reduced levels of Fibulin-4 lead to excessive ECM deposition, over-activation of 
the TGFβ pathway and cytoskeleton fibers aberrations. Although these models show opposite 
effects, both mutations lead to aneurysm formation. Moreover, we conclude that not only TGFβ 
signaling, but also cytoskeleton dynamics could be causative for aortic aneurysmal disease. 
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Movie_1 Migration of Fibulin-4
f/+
 VSMC. Paxillin-EGFP overexpression is depicted in green and actin 
(SiR-Actin) is depicted in red. Scale bar represents 50 µm. 
Movie_2 Migration of Fibulin-4
f/-
 VSMC. Paxillin-EGFP overexpression is depicted in green and actin (SiR-
Actin) is depicted in red. Scale bar represents 50 µm. 
Movie_3 Migration of Fibulin-4
f/+
 VSMCs. Actin (SiR-Actin) is depicted in red. Scale bar represents 50 
µm. Individual VSMCs were tracked to measure migration velocity by path length over time.
Movie_4 Migration of Fibulin-4
f/-
 VSMCs. Actin (SiR-Actin) is depicted in red. Scale bar represents 50 µm. 
Individual VSMCs were tracked to measure migration velocity by path length over time.
Movie_5 Migration of Fibulin-4
+/+
 VSMCs. Actin (SiR-Actin) is depicted in red. Scale bar represents 50 
µm. Individual VSMCs were tracked to measure migration velocity by path length over time. 
Movie_6 Migration of Fibulin-4
R/R
 VSMCs. Actin (SiR-Actin) is depicted in red. Scale bar represents 50 
µm. Individual VSMCs were tracked to measure migration velocity by path length over time. 
143




DECREASED MITOCHONDRIAL RESPIRATION IN 
ANEURYSMAL AORTAS OF FIBULIN-4 MUTANT MICE IS 
LINKED TO PGC1A REGULATION
I. van der Pluijm1,2, J. Burger2,3*, P.M. van Heijningen2*, A. IJpma3,4, N. van Vliet2, C. Milanese2,5, 
K. Schoonderwoerd3, W. Sluiter2, L.J. Ringuette6, D.H.W. Dekkers7,  I. Que8, E.L. Kaijzel8, L. 
te Riet1,9, E. MacFarlane10, D. Das2,11, R. van der Linden12, M. Vermeij13, J.A. Demmers7, P.G. 
Mastroberardino2, E.C. Davis6, H. Yanagisawa14,15, H. Dietz10, R. Kanaar2,16, J. Essers1,2,16
* These authors contributed equal
1Department of Vascular Surgery, Erasmus MC, Rotterdam, The Netherlands; 2Department of Molecular Genetics, Erasmus 
MC, Rotterdam, The Netherlands; 3Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands; 4Clinical 
Bioinformatics Unit, Department of Pathology, Erasmus MC, Rotterdam, The Netherlands; Department of Anatomy and Cell 
Biology, McGill University, Montreal, Canada; 6Proteomics Center, Erasmus MC, Rotterdam, The Netherlands; 7Department 
of Radiology, Leiden University Medical Center, Leiden, The Netherlands; 8Department of Pharmacology, Erasmus MC, 
Rotterdam, The Netherlands; 9Department of Surgery, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins 
University School of Medicine, Baltimore, USA; 10Stem cell Institute, Erasmus MC, Rotterdam, The Netherlands; 11Department of 
Pathology, Erasmus MC, Rotterdam, The Netherlands; 12Life Science Center, Tsukuba Advanced Research Alliance, University 
of Tsukuba, Tsukuba, Japan; 13Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA; 
14Division of Pediatric Cardiology, Department of Pediatrics, and Department of Medicine, Johns Hopkins University School of 
Medicine, Baltimore, USA; 15Department of Radiation Oncology, Erasmus MC, Rotterdam, The Netherlands; and 16Department 
of Molecular Genetics, Oncode Institute, Erasmus MC, Rotterdam, The Netherlands





Thoracic aortic aneurysms are a life-threatening condition often diagnosed too late. To discover 
novel robust biomarkers, we aimed to better understand the molecular mechanisms underlying 
aneurysm formation. 
Methods and Results
In Fibulin-4R/R mice, the extracellular matrix protein Fibulin-4 is 4-fold reduced, resulting in 
progressive ascending aneurysm formation and early death around 3 months of age. We 
performed proteomics and genomics studies on Fibulin-4R/R mouse aortas. 
Intriguingly, we observed alterations in mitochondrial protein composition in Fibulin-4R/R 
aortas. Consistently, functional studies in Fibulin-4R/R vascular smooth muscle cells (VSMCs) 
revealed lower oxygen consumption rates, but increased acidification rates. Yet, mitochondria 
in Fibulin-4R/R VSMCs showed no aberrant cytoplasmic localization. We found similar reduced 
mitochondrial respiration in Tgfbr-1M318R/+ VSMCs, a mouse model for Loeys-Dietz syndrome. 
Interestingly, also human fibroblasts from Marfan (FBN1) and Loeys-Dietz syndrome (TGFBR2 
and SMAD3) patients showed lower oxygen consumption. While individual mitochondrial 
complex I-V activities were unaltered in Fibulin-4R/R heart and muscle, these tissues showed 
similar decreased oxygen consumption. Furthermore, aortas of aneurysmal Fibulin-4R/R mice 
displayed increased ROS levels. Consistent with these findings, gene expression analyses 
revealed dysregulation of metabolic pathways. Accordingly, blood ketone levels of Fibulin-4R/R 
mice were reduced and liver fatty acids were decreased, while liver glycogen was increased, 
indicating dysregulated metabolism at the organismal level. As predicted by gene expression 
analysis, the activity of PGC1α, a key regulator between mitochondrial function and organismal 
metabolism, was downregulated in Fibulin-4R/R VSMCs. Increased TGFβ reduced PGC1α levels, 
indicating involvement of TGFβ signalling in PGC1α regulation. Activation of PGC1α restored 
the decreased oxygen consumption in Fibulin-4R/R VSMCs and improved their reduced growth 
potential, emphasizing the importance of this key regulator. 
Conclusion
Our data indicate altered mitochondrial function and metabolic dysregulation, leading to 
increased ROS levels and altered energy production, as a novel mechanism, which may 
contribute to thoracic aortic aneurysm formation.
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INTRODUCTION
Disorders of the heart and blood vessels, together known as cardiovascular disease (CVD), are 
a leading cause of death. Most often patients present with symptoms at a late and irreversible 
stage. A striking example is aneurysmal disease, of which the incidence increases with age. 
Aneurysms are large dilatations of the aorta that, when not detected in time, will result in aortic 
rupture associated with high mortality. This dilation of the aorta frequently occurs unnoticed 
up to a point where surgery is the only optional treatment left. Although most risk factors, such 
as lifestyle and age are known, the molecular mechanisms involved are often not yet fully 
understood. Without this knowledge, proper diagnosis and intervention treatments are difficult 
to implement. 
The most important factors known to be involved to date are extracellular matrix (ECM) 
degeneration and alterations in the renin-angiotensin system (RAS) and transforming growth 
factor β (TGFβ) signalling pathways[1-12]. In fact, intervention strategies based on these 
targets are being explored[13]. Although some mitigating effects on degeneration and dilatation 
of the aorta have been observed, none of these treatments rescue the disease or reverse 
symptoms[14-16]. This must mean that still many processes and molecules involved need to be 
identified to complete the picture of how aneurysms are formed and progress.
To study the molecular mechanisms that underlie aneurysm formation we developed a Fibulin-4 
mouse model[17-19]. Fibulin-4 is a secreted glycoprotein, which is expressed in medial layers 
of blood vessels and is a critical component for the structural integrity and elasticity of the aortic 
wall[20-22]. Fibulin-4 protein levels in the aorta are essential for vascular maturation. The protein 
is located in microfibril bundles which tether elastic fibres to smooth muscle cells via integrin-
mediated binding to regions of the cell membrane that are occupied by intracellular membrane-
associated anchoring sites for actin filaments[23]. Insufficient levels of fibulin-4 compromise 
the structural integrity of the aortic wall, which can lead to aneurysm formation. In agreement, 
patients with mutations in Fibulin-4 suffer from cardiovascular complications including aortic 
aneurysms, arterial tortuosity and elastin abnormalities[24-27]. 
Fibulin-4 is an essential gene and complete deletion of this gene in the mouse leads to perinatal 
lethality[28, 29]. However, in our Fibulin-4R/R mouse model, Fibulin-4 is 4-fold reduced[17], 
resulting in severe aortic aneurysms with associated aortic valve disease, thereby closely 
mimicking aneurysm formation of genetically affected patients. Notably, genome-wide aorta 
transcriptome and histological analyses of young Fibulin-4R/R animals revealed TGFβ signalling 
as one of the critical events in the pathogenesis of the observed aneurysm formation[17].
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In this study, in order to identify additional underlying molecular mechanisms that may contribute 
to aneurysm formation, we performed proteomics, genomics and functional experiments on 
aortas of adult Fibulin-4R/R animals. Mostly, proteomics data reports on the absence or presence 
of certain proteins, whereas gene expression profiling data is subjected to pathway analysis. We 
hypothesized that by performing pathway analysis on our proteomics data, and by comparing 
gene and protein expression, this would hint us towards new important pathways that additionally 
play a role in aneurysm formation. Our -omics data point to the fact that altered mitochondrial 
function and metabolism accompany aneurysm formation in Fibulin-4R/R mice, which we 
substantiate with functional experiments. These findings offer new mechanistic insights into the 
complex disease of aneurysm formation. 
MATERIALS AND METHODS 
Experimental Animals
Fibulin-4+/R animals were bred into in a C57BL6 background to obtain Fibulin-4R/R and Fibulin-4+/+ 
experimental animals (backcross 7). Fibulin-4SMKO animals were kindly provided by Hiromi 
Yanigasawa[30] and bred into the same C57BL6 background. The numbers of animals used 
for each experiment are described in the results section, and mentioned in figures and/or figure 
legends. For each experiment with mutant animals, littermate controls were used unless stated 
otherwise. Animals were housed at the Animal Resource Centre (Erasmus University Medical 
Centre), which operates in compliance with the “Animal Welfare Act” of the Dutch government, 
using the “Guide for the Care and Use of Laboratory Animals” as its standard. As required by 
Dutch law, formal permission to generate and use genetically modified animals was obtained 
from the responsible local and national authorities. An independent Animal Ethics Committee 
consulted by Erasmus Medical Center (Stichting DEC Consult) approved these studies (permit 
number 140-12-05), in accordance with national and international guidelines. For the described 
experiments animals were sacrificed by CO2 inhalation, unless stated otherwise.
Preparation of aorta protein extracts and MS/MS protein identification
Fibulin-4R/R and Fibulin-4+/+ littermate control mice (n=2 per group, female) were sacrificed at an 
age of 80-90 days, and thoracic aortas were collected. Next, aorta protein extracts were made 
and protein concentration was determined as described[31]. Equal amounts of total protein 
were loaded and size separated on a gradient (5-20%) SDS gel. Subsequently, gels were stained 
with Coomassie Brilliant Blue. Lanes were excised from the gel and 5mm slices were subjected 
to destaining, in-gel reduction with dithiothreitol, alkylation with chloroacetamide and digestion 
with trypsin (Promega, sequencing grade), essentially as described[32]. For Nanoflow LC-MS/
MS details see online supplement. The analysis was performed in duplicate on independent 
samples (n=2 per genotype). Proteins with a Mascot score of 60 and higher with a unique 
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peptide count of at least 1, were taken into account for both genotypes separately. To perform 
an Ingenuity Pathway Analysis, lists of proteins identified in Fibulin-4R/R and Fibulin-4+/+ aortas 
were aligned and assessed for proteins only present in one or the other, or both. Next, proteins 
only present in Fibulin-4R/R aortas were designated ‘up’. Likewise, proteins only present in 
Fibulin-4+/+ aortas, thus absent in Fibulin-4R/R were designated ‘down’. Also, for enrichment of 
the IPA analysis, we took into account proteins present in both genotypes; proteins with a unique 
peptide count either 2-fold higher or 2-fold lower in Fibulin-4R/R compared to Fibulin-4+/+ were 
designated ‘up’ and ‘down’, respectively. For proper IPA analysis arbitrary signs of +2 and -2 
were given to a protein designated up or down, respectively. A total of 374 proteins were fed into 
IPA (80 down, 294 up; also see Table S1 and S2). 
GO term analysis
To classify proteins according to GO terms, we used the AgBAse GOretriever for GO-term retrieval, 
which classifies proteins on the basis of cellular components (http://agbase.msstate.edu/cgi-
bin/tools/goretriever_select.pl). For the 374 proteins that were identified as different between 
Fibulin-4R/R and Fibulin-4+/+, 342 could be assigned with a GO-term. These were separated into 
12 categories: Nucleus, Cytoplasm, Cytoskeleton, ECM, Mitochondrion, Proteasome, Plasma 
membrane, Ribosomes, Endoplasmatic Reticulum and Sarcoplasmic Reticulum (ER and SR), 
Golgi and Other (includes all other cellular components not mentioned before) and Unknown. 
For each category percentages were calculated by dividing proteins present in such category by 
all proteins assigned with a GO-term.
Micro array experiments 
Total thoracic aorta RNA of 3-month old Fibulin-4+/+ (n=3) and Fibulin-4R/R (n=2) was obtained 
using standard procedures (Qiagen). Labelling, hybridization, and scanning of Affymetrix 
Mouse Exon 1.0 ST microarrays (Affymetrix, Mountain View, CA) were performed according 
to standard Affymetrix protocol (http://www.affymetrix.com/support/technical/byproduct.
affx?product=moexon-st). Raw intensity values of all samples were normalized by robust 
multichip analysis normalization (background correction and quantile normalization) using 
Partek version 6.5 (Partek Inc., St. Louis, MO).  Principal Component Analysis showed good 
separation of the 2 sample sets.   Differential expressed genes were identified using ANOVA 
(Partek). Cut-off values for significantly expressed genes:  p-value=<0.03 and -1.5 <= fold 
change=> +1.5. Functional analysis was performed using IPA (Ingenuity, Redwood City, CA). 
Upstream regulators were selected by p-value <0.01, Bias-corrected z-score >2 and <-2. For 
the comparison of adult and newborn Fibulin-4R/R gene expression data, we used the Fibulin-
4R/R newborn data previously published by Hanada et al[17]. This comparison resulted in 106 
overlapping, significantly regulated genes (FC>1.2; p<0.05), of which 99 were regulated in 
the same direction. These 106 overlapping genes were used for pathway analysis in IPA. For 
upstream regulator analysis the same selection criteria were used as mentioned above.
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RNA isolation and realtime PCR
Liver and aortic tissue from Fibulin-4+/+ and Fibulin-4R/R mice, snap frozen and stored at -80 
ᵒC, was used for this experiment. RNA from aortic tissue was isolated with the miRNeasy mini 
kit (Qiagen) and liver RNA with RNeasy mini kit (Qiagen). cDNA was made with iScript cDNA 
synthesis kit (Biorad) according to manufacturing protocol. Q-PCR was performed with 200 nM 
forward and reverse primers and iQ™ SYBR® Green Supermix (biorad) on the CFX96 system 
(Biorad); denaturation at 95oC for 3 min, 40 cycles denaturation at 95oC for 15 sec, annealing/
extension at 55oC for 30 sec. 
Table 1. Primer sequences used for realtime PCR
 Fw seq Rev seq Size
PPARα AACATCGAGTGTCGAATATGTGG CCGAATAGTTCGCCGAAAGAA 99
PPARγ CACAATGCCATCAGGTTTGG GCTGGTCGATATCACTGGAGATC 82
PGC1α CTGCGGGATGATGGAGACAG TCGTTCGACCTGCGTAAAGT 101
PGC1β GGGAAAAGGCCATCGGTGAA CAGCACCTGGCACTCTACAA 122
B2M CTCACACTGAATTCACCCCCA GTCTCGATCCCAGTAGACGGT 98
B2M was used as a housekeeping gene. Relative gene expression levels were determined with 
the comparative Ct method. 
Cell culture 
Mice (aged 100 days) were euthanized by an overdose of CO2 and autopsied according to 
standard protocols. Primary VSMCs were isolated according to the method of Proudfoot 
and Shanahan[33], from the thoracic aorta of Fibulin-4+/+, Fibulin-4R/R and Fibulin-4SMKO mice 
and cultured on gelatinized dishes in Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza 
BioWhittaker) supplemented with 1% penicillin-streptomycin (PS) and 10% fetal calf serum (FCS) 
(also see Kobayashi et al., 2004). Tgfbr-1M318R/+ and control VSMCs were kindly provided by Hal 
Dietz and Elena MacFarlane [34]. VSMCs were used until passage 10 for experiments described 
unless stated otherwise. Human patient fibroblasts with Fibrillin-1 (FBN1 c.4817-1G>A: FBN1 
ex 39), TGFβ receptor 2 (TGFBR2 c.1573delA: TGFBR2 ex 07) and Smad3 (SMAD3 c.859C>T, 
p.R287W: SMAD3 ex 9) mutations were kindly provide by D.F. Majoor-Krakauer, I.B.M.H. van der 
Laar and J.M.A. Verhagen. All patients provided written informed consent for participation in the 
study. 
151
REDUCED MITOCHONDRIAL RESPIRATION IN FIBULIN-4 MICE
5
For the proliferation assay, cells were used at passage 7 and 8. Fibulin-4+/+ and Fibulin-4R/R 
VSMCs were seeded in triplicate in 6 cm dishes (5000 cells/dish) and allowed to attach. Cells 
were fixed overnight at 4°C with 10% trichloroacetic acid (TCA, Sigma-Aldrich, T9159) at day 
1, 2, 3, 6, and 7 after seeding. A sulforhodamine beta (SRB) assay [35] for proliferation was 
performed after collection of all time points. The fixed and dried dishes were incubated for 20 
minutes with 0.5% SRB solution (Sigma-Aldrich, S9012) in 1% acetic acid and excess SRB was 
removed by washing with 1% acetic acid. After drying, bound SRB was dissolved in 10mM TRIS 
(Sigma-Aldrich, T6066). Absorbance was measured at 560nm and the percentage of growth was 
calculated at each day relative to the number of cells at day 1.
Mitochondrial respiration
Oxygen consumption rates (OCR) and extracellular acidification rate (ECAR) were measured 
using an XF-24 Extracellular Flux Analyzer (Seahorse Bioscience). Respiration was measured in 
XF assay media (non-buffered DMEM containing 2mM L-glutamine, 100 mM sodium pyruvate 
and 5mM glucose), in basal conditions and in response to 1 µM oligomycin (ATP synthase 
inhibitor), 1 µM fluoro-carbonyl cyanide phenylhydrazone (FCCP, uncoupler), 1 µM rotenone 
(complex I inhibitor), 1 µM antimycin A (complex III inhibitor). VSMCs and MEFS were seeded 
at a density of 30,000 cells/well and analysed after 24 hours. Optimal cell densities were 
determined experimentally to ensure a proportional response to FCCP with cell number. ECAR 
was measured during the entire experiment. For these experiments three independent cell lines 
were used per genotype, for which 6-8 wells were measured per time point.
Oxygraph and Mitochondrial complex activity measurements 
Tissue homogenates were prepared from frozen muscle in 0.25 M sucrose, 10 mM N-[2-
hydroxyethyl] piperazine-N′-[2 ethylsulfonic acid](HEPES) and 1 mM Ethylene Diamine Tetra-
acetic Acid (EDTA), pH 7.4. Mitochondrial respiratory activity, measured as oxygen consumption 
rate (flux in pmol O2/second/mg mitochondrial protein) was assessed at 37°C by high-resolution 
respirometry (Oxygraph-2k, Oroboros Instruments). Complex I- and II-dependent respiration were 
measured in state 2 (respectively, in the presence of 2 mmol/L malate and 10 mmol/L glutamate, 
and in the presence of 10 mmol/L succinate) and state 3 (in the presence of substrates and 
0.25 mmol/L ADP). To prevent retrograde flux of electrons via complex I, complex II-dependent 
respiration was measured in the presence of 0.5 µmol/L of the complex I inhibitor rotenone. 
Respiratory adenylate control index (RCI) was calculated by dividing oxygen flux in state 3 by the 
flux in state 2. For complex activity measurements see online supplement.
Registration of reactive oxygen species with molecular imaging
Mice were anaesthetized (isoflurane 2%, O2 2 L/min) and visualized using the IVIS spectrum 
imaging system (Perkin Elmer). L-012 (8-amino-4-chloro-7-phenylpyridol[3,4-d]pyridazine-
1,4(2H,3H)dione, a chemitransluminescent probe and derivative of luminol, was purchased from 
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Wako Chemical (Neuss, Germany) and dissolved in H2O. A concentration of 75 mg/kg in a 
volume of 100 µl was administered intravenously. Images were taken with the IVIS Spectrum 
imaging system (Perkin Elmer). For molecular imaging, mice were sacrificed after an hour by an 
overdose of anaesthesia and the chest was opened according to standard necropsy protocols. 
Data acquisition and analysis was performed using IVIS imaging software Living Image (Caliper). 
The photon flux was quantified within a region of interest encompassing the thoracic chest region 
of each mouse. The signal was normalized against an illumination profile for the selected field of 
view. Also see reference [36].
DHE staining
Cryosections 10 µm thick were stored at −80°C. After thawing the sections, they were stained by 
5 µM dihydroethidium (DHE) and 0.5 µg/ml Hoechst 33258 in phosphate buffered saline (PBS) 
for 30 min at 37°C in a humidified atmosphere. The fluorescence of the superoxide specific 
reaction product of DHE oxidation was measured using a fluorescence inverted microscope 
(Olympus IX50) equipped with a 460–490 nm band pass excitation filter and 515 nm emission 
IF-barrier filter, digitized with an F-view camera (Soft Imaging System, Münster, Germany), and 
analysed offline (AnalySIS 3.1; Soft Imaging System). To determine the integrated density ratio, 
we first determined the sum of the fluorescence values of the pixels in the ethidium (red) and 
2-OH-ethidium (green) selection separately. Subsequently the integrated intensity ratio was 
determined by dividing the 2-OH-ethidium (green) values over the ethidium (red) values for the 
individual samples.
PGC1α luciferase assay
Fibulin-4+/+ and Fibulin-4R/R VSMCs were transiently transfected using lipofectamine 2000 
(Invitrogen). Cells were dually transfected with PGC1α 2kb firefly luciferase plasmid (Addgene 
plasmid 8887 [37]) and SV40-renilla luciferase plasmid (10:1). After 24 hours, cells were washed 
with PBS, replenished with medium containing low serum (0.2% FCS) and cells were either 
treated overnight with TGFβ1 (5 ng/ml, Biovision) to stimulate TGFβ signalling, SB431542 hydrate 
(10 µM, Sigma), inhibitor of the TGFβ receptor, forskolin (10 µM, Sigma) for PGC1α activation, 
or DMSO as a negative control. After 24 hours, cells were lysed and firefly/renilla luciferase 
ratio was determined with the dual-luciferase assay system (Promega) using Glomax- multi+ 
detection (Promega) for each cell line. Relative luciferase levels were calculated by using the 
untreated Fibulin-4+/+ VSMCs (control) as reference value.
Statistical analysis
All experiments described were performed blinded by using cell line and mouse numbers 
without genotypes. Normal distribution of the data was assessed using the Shapiro Wilk test. 
The unpaired 2-tailed Student t-test was performed to analyse the specific sample groups for 
significant differences. All results are expressed as mean ± SEM. However, for data with non-
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normal distribution, log-transformation of the data, followed by the Student t-test, was performed. 
A p-value <0.05 was considered to indicate a significant difference between groups. In the 
figures p<0.05 or p<0.01 is shown with *, and p<0.001 with **. All analyses were performed 
using IBM SPSS Statistics version 21.0 (SPSS Inc., Chicago, IL, USA) or Graphpad.
RESULTS
Proteomics analysis identifies increased mitochondrial proteins levels in Fibulin-4R/R 
aortas 
For the proteomics analysis, Fibulin-4R/R and Fibulin-4+/+ protein extracts isolated from 3 month 
old thoracic aortas Fibulin-4R/R and Fibulin-4+/+ animals were used. Reduction of Fibulin-4 protein 
was confirmed by western blot (Fig S1 A, left panel). Proteome expression profiles were analysed 
using a 1D gradient gel of total aorta protein extract. Next, proteins separated on the gel were 
trypsin digested and identified by an MS/MS method coupled to Mascot database searches 
(Table S1). A duplicate analysis of the samples identified more than 75% of the proteins in the 
first analysis. Analysis of an independent set of aorta extracts identified more than 65% of the 
previously identified proteins. 
To determine differences in the proteome of Fibulin-4R/R and Fibulin-4+/+ aortas, we used a 
Mascot score cut-off of 60. This resulted in a total of 695 proteins, of which 494 identified proteins 
for Fibulin-4+/+ and 655 identified proteins for Fibulin-4R/R aorta. Ingenuity Pathway Analysis (IPA) 
was performed on a selection of proteins that were either present or absent, as well as proteins 
with a 2-fold higher or lower peptide count, in Fibulin-4R/R versus Fibulin-4+/+ aorta, designated 
over- and underrepresented, respectively. This resulted in 80 proteins that were overrepresented 
in Fibulin-4+/+ compared to Fibulin-4R/R aorta and 294 proteins that were overrepresented in 
Fibulin-4R/R compared to Fibulin-4+/+, leaving 321 proteins designated as ‘not changed’ between 
Fibulin-4+/+ and Fibulin-4R/R (Table S2 and Fig 1A).
To verify this approach, we subsequently checked whether we could find proteins known to 
be associated with aneurysm formation based on three important associated factors: the 
ECM, TGFβ and RAS signalling. We used the AgBAse GOretriever for GO-term retrieval, which 
classifies proteins on the basis of cellular components (http://agbase.msstate.edu/cgi-bin/tools/
goretriever_select.pl). Of the 374 proteins in total that were differentially expressed between 
Fibulin-4R/R and wildtype mice, 342 GO-terms could be assigned. Here we observed that 14% 
of these proteins fell into the category ‘ECM’ (Fig1B). Moreover, compared to wildtype, in the 
Fibulin-4R/R aorta we observed overrepresentation of the ECM proteins elastin, fibrillin, fibronectin, 
laminin and different collagen subtypes. We performed confocal 3D imaging on aortic walls of 





Rho regulation of Actin-based Motility
Germ/Sertoli Cell Junction Signaling
Fibulin-4+/+ Fibulin-4R/R












TGFB1 Transforming growth factor, beta 1 growth factor Activated 3,54 2,10E-15
TP53 Tumor protein p53 transcription regulator Activated 2,31 1,53E-04
AGT Angiotensinogen growth factor Activated 2,10 2,69E-06
SREBF2 Sterol regulatory element binding transcription factor 2 transcription regulator Inhibited -3,76 1,79E-04
MLXIPL MLX interacting protein-like other Inhibited -3,27 3,03E-06
SREBF1 Sterol regulatory element binding transcription factor 1 transcription regulator Inhibited -3,22 5,45E-09
HNF4A Hepatocyte nuclear factor 4, alpha transcription regulator Inhibited -3,00 8,66E-07
T3-TR-RXR TR/RXR Activation complex complex Inhibited -2,93 4,98E-03
PDGF BB PDGF complex complex Inhibited -2,19 2,42E-04
ATP7B ATPase, Cu++ transporting, beta polypeptide transporter Inhibited -2,16 4,15E-03
IRF4 Interferon regulatory factor 4 transcription regulator Inhibited -2,05 1,74E-03
PPARA Peroxisome proliferator-activated receptor alpha ligand-dependent nuclear receptor Inhibited -2,00 1,00E-09
-Log (p-value)





















Figure 1. Proteomics analysis of Fibulin-4R/R  and Fibulin-4+/+ thoracic aortas identifi es mitochondrial 
function as potentially affected.
A) Venn diagram comparison of proteins identifi ed in Fibulin-4+/+ (left circle) and Fibulin-4R/R (right circle) 
aortas; on the left side proteins overrepresented in Fibulin-4+/+ aortas (light grey), on the right side proteins 
overrepresented in Fibulin-4R/R aortas (dark grey). Overlap between the two circles represents proteins that 
exhibit no chance between the two groups. B) Pie graph of GO-term distribution of proteins differentially 
regulated in Fibulin-4R/R compared to Fibulin-4+/+ aorta. Cytoskeleton (17%), extracellular matrix (ECM, 
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14%) and mitochondria (17%) together comprise 48% of differentially regulated proteins. C) Table depicting 
predicted activation or inhibition of Upstream Regulators (-2> bias-corrected z-score>2, p-value <0.01), 
derived from an IPA analysis based on differentially regulated proteins in Fibulin-4R/R compared to Fibulin-4+/+ 
aortas. Notably, TGFβ1 and Angiotensinogen (AGT) are predicted to be upregulated, which is known from 
literature, thus validating this prediction approach. D) Graph depicting the top 10 significantly changed 
(p<0.01) canonical pathways, derived from an IPA analysis based on the differentially regulated proteins in 
Fibulin-4R/R compared to Fibulin-4+/+ aortas. Mitochondrial dysfunction is the 6th most significantly changed 
canonical pathway.
structure in the latter (Fig S1B). In addition, western blot analysis showed increased amounts 
of elastin protein in Fibulin-4R/R compared to Fibulin-4+/+ aortic extracts (Fig S1C). Both results 
confirm the overrepresentation of the ECM proteins that we observed in proteomics data. Next 
to this overabundance of ECM proteins, 17% of the proteins fell into the category ‘cytoskeleton’. 
Cytoskeleton proteins are closely connected to the ECM via integrins. Unexpectedly, we also 
observed that 17% of all proteins with significantly changed expression fell into the category 
‘mitochondria’ (Fig 1B). 
Next, the 374 deregulated proteins were loaded into IPA for further analysis. Of these 374 protein 
IDs, 369 were mapped by IPA. We performed both a pathway and an upstream regulator analysis 
to get an idea of the changes in processes involved. TGFβ1 itself turned out to be upregulated 
and was also predicted to be activated (based on 69 deregulated target molecules) as part of 
the upstream regulator analysis (Fig 1C). Thus, the proteomics data points to involvement of 
TGFβ signalling in Fibulin-4 associated aneurysms as previously reported[17, 27, 38]. Both ACE 
as well as Rac1, which are part of the RAS pathway, were upregulated in the protein dataset of 
Fibulin-4R/R compared to Fibulin-4+/+. Moreover, angiotensinogen, a key molecule in the RAS 
pathway, was predicted to be upregulated (Fig 1C). Indeed, previous analysis of mouse aortas 
showed that angiotensinogen is increased in Fibulin-4R/R animals compared to Fibulin-4+/+ [8, 
10]. In conclusion, our proteome analysis reveals deregulation of TGFβ signalling and RAS, 
processes already known to be changed in Fibulin-4 R/R aneurysms, validating our approach.
Canonical pathway analysis (IPA) pointed towards changes in cytoskeleton and integrin signalling 
(Fig 1D), as did the GO-analysis, which fits with fibulin-4’s functions within the ECM. Interestingly, 
mitochondrial dysfunction was also a significantly changed canonical pathway, which fits with the 
findings of the GO analysis showing a protein overrepresentation in the category ‘mitochondria’. 
Taken together, next to factors known to be changed in aneurysm formation, our proteomics data 
analysis suggests changes in mitochondrial function in the aortas of Fibulin-4R/R animals.
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Decreased oxygen consumption rate in mutant Fibulin-4 and TGFβ-1 receptor VSMCs 
To investigate mitochondrial function, we analysed mitochondrial respiration using a Seahorse 
XF-24 Extracellular Flux Analyzer, which allows simultaneous measurement of the oxygen 
consumption rate (OCR) and the extracellular acidification rate (ECAR). While OCR indicates 
respiration, ECAR reflects lactate production and thus glycolytic flux. OCR and ECAR thus 
provide a comprehensive estimate of the bioenergetics properties of the studied specimen. 
We observed a significantly decreased basal respiration (without addition of any inhibitor) in 
Fibulin-4R/R vascular smooth muscle cells (VSMCs) compared to Fibulin-4+/+ controls (Fig 2A-B, 
phase I, p<0.01). While no differences were observed in respiration after injection of the ATP 
synthase inhibitor oligomycin, the addition of FCCP, an oxidative phosphorylation (OXPHOS) 
uncoupler eliciting maximal respiration, indicated a significantly lower maximal OCR in Fibulin-
4R/R VSMCs (Fig 2A-B, phase III, p<0.01). Complete repression of respiration by the combined 
addition of complex I inhibitor rotenone and complex III inhibitor antimycin A, led to the same 
OCR in Fibulin-4R/R and Fibulin-4+/+ VSMCs, indicating that besides mitochondrial respiration, 
oxygen consumption differences due to other cellular processes are negligible (Fig 2A). 
Experiments were repeated three times with two independent cell lines per genotype which gave 
similar consistent results (Fig 2B). Interestingly, ECAR was consistently higher in Fibulin-4R/R 
compared to Fibulin-4+/+ VSMCs (Fig 2C-D, p<0.01), which might be indicative of metabolic 
rearrangements to compensate for mitochondrial defects in Fibulin-4R/R cells. Interestingly, lower 
basal and maximum OCR were also observed in mouse embryonic fibroblasts of Fibulin-4R/R 
mice compared to Fibulin-4+/+ control mice, highlighting that decreased oxygen consumption is 
a general phenomenon in the Fibulin-4 R/R mouse model (Fig S2, p<0.01).  
We next wanted to verify that the observed defect in mitochondrial function is due to reduced 
Fibulin-4 in Fibulin-4R/R cells, rather than potential secondary effects associated with the 
engineered allele. To this end we isolated Fibulin-4SMKO VSMCs from the Fibulin-4SMKO mouse, in 
which Fibulin-4 is knocked out in the smooth muscle cells specifically. Absence of Fibulin-4 in 
Fibulin-4SMKO aortic extracts was verified by western blot (Fig S1A right panel). We then performed 
the same Seahorse experiments as described above for the Fibulin-4R/R VSMCs. Interestingly, 
also these Fibulin-4SMKO VSMCs showed a significant reduction in both basal and maximal OCR 
compared to Fibulin-4+/+ VSMCs (Fig 2E, p<0.01), demonstrating that Fibulin-4 deletion results 
in the observed defects in mitochondrial respiration similar to those in the Fibulin-4R/R VSMCs. 
We did not observe significant changes in the ECAR compared to Fibulin-4+/+ VSMCs (data not 
shown).
We were interested whether the same decreased oxygen consumption rate was present in 
VSMCs from other aneurysmal syndromes. This prompted us to first measure mitochondrial 
respiration in VSMCs obtained from the Tgfbr-1M318R/+ mouse, a model for Loeys-Dietz syndrome 
(LDS)[34]. Similar to Fibulin-4R/R and Fibulin-4SMKO VSMCs, Tgfbr-1M318R/+ VSMCs showed a 
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Figure 2. Reduced OCR and increased ECAR in Fibulin-4 deficient VSMCs. 
A) Graph depicting the Oxygen Consumption Rate (OCR) in Fibulin-4R/R VSMCs (dark blue squares) and 
Fibulin-4+/+ VSMCs (light blue squares) at basal level (I) and after addition of oligomycin, a complex V 
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inhibitor (II), FCCP, an OXPHOS uncoupler, for maximum OCR measurement (III), and a combination of 
rotenone (complex I inhibitor) and antimycin A (complex III inhibitor), showing potential OCR differences not 
due to mitochondria (IV). B) Both at basal level (I) and at maximum oxygen consumption level (III) Fibulin-
4R/R VSMCs show a significantly lower OCR compared to Fibulin-4+/+ (p<0.01, Student t-test), indicating 
altered mitochondrial function. The scatter plot shows absolute OCR levels from three experiments that were 
performed in two independent cell lines per genotype. C) Graph depicting the Extracellular Acidification Rate 
(ECAR) in Fibulin-4R/R and Fibulin-4+/+ VSMCs. D) ECAR is significantly elevated in Fibulin-4R/R compared to 
Fibulin-4+/+ VSMCs (p<0.01, Student t-test), quantified at basal (I) and maximum OCR (III). The scatter plot 
shows ECAR levels from three experiments that were performed in two independent cell lines per genotype. 
E) Scatter plots showing basal (I) and maximum (III) OCR levels in Fibulin-4SMKO VSMCs (dark blue circles), 
which are knock-out for Fibulin-4 in VSMCs specifically, and Fibulin-4+/+ VSMCs (light blue circles), for three 
experiments that were performed in two independent cell lines per genotype. Fibulin-4SMKO VSMCs show a 
significantly lower OCR compared to Fibulin-4+/+ (p<0.01, Student t-test) F) Scatter plots showing basal 
(I) and maximum (III) OCR levels in Tgfbr-1M318R/+ (dark blue triangles) and Tgfbr-1+/+ VSMCs (light blue 
triangles), of three experiments that were performed in two independent cell lines per genotype. Both at 
basal (I) and at maximum OCR level (III) Tgfbr-1M318R/+ VSMCs show a significantly lower OCR compared 
to Tgfbr-1+/+ (p<0.01, Student t-test) G) Graph depicting the Oxygen Consumption Rate (OCR) in three 
different human fibroblast cell lines derived from aneurysmal patients with a Fibrillin-1 (FBN1, dark blue 
squares), TGFβ receptor 2 (TGFBR2, blue  diamonds) and SMAD3 (light blue circles) mutation, as well as 
the mean of three control cell lines (light blue squares). H) Scatter plots showing basal (I) and maximum 
(III) OCR levels, which are significantly lower for the human mutant fibroblasts compared to control (p<0.01, 
Student t-test). OCR observations were made in two independent experiments, in case of the controls for 
three independent cell lines. 
reduced basal and maximal OCR compared to Tgfbr-1+/+ VSMCs (Fig 2F). We did not observe 
an obvious decrease in ECAR as seen for Fibulin-4R/R  VSMCs (data not shown). To examine 
whether oxygen consumption is also affected in cells of Marfan and Loeys-Dietz patients, we set 
out to measure mitochondrial respiration in patient cell lines. Although we did not have access 
to human VSMCs, we were able to obtain human fibroblasts from aneurysmal patients with 
Fibrillin-1 (FBN1 c.4817-1G>A: FBN1 ex 39), TGFβ receptor 2 (TGFBR2 c.1573delA: TGFBR2 ex 
07) and Smad3 (SMAD3 c.859C>T, p.R287W: SMAD3 ex 9) mutations, as well as 3 control cell 
lines. We next used the human patient fibroblasts to perform seahorse experiments. Interestingly, 
all three patient cell lines showed a significantly reduced basal and maximum OCR compared to 
the control cell lines (Fig 2G and H). From these data we conclude that the altered mitochondrial 
oxygen consumption in aneurysms is not restricted to Fibulin-4 mutations per se, but is present 
in VSMCs and fibroblasts of multiple thoracic aneurysmal aorta syndromes.
Complex I, III, IV and V levels and activity in Fibulin-4R/R VSMCs and tissues
To investigate whether mitochondrial localization was affected by Fibulin-4 mutation, we first 
stained two independent Fibulin-4R/R and Fibulin-4+/+ VSMC cell lines used in the Seahorse 
experiments with Mitotracker CMX Ros and SiR-Actin. We observed no differences in 
mitochondrial localization or obvious differences in cytoskeletal composition between Fibulin-4 
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mutant or control cell lines (Fig 3A). We next performed fluorescence-activated cell sorting (FACS) 
experiments using Fibulin-4R/R and Fibulin-4+/+ VSMCs with the Mitotracker CMX Ros probe to 
determine the number of mitochondria per cell. From this analysis we observed no differences 
in mitochondrial signals, indicating no change in number of mitochondria per cell (Fig 3B). The 
observed differences in mitochondrial function in Fibulin-4R/R and Fibulin-4+/+ cells prompted 
us to examine mitochondrial structure in VSMCs of the aorta by electron microscopy (EM). The 
mitochondrial ultrastructure in Fibulin-4+/+ and Fibulin-4R/R cells appeared similar, although the 
Fibulin-4R/R mitochondria seemed somewhat reduced in size (Fig 3C). 
The clear differences in mitochondrial respiration, without affecting the number of mitochondria 
per cell, could imply an altered mitochondrial mass (i.e. total mitochondrial volume in the 
cell) in Fibulin-4R/R VSMCs. In turn, this could indicate less mitochondrial complexes per cell, 
leading to decreases in OCR. However, the proteomics data showed a higher expression of 
mitochondrial complex proteins involved in oxidative phosphorylation. To investigate expression 
of mitochondrial complex proteins, we performed Western blot analysis using thoracic aorta 
tissue with an antibody cocktail directed against five specific OXPHOS I-V complex subunits 
that are labile when its complex is not assembled. Interestingly, when compared to Fibulin-4+/+, 
the protein level of complexes I through IV was significantly (p<0.05) increased in Fibulin-4R/R 
aortas, whereas complex V showed no significant change (Fig 3D-E). This is in agreement with 
the results from the proteomics analysis which showed that several individual mitochondrial 
complex proteins are upregulated. This could indicate a partial compensatory reaction of the 
respiratory electron transport chain (ETC) to counteract the decrease in mitochondrial mass. We 
also performed this western blot on Fibulin-4SMKO aortic extracts and littermate controls, to see if 
deleting Fibulin-4 in VSMCs alone could result in overexpression of these complexes. Indeed, 
we observed overexpression of Complex I-IV in Fibulin-4SMKO (Fig S1D), however this was not 
a significant difference, indicating that other cells in the aorta of Fibulin-4R/R animals may also 
contribute to this effect.
To see if decreased OCR is not limited to the aorta, we measured respiratory capacity in aorta, 
heart, muscle and liver of Fibulin-4+/+ and Fibulin-4R/R animals. Unfortunately, we were unable to 
determine OCR in aortic extracts, probably due to rigidity of the tissue because of ECM content. 
Nevertheless, heart and skeletal muscle, containing large amounts of muscle cells and highly 
dependent on mitochondrial activity, both showed a significantly lower OCR (Fig 3F). The liver did 
not show a lower, but somewhat higher (non-significant) OCR (Fig 3F), which we would expect if 
the observed OCR decrease is muscle cell specific. To determine whether the decreased oxygen 
consumption was due to reduced mitochondrial complex activity, we measured individual 
Complex I, III, IV and V activities (II is not subject to change), but observed no significant change 
(Fig 3G). These data fit with the observation that more Complex I-IV proteins are present in the 
aorta (Fig D-E). Taken together, we can conclude that the reduced oxygen consumption is not 
due to lower complex activity.    
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Figure 3. Mitochondrial size and complexes are affected in the thoracic aorta of Fibulin-4R/R  animals. 
A) Mitotracker and SiR-Actin staining of Fibulin-4R/R and Fibulin-4+/+ VSMCs showing a very similar distribution 
and pattern. B) Scatter plot depicting mitotracker (CMXRos) signal per cell, a measure for mitochondrial 
number per cell. No signifi cant difference was observed (Student t-test). Mitotracker experiments were 
performed for n=3 (Fibulin-4R/R) and n=5 (Fibulin-4+/+) cell lines, with the same result. C) Representative 
electron micrographs of VSMCs in Fibulin-4+/+ and Fibulin-4R/R aortas, showing no obvious structural 
changes, except for smaller mitochondrial size in the latter. D) Representative western blot for mitochondrial 
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complexes I-V proteins in Fibulin-4+/+ and Fibulin-4R/R aorta lysates with β-catenin as loading control. Please 
note that complex IV is lower in size than complex III. Although detection was done on the same Western 
blot, it is divided into three pieces as the pictures were taken with different exposure times; 1, 2 and 5 
minutes for β-catenin, complex II-V and complex I, respectively. E) Quantification of the different complexes 
for wildtype and Fibulin-4R/R aortas, showing significant increases in complexes I-IV in Fibulin-4R/R aortas 
compared to wildtype (n=4 per genotype, *p<0.05. **p<0.01, Student t-test on log-transformed data). 
F) OCR measurements in heart, muscle and liver, showing lower OCR in Fibulin-4R/R animals compared to 
their respective Fibulin-4+/+ littermates (n=3 per genotype, p<0.05, Student t-test on log-transformed data). 
G) Complex activity measurements in Fibulin-4+/+ and Fibulin-4R/R heart and muscle showing no significant 
difference (n=3 per genotype) 
Molecular imaging reveals increased ROS in the aorta of Fibulin-4R/R animals
The observed imbalance between mitochondrial mass and the expression and activity of 
mitochondrial enzyme complexes may lead to an increase in generation of reactive oxygen 
species (ROS). In this context, we did observe a somewhat lower ADP ratio in Fibulin-4R/R 
muscular tissues (data not shown), which would imply less efficient ATP production that could 
lead to more radical formation. To investigate if indeed more radicals are present, we performed 
molecular imaging using the L-012 probe. This probe emits a luminescent signal upon interaction 
with reactive oxygen and nitrogen species that is quantified using an IVIS spectrum imaging 
system. We injected Fibulin-4R/R and Fibulin-4+/+ animals with the L-012 probe and recorded 
the luminescent signal from the opened chest of mice after 1 hour to determine the signal 
localization. Experiments were performed three times with each Fibulin-4R/R animal matched to 
a Fibulin-4+/+ littermate control. We observed a significant increase in average L-012-derived 
luminescence in Fibulin-4R/R aortas compared to Fibulin-4+/+ (Fig 4A-B, p<0.05). Consistently, 
staining of Fibulin-4R/R aortic sections with the superoxide indicator DHE showed increased 
2-OH-ethidium fluorescence compared to Fibulin-4+/+, indicative of increased superoxide levels 
(Fig 4C, p<0.05). Together, these data show that ROS levels are elevated in Fibulin-4R/R aortas.
Systemic metabolic analyses indicate a metabolic switch towards fatty acid oxidation 
in Fibulin-4R/R animals 
Previous gene expression studies performed on young Fibulin-4R/R animals gave insight into 
the mechanism of aneurysm formation, amongst which were cytoskeleton re-organization and 
perturbed TGFβ signalling[17]. As we observed many changes at the protein level pointing 
towards mitochondrial involvement, we wondered whether this would also be reflected at the 
transcriptional level. Additionally we were interested whether gene expression profiles could 
point to potential mechanisms and targets involved. Therefore, we performed gene expression 
analyses on 3-month old Fibulin-4+/+ and Fibulin-4R/R thoracic aortas by using GeneChip mouse 
exon 1.0 ST arrays (Affymetrix). The obtained gene expression differences (p-value of 0.03; Fold 
Change 1.2) were uploaded and analysed in IPA. Canonical pathway analysis pointed towards 









































































Figure 4.  Molecular imaging reveals increased ROS levels in Fibulin-4R/R animals. 
A) Representative pictures of 3 independent experiments showing increased LO12 probe signal intensity 
(emits light after ROS binding) in Fibulin-4R/R (right) animals compared to respective Fibulin-4+/+ (left) 
littermates. B) Quantification of the average radiance at the site of the aorta, a measure for the amount of 
ROS reacting with LO12 probe, shows significantly higher levels in the Fibulin-4R/R compared to Fibulin-4+/+ 
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mice (n=3 per genotype, *p=0.01, Student t-test). C) Left panel: Representative sections of DHE staining 
for superoxide anion, in aortic sections from Fibulin-4R/R, counterstained with ethidium for DNA content (red), 
show increased 2-OH-DHE fluorescence (green) compared to Fibulin-4+/+ as shown in the merged picture 
(left, predominantly green in Fibulin-4R/R versus yellow in Fibulin-4+/+). The white line indicates a length of 100 
µm. Right panel: Scatter plot depicting the integrated intensity ratio for Fibulin-4+/+ and Fibulin-4R/R, showing 
an increase in the latter (n=3 per genotype, *p<0.05, Student t-test).
canonical pathways predicted to be significantly changed (p<0.01), 73% are directly involved 
in metabolic processes (data not shown). Moreover, when we examine the first 10 networks 
significantly changed based on our gene dataset, at the first position we find ‘Energy Production/
Lipid Metabolism/Small Molecule Biochemistry’ (Fig S3). 
To investigate if metabolic changes observed in the thoracic aorta are also reflected systemically 
in the mouse, we first analysed body weights of the mice. Indeed, Fibulin-4R/R animals (n=38) 
had a significantly lower body weight than Fibulin-4+/+ animals (Fig 5B, p<0.05). Next, we 
examined three important metabolic parameters; glucose, lactate and ketones in blood of non-
fasted Fibulin-4+/+ and Fibulin-4R/R animals. These parameters together  shed light on the main 
metabolic processes used to generate ATP. Both blood glucose levels as well as blood lactate 
did not show significant differences between the two genotypes (Fig 5C-D). However, blood 
ketone levels were significantly lower in Fibulin-4R/R compared to Fibulin-4+/+ animals (Fig 5E, 
p<0.01). Interestingly, in our gene expression analysis, we found that the key enzyme responsible 
for breakdown of ketones, is significantly upregulated in the aorta (3-oxoacid CoA transferase, 
OXCT1, 1.3 fold, p=0.03, Fig S6A). In addition, IPA analysis revealed many genes involved in the 
citric acid cycle (tricarboxylic acid cycle, TCA) pathway significantly downregulated in Fibulin-4R/R 
compared to Fibulin-4+/+ aortas (Fig S4A). 
The liver is a central organ involved in metabolism and adjusts metabolic processes to energy 
demands of the different tissues within an organism. Since ketones are products of fatty acid 
oxidation in the liver, we next performed oil-red-o staining on livers isolated from Fibulin-4+/+ 
and Fibulin-4R/R animals (n=5 per group) that were normally fed. These animals did not show 
signs of malnutrition, or malabsorption of food in the intestine, and the liver showed no overt 
abnormalities on H&E-stained sections (data not shown). Yet, livers of Fibulin-4R/R animals clearly 
showed reduced oil-red-o staining in all five animals examined as compared to their respective 
Fibulin-4+/+ littermates (Fig 5F, p<0.01). In contrast, periodic acid-Schiff (PAS) staining for 
glycogen showed the exact opposite; all five Fibulin-4R/R animals showed increased glycogen 
accumulation compared to their respective Fibulin-4+/+ littermates (Fig 5G, p<0.01). We found 
no direct evidence for malfunctioning mitochondria of the liver regarding the process of OXPHOS, 
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Figure 5. Gene expression analysis and metabolic parameters show altered metabolism in Fibulin-4R/R 
animals. 
A) Graph depicting the top 10 significantly changed (p<0.01) canonical pathways, derived from an IPA 
analysis based on the differentially regulated genes between Fibulin-4R/R and Fibulin-4+/+ aortas, showing 
an overrepresentation of pathways involved in energy metabolism. B) Scatter plot depicting body weights 
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of Fibulin-4R/R and Fibulin-4+/+ animals, showing significant reduction in Fibulin-4R/R compared to Fibulin-4+/+ 
animals at 3 months (n=38 and 35, respectively, p<0.05, Student t-test). C), D) and E) Scatter plots 
depicting glucose (Fibulin-4+/+ n=6, Fibulin-4R/R n=7), lactate (Fibulin-4+/+ n=6, Fibulin-4R/R n=5) and 
ketone levels (Fibulin-4+/+ n=6, Fibulin-4R/R n=7), respectively, in blood of Fibulin-4R/R and Fibulin-4+/+ 
animals, showing a significant reduction in serum ketone levels for Fibulin-4R/R animals (p<0.01, Student 
t-test). F) Representative pictures of oil-red-o staining for lipids in Fibulin-4R/R and Fibulin-4+/+ livers (left), and 
quantification of oil-red-o ratio (right). Compared to their Fibulin-4+/+ littermates, Fibulin-4R/R show decreased 
oil-red-o staining in the liver (p<0.01, Student t-test) (n=5 per genotype).  G) Representative pictures of 
PAS staining for glycogen in Fibulin-4R/R and Fibulin-4+/+ livers (left), and quantification of PAS ratio (right). 
Compared to their Fibulin-4+/+ littermates, Fibulin-4R/R show increased PAS staining in their livers (p<0.01) 
(n=5 per genotype). The white line indicates a length of 100 µm.
Fibulin-4+/+ animals did not show differences in the amount of the various OXPHOS complexes 
(Fig S4B). This could be due to absence or low expression of Fibulin-4 in the liver. Thus, based 
on the reduction of fatty acids in the liver together with reduction of ketones in the blood, it is 
likely that metabolism in the liver of Fibulin-4R/R mice has shifted to fatty acid β-oxidation and the 
production of ketone bodies, to meet the altered demand in energy carrier type (ketone bodies 
versus glucose) by the aneurysmal aorta.
We next compared the gene expression data of newborn Fibulin-4R/R aortas, previously 
published by Hanada et al.[17], with the gene expression data of adult Fibulin-4R/R aortas. This 
comparison resulted in 106 overlapping, significantly regulated genes (FC>1.2; p<0.05) used 
for IPA analysis, of which 99 were regulated in the same direction. Canonical pathway analysis 
showed processes involved in fat and glucose metabolism significantly regulated, such as 
atherosclerosis signalling, PPARα/RXRα signalling and glycolysis, in common between newborn 
and adult aortas (Fig S5A), which may hint to processes that are important form an early time point 
on for aneurysm formation in these animals. Moreover, upstream regulator analysis predicted, 
amongst others, TGFB1, miR-29b and PPARG to be significantly differentially regulated (Fig 
S5B). Interestingly, TGFB1 and miR-29b have previously been published to be altered in Fibulin-
4R/R aortas [17, 38, 39], and are here also found to be important key regulators. PPARG was not 
previously identified, but plays an important role in fat metabolism. As we observed changes 
in fat and glycogen deposition in adult Fibulin-4R/R livers compared to Fibulin-4+/+ livers, we 
performed the same staining on newborn livers. However, we did not observe obvious changes 
in fat or glycogen deposition between Fibulin-4R/R and Fibulin-4+/+ newborn livers (Fig S5C, n=5 
per genotype). These data together could indicate that the aneurysmal induced changes in 
metabolic processes may precede the metabolic changes in the liver.    
  
Reduced PGC1α expression and activity in aortas and VSMCs of Fibulin-4R/R animals
Since we discovered changes in mitochondrial function in thoracic aortas of Fibulin-4R/R animals, 
it would be interesting to know which process or subset of factors is responsible. To investigate 
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this, we looked at upstream regulators that are predicted to be significantly changed based 
on the gene expression data in the thoracic aorta of Fibulin-4R/R animals. Interestingly, PGC1α 
and PGC1β (peroxisome proliferator-activated receptor gamma, coactivator 1 α and β) as well 
as PPARα, PPARδ and PPARγ (peroxisome proliferator-activated receptor α, δ and γ) were 
predicted to be significantly downregulated (Table 1). In addition, we noticed that they were also 
all significantly downregulated at the gene expression level, except for PPARδ, which showed 
no significant change (Table 1). Next, we performed real-time PCR analysis to check the mRNA 
expression levels of PGC1α, PGC1β, PPARα and PPARγ in thoracic aorta extracts of Fibulin-
4R/R and Fibulin-4+/+ animals. We found that mRNA levels of PGC1α and PGC1β were both 
significantly downregulated in Fibulin-4R/R compared to Fibulin-4+/+ aortas (Fig 6A, p<0.05, n=11 
and n=7, respectively), whereas levels of PPARα and PPARγ were lower but not significantly 
different from Fibulin-4+/+ (Fig S4C). Interestingly, in the liver we found that PGC1α was 
significantly upregulated (Fig S4D, p<0.05), which would be consistent with the observed lower 
lipid content (higher lipid usage) of the liver (Fig 5F) and the somewhat higher OCR (Fig 3G). 
PGC1α is the master switch between mitochondrial biogenesis and organismal metabolism, and 
signals to PPARs, essential regulators of lipid metabolism, making these interesting molecules 
for further investigation. Moreover, when examining the networks predicted to be significantly 
regulated in our gene expression dataset, the highest significantly regulated network is ‘Energy 
Production/Lipid Metabolism/Small Molecule Biochemistry’ (Fig S3). The visual representation 
of this network, derived from IPA, highlights that PPARα and PPARγ play a central role (Fig S6A).
Next, we performed a gene to protein comparison, where we compared the lists of significantly 
regulated genes and proteins in adult Fibulin-4R/R aortas to Fibulin-4+/+. This comparison revealed 
30 molecules that changed both at the gene and protein level (Fig S6B). This list included key 
genes/proteins involved in metabolism, like glucose-6-phosphate dehydrogenase and fatty acid 
synthase (Fig S6B). Strikingly, when we asked whether IPA could find a connection between the 
30 overlapping molecules (core analysis on the 30 genes/proteins in common), we indeed found 
the highest network regulated to be Lipid Metabolism, in which again PPARα and PGC1α are 
involved as key regulators (Fig S6C). 
In order to check PGC1α activity in VSMCs, we used a luciferase-based assay. We transfected 
plasmids containing firefly luciferase under the control of the PGC1α promoter in Fibulin-4R/R and 
Fibulin-4+/+ VSMCs, with plasmids containing renilla luciferase as transfection control. Relative 
luciferase levels, a measure for PGC1α activity, were significantly lower in Fibulin-4R/R VSMCs 
(Fig 6B, p<0.01). It was reported that TGFβ signalling negatively regulates PGC1α [40-42]. As 
we previously found TGFβ signalling to be increased in Fibulin-4R/R aortas and cells [17, 38], we 
next investigate the effect of TGFβ signalling on PGC1α. We performed the PGC1α luciferase-
based assay on Fibulin-4+/+ and Fibulin-4R/R VSMCs with either TGFβ treatment, TGFβR inhibition 
(SB431542), or forskolin, a potent inducer of PGC1α activity. In both Fibulin-4+/+ and Fibulin-
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Figure 6. PGC1α expression and activity changes in Fibulin-4R/R aortas and VSMCs 
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A) Real-time PCR analysis shows significantly downregulated mRNA levels of PGC1α and PGC1β in 
Fibulin-4R/R compared to Fibulin-4+/+ aortas (p<0.05, n=7 and n=11, respectively, Student t-test on log-
transformed data). B) Relative luciferase levels show decreased PGC1α transcriptional activation in Fibulin-
4R/R compared to Fibulin-4+/+ VSMCs (p<0.01, Student t-test on log-transformed data). C) Relative luciferase 
levels show decreased PGC1α transcriptional activation after TGFβ treatment in both Fibulin-4R/R (right) 
and Fibulin-4+/+ (left) VSMCs compared to the untreated (NT) control. Forskolin, a potent PGC1α activator, 
significantly increases PGC1α transcriptional activation in both Fibulin-4R/R and Fibulin-4+/+ VSMCs to the 
same extent as compared to the untreated control. Data is shown for 3 independent experiments, n=3 
cell lines per genotype. TGFβ inhibition does not significantly increase PGC1α activity. D) Scatter plots 
depicting the basal and maximum Oxygen Consumption Rate (OCR) in Fibulin-4+/+ and Fibulin-4R/R VSMCs 
after forskolin treatment, which activates PGC1α, compared to the untreated controls, and TGFβ inhibition. 
Both Fibulin-4+/+ and to Fibulin-4R/R show a significant increase in basal and maximum OCR compared to 
the untreated controls (p<0.01, Student t-test) after forskolin treatment. TGFβ inhibition does not show a 
significant increase. Experiments were performed twice, n=2 cell lines per genotype. E) Growth curves 
of Fibulin-4R/R and Fibulin-4+/+ VSMCs showing that activation of PGC1α significantly restores the reduced 
growth of Fibulin-4R/R VSMCs compared to the untreated situation (NT) (p<0.01, non-linear fit of exponential 
decay). Experiments were performed twice, n=2 cell lines per genotype, the mean of two cell lines is shown.
4R/R VSMCs, treatment with TGFβ significantly reduced PGC1α transcription (Fig 6C, p< 0.01), 
showing that also in VSMCs TGFβ signalling negatively regulates PGC1α. Yet, TGFβR inhibition 
did not significantly increase PGC1α activation, pointing to the involvement of non-canonical 
TGFβ signalling as SB431542 does not inhibit JNK, p38MAPK or ERK signalling. Forskolin 
significantly induced PGC1α activity in both Fibulin-4R/R and Fibulin-4+/+ VSMCs (Fig 6C, p<0.01); 
in both cases a 3-fold induction compared to the untreated situation. These data point to an 
active inhibition of PGC1α activity in VSMCs of Fibulin-4R/R aortas. We next performed seahorse 
experiments in which we either examined the effect of TGFβR inhibition, or PGC1α activation. 
Interestingly, activation of PGC1α increased basal and maximum oxygen consumption in both 
Fibulin-4+/+ and Fibulin-4R/R VSMCs (Fig 6D, p<0.05), whereas TGFβR inhibition did not have 
the same effect. It was previously found that Fibulin-4R/R VSMCs show low proliferation rates 
compared to Fibulin-4+/+ VSMCs, which can be rescued by inhibiting TGFβ [38]. As TGFβ 
negatively regulates PGC1α levels, we  examined whether increased PGC1α levels would also 
rescue this low proliferation rate. Indeed, PGC1α activation was able to significantly increase 
the proliferation rate of Fibulin-4R/R VSMCs specifically (Fig 6E, p<0.01). Taken together, these 
results show that PGC1α, an important molecular switch between mitochondrial biogenesis and 
organismal metabolism, is downregulated in aortas of Fibulin-4R/R animals due to increased 
TGFβ signalling. When activated, PGC1α can restore the decrease in oxygen consumption and 
the decreased proliferation in Fibulin-4R/R VSMCs.
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DISCUSSION
In this study we took an integrative approach to better understand the molecular mechanisms 
involved in aneurysm formation, by using a combination of proteomics, genomics and functional 
experiments on thoracic aortas of aneurysmal Fibulin-4R/R animals. Interestingly, these data 
indicated changes in mitochondrial function and energy metabolism. Indeed, we measured a 
decrease in oxidative phosphorylation in VSMCs derived from the thoracic aorta of Fibulin-4R/R and 
Fibulin-4+/+ animals. In addition, we observed smaller mitochondria, but not less mitochondria or 
lower activity of mitochondrial complexes. Furthermore, in Fibulin-4R/R compared to Fibulin-4+/+ 
mice, we observed aortic gene expression differences that indicated altered aortic metabolic 
processes. Upstream regulator analysis on gene and protein expression data indicated PGC1α, 
PPARα and PPARγ as significant regulators in this process. Moreover, we found that PGC1α 
transcriptional activation was greatly reduced in VSMCs derived from Fibulin-4R/R aortas, and 
once PGC1α was activated in these VSMCs, this restored the decreased OCR observed in 
Fibulin-4R/R VSMCs as well as their reduced growth rate.
We verified that the observed defect in mitochondrial function was due to reduced Fibulin-4 in 
Fibulin-4R/R cells, rather than potential secondary effects associated with the engineered allele; 
to this end, we used the Fibulin-4SMKO mouse model as a control, in which the Fibulin-4 gene 
is completely knocked out in VSMCs specifically. Indeed, these Fibulin-4SMKO VSMCs showed 
a diminished oxygen consumption rate, as we observed for Fibulin-4R/R VSMCs, showing that 
complete deletion of Fibulin-4 has a similar effect on mitochondrial respiration as the Fibulin-4 
reduced allele. 
Although very little data are available on involvement of mitochondria in aneurysm formation 
and development, some evidence points in this direction. For example, mutations in SLC2A10 
result in Arterial Tortuosity Syndrome (ATS, OMIM#208050,[43]) a connective tissue disorder 
characterized by elongation and tortuosity of the major arteries including the aorta. SLC2A10 
encodes for GLUT10, a glucose transporter that transports l-dehydro ascorbic acid (DHA) into 
mitochondria. The absence of GLUT10 leads to decreased DHA recycling and thus to more 
oxidative damage. In zebrafish, defects in this gene lead to problems in development of the 
cardiovascular system in parallel to mitochondrial dysfunction[44]. In line with this notion, we 
demonstrate that VSMCs from the Tgfbr-1M318R/+ mouse, a model for LDS[34], similarly show 
reduced OCR. Moreover, we find that Marfan and Loeys-Dietz patient fibroblasts with mutations 
in the FBN1, TGFBR2 and SMAD3 genes also show reduced OCR. These observations support 
the concept that altered mitochondrial function plays a role in aneurysmal disease. 
An important question is how a deficiency in a protein involved in structural integrity of the ECM 
can lead to altered mitochondrial function and metabolism. External cues can lead to cytoskeleton 
170
CHAPTER 5
rearrangements since the ECM is connected to the cytoskeleton via integrins. Alternatively, ECM 
disturbances could invoke alterations in mechanotransduction that lead to modifications in the 
cytoskeleton or maybe even to its disintegration. Mitochondria depend on the cytoskeleton 
for their motility and proper function (for review see[45]). Thus, if the ECM disintegrates, this 
could lead to cytoskeleton disintegration due to loss of connections. In turn, this could lead to 
structural or functional defects in mitochondria. In fact, several genes that are components of 
the cytoskeleton are mutated in aneurysmal disease, exemplifying that the cytoskeleton is an 
important factor. One example is ACTA2, encoding αSMA, which is a major constituent of the 
contractile apparatus, that when mutated, leads to ascending aortic aneurysms and dissection 
(AAT6, OMIM##611788 [6, 46]). However, although we did observe mitochondrial function 
changes and a reduction in mitochondrial size, mitochondrial structure and appearance did not 
seem to be affected. Also, mitochondria are still aligned along the actin cytoskeleton as could 
be inferred from EM pictures and stainings for actin. 
In addition, Fibulin-4R/R mice show increased TGFβ signalling. Notably, several papers recently 
reported that TGFβ signalling negatively regulates PGC1α levels [40-42]. Interestingly, 
derived from our -omics data, PGC1α, PPARα and γ were identified as key components in the 
mitochondrial biogenesis signalling process. PGC1α is a transcriptional co-activator and is 
expressed in tissues with high oxidative capacity, where it serves important roles in regulation of 
mitochondrial functional capacity and cellular energy metabolism[47]. Physiological conditions 
that demand increased mitochondrial energy production, such as exercise and fasting, induce 
PGC1α activity. Likewise, low PGC1α levels imply reduced mitochondrial function. Accordingly, 
studies on PGC1α deficient (PGC1α-/-) mice have shown that PGC1α is necessary for regulation 
of mitochondrial function and cellular metabolism[48, 49]. Both mitochondrial volume density 
and respiratory capacity are reduced in these mice and there is no normal control of body 
fat mass, which emphasizes the importance of PGC1α in fatty acid β-oxidation. Furthermore, 
PGC1α-/- mice do not respond normally to increased demands for energy[49]. PGC1α is involved 
in the mitochondrial oxidation of fatty acids for energy in the cell through direct co-activation 
of PPARs[47, 50]. Recently it was shown that PGC1α protein expression is also lowered 
in aortic material isolated from patients with abdominal aneurysms[51], which indicates that 
PGC1α expression may play a regulatory role in both thoracic and abdominal aneurysms [51]. 
Moreover, increasing mitochondrial function via PGC1α activation has a positive effect on aging 
and longevity[52, 53]. Interestingly, we not only found lower PGC1α expression in Fibulin-4R/R 
thoracic aortas, but also PGC1α transcriptional activation itself was down in Fibulin-4R/R VSMCs. 
However, this activation could be enhanced by forskolin, a PGC1α activator, and enhancement 
of PGC1α activation was able to restore the decreased oxidative respiration observed in Fibulin-
4R/R VSMCs. 
We also found that TGFβ decreased PGC1α transcriptional levels in Fibulin-4+/+ and Fibulin-
4R/R VSMCs, implying that the increased TGFβ signalling in Fibulin-4R/R aortas and VSMCs 
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is responsible for the decreased PGC1α levels, thus impacting mitochondrial respiration. 
This would also explain why we find reduced mitochondrial respiration in cells derived from 
other aneurysmal syndromes that show increased TGFβ signalling, such as LDS and Marfan. 
Ramnath et al showed that lowering of TGFβ levels in Fibulin-4R/R VSMCs restored their reduced 
proliferation rate [38]. Similarly, we now show that by activating PGC1α, we can also increase this 
proliferation rate, suggesting that this reduced proliferation phenotype is induced by increased 
TGFβ levels, possibly via PGC1α reduction. 
It is evident that mitochondria are major cellular sources of ROS and changes in metabolism can 
alter mitochondrial function and the resulting ROS production. Likewise, in Fibulin-4R/R animals, 
we find evidence for increased ROS in the aorta. In this regard, changes in mitochondrial 
metabolism could also be an attempt to adapt to increased ROS, or to reduce ROS in response 
to a potential source of damage, at the organismal level. In line with this, we also find reduced 
oxygen consumption in other muscle cell containing organs; heart and skeletal muscle, but not 
in kidney or liver. Furthermore, in Fibulin-4R/R animals we observe a relative shift from glucose 
utilization to fatty acid usage as evidenced from metabolic parameters in blood and liver, as well 
as from our aortic gene expression analysis. The accumulation of glycogen in the liver might 
indicate increased storage of glucose into glycogen, in accordance to a relative increase in fatty 
acid β-oxidation that provides the energy for gluconeogenesis in the absence of an increased 
demand for glucose from the liver. Interestingly, newborn livers do not yet show these changes 
in liver metabolism. However, they do already show aneurysms, which may indicate that the 
aortic structural and/or signalling changes induce the liver metabolic changes at a later stage. 
The observed metabolic changes in adult Fibulin-4R/R mice are even more interesting since 
we did not detect changes in the liver mitochondrial complexes themselves, but did observe 
upregulation of PGC1α mRNA levels, pointing to a normal response of the liver to a change in 
demand of energy carrier type. Plasma measurements of Fibulin-4R/R mice show significantly 
lower levels of ketone bodies compared to their wildtype littermates. Taken together, this could 
indicate that the thoracic aorta of Fibulin-4R/R mice retrieves its energy from ketone bodies rather 
than from glucose, which could be the underlying reason for the liver to switch from glucose 
to fatty acid usage. In fact, adapting organismal metabolism under conditions of stress, such 
as organ damage, is a well-known survival mechanism in aging that attempts to preserve the 
organism by allowing time and energy for repair[54-56]. Actually, mitochondrial dysfunction 
itself is considered an important hallmark of aging[57]. ROS and mitochondrial dysfunction both 
increase with age, resulting in decreased bioenergetic efficiency. In fact, age-related aneurysms 
show many vascular aging characteristics such as elastin breakdown, collagen deposition as 
well as morphological changes in VSMCs [58]. Previously, we identified similar overexpression 
of miR-29b in Fibulin-4R/R aneurysmal aortas and aging mouse aortas, concomitant with reduced 
ECM protein expression thereby sensitizing the aorta for aneurysms formation[39]. In line with 
this, structural ECM changes could induce signalling processes that are partly mediated by 
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TGFβ, including those involving mitochondrial biogenesis. These signalling responses would 
then attempt to reduce aortic damage, similar to the organismal response observed in aging. 
In this context, it would be interesting to see the effect of PGC1α activators on aneurysm formation 
in the Fibulin-4R/R mouse. Previously, calorie restriction has been shown to have positive effects 
on mitochondrial biogenesis as well as many aging characteristics in different species[59-62], 
and notably also affects PGC1α signalling by increasing PGC1α. In line with this, the results 
reported here could open up the exciting possibility of nutritional interventions as a possible 
treatment for aneurysmal disease.
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SUPPLEMENTAL METHODS
Preparation of aorta protein extracts and MS/MS protein identification continued
Nanoflow LC-MS/MS was performed on an 1100 series capillary LC system (Agilent 
Technologies) coupled to an LTQ mass spectrometer (Thermo) operating in positive mode and 
equipped with a nanospray source. Peptide mixtures were trapped on a ReproSil C18 reversed-
phase column (Dr Maisch GmbH; column dimensions 2 cm × 100 µm, packed in-house) at a 
flow rate of 8 µl min−1. Peptide separation was performed on a ReproSil C18 reversed-phase 
column (Dr Maisch GmbH; column dimensions 20 cm × 75 µm, packed in-house) using a linear 
gradient from 0% to 80% B (A = 0.1% formic acid; B = 80% (v/v) acetonitrile, 0.1% formic acid) 
in 90 min and at a constant flow rate of 200 nl min−1. The column eluent was directly sprayed 
into the ESI source of the mass spectrometer. Mass spectra were acquired in continuum mode; 
fragmentation of the peptides was performed in data-dependent mode by CID. Peak lists were 
created from raw data files using the Mascot Distiller software (version 2.4; MatrixScience). 
The Mascot algorithm (version 2.3; MatrixScience) was used for searching against a Uniprot 
database (release 2012_02.fasta, taxonomy: Mus musculus (mouse)). Peptide tolerance was 
set to 2Da. and fragment ion tolerance was set to 0.8 Da. A maximum number of two missed 
cleavages by trypsin was allowed and carbamidomethylated cysteine and oxidized methionine 
were set as fixed and variable modifications, respectively.
Immunofluorescent stainings 
VSMC cultured on collagenized glass slides were stained with Mitotracker CMX Ros for 30 min 
at 37oC. After incubation cells were washed with PBS and fixed with 2% paraformaldehyde for 
15 min at room temperature. Excess Mitotracker staining was removed by 5 min incubation with 
80% ice cold acetone. Slides were mounted with vecthashield including dapi.
Mitotracker experiments
Single cells were prepared by trypsinization and spinning at 1000 rpm (corresponding to 18g) 
for 5 minutes. Resulting pellets were replenished with DMEM culture medium without phenol 
red, supplemented with 5% FCS. Per experiment 400.000 cells were stained with Hoechst 33342 
(10µg) and Mitotracker CMX Ros (25nM) for 30 min at 37°C. Single and double stained FL cells 
were used for the setup of gaitings and as controls. All analysis and sorting experiments were 
performed on a BD SORP FACS Aria  II cell sorter (BD Biosciences). For the combined mitotracker 
and SiR-Actin staining, VSMCs were seeded on  collagen coated coverslips in a concentration 
of 2x104 cells/ml. After 2 days 0.1nM SiR-Actin was added to the cells for 19h, after which cells 
were washed with PBS and replenished with medium containing 200nM of mitotracker for 30 
min of pulse labeling. Then, cells where washed with PBS, fixated with 2% paraformaldehyde 
for 10 minutes. Coverslips containing the cells were mounted with vectashield containing dapi. 
Fluorescence imaging was done on a Axio Imager.D2 (Zeiss) equipped with a CoolSNAP MYO 
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CCD camera (Photometrics) and a PhotoFluor LM-75 Long FL Lamp (89north). Images were 
recorded using a 63x 1.4NA Plan Apochromat objective and the following filtercubes (Chroma 
Technology Corp.): 49000 ET_DAPI,  49008 ET-mCherry/Texas Red, and 49009 ET-Cy5.
Electron microscopy 
Following cardiac perfusion thoracic aortas were harvested, dissected into small segments and 
left in fixative (3% in glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4)) overnight at 4°C. 
After extensive washing in 0.1 M sodium cacodylate buffer, the tissues were sequentially treated 
with osmium tetroxide, tannic acid and uranyl acetate, then dehydrated and embedded in Epon 
as previously described.  Thin sections (60 nm) were counterstained with methanolic uranyl 
acetate and lead citrate and viewed using a Tecnai 12 transmission electron microscope at 120 
kV. ImageJ was used to quantify the perimeter and area of 30 mitochondria from two different 
animals of each genotype obtained by TEM. A Student t-test was used to calculate the p-values. 
To ensure that the mitochondria were oriented in the right direction (following the orientation of 
the actin filaments); cross sections and longitudinal sections of aorta were viewed by TEM.
Western Blots 
Liver and thoracic aortic tissue from Fibulin-4+/+ and Fibulin-4R/R mice, snap frozen and stored 
at -80 ᵒC, was used for this experiment. Tissue was lysed in radioimmunoprecipitation assay 
(RIPA) buffer (50 mM Tris-HCl pH 8, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 150 mM NaCl) 
containing complete protease inhibitor cocktail (1:100) (Roche applied science), to exclude 
degradation of proteins within the tissue. Lysates were sheared and denatured at 50 0C. To 
detect ECM proteins Fibulin-4 and Elastin aortic lysates were obtained via the urea extraction 
method. In short, 250ul of 8M urea in 16 mM Na2HPO4 at pH7 with 1x protease inhibitor and 
a metal bead was added to each aorta. Samples were homogenized for 3 min. Supernatant 
was incubated at 4oC overnight on rocker. Next, supernatant was centrifuged 14000 rpm for 3 
min. to remove debris. The resulting supernatant was diluted with 16mM Na2HPO4 for a final 
concentration of 2M urea. Then,10% TCA solution at 1/4th volume of protein supernatant volume, 
was added to each sample and incubated on ice for 1 hr, after which an equal volume of cold 
acetone was added and incubated on ice for 1 hr. Samples were then centrifuged at 14k rpm for 
10 min 4 oC, pellets were washed with 750 uL of cold acetone, again centrifuge at 14k rpm for 
10 min 4 oC. The washing step was repeated twice. Protein concentration in tissue lysates was 
determined by Lowry protein assay. 15µg of total protein lysate was fractionated on 4-20% mini-
protean TGX gel (Biorad) by SDS-PAGE. The fractionated proteins were transferred to a PVDF 
membrane (Immobilon) by western blot procedure (1hour, 100V). To block nonspecific binding 
of the antibodies, the membrane was incubated in 5% nonfat milk|0.1% Tween in PBS for 1 hour 
at room temperature. The protein of interest was detected by primary antibody incubation in 
1% nonfat milk, 0.1% Tween in PBS (overnight at 4 0C). See Table 3 for primary antibodies. The 
membrane was washed 4 times with 0.1% Tween in PBS for 8 minutes after which the membrane 
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was incubated with the horseradish peroxidase-labeled secondary antibody: sheep anti-
mouse IgG (1:2500) or goat anti-rabbit IgG (1:2500) (Jackson ImmunoResearch Laboratories). 
The secondary antibody was detected through autoradiography (Alliance 2.7 UVItec) using a 
chemiluminescence (ECL) system (Amersham Pharmacia Biotech). The expression of the bands 
was quantified with the Fiji image analyzing software Quantity-One.
Table 3: Primary antibodies used for Western Blot analysis






Mitoprofile total OXPHOS 












1:500 Mouse MitoSciences, 
Eugene
Mouse anti-β-catenin IgG β-Catenin 
Clone 14
92 1:2000 Mouse BD Transduction 
laboratories
Rabbit anti-Fibulin-4 IgG Fibulin-4 50 1:1000 Rabbit Gift from 
Carmen Halabi
Rabbit anti-Elastin IgG Elastin 68 1:1000 Rabbit Abcam
Oxygraph and Mitochondrial complex activity measurements continued
Enzyme activities were measured in the homogenates. Citrate synthase, an indicator of the 
mitochondrial number was measured according to [1]. Mitochondrial complex activities were 
determined in muscle homogenates by spectrophotometric methods as described before [2, 
3]. Complex I or NADH-Coenzyme Q reductase was determined kinetically by following the 
rotenon sensitive decrease in NADH amount. Complex III or Ubiquinol-cytochrome c reductase 
was determined by following the Antimycin A sensitive reduction of cytochrome c by reduced 
decylubiquinol as described [4]. Complex IV or cytochrome c oxidase was measured by 
following the formation of oxidized cytochrome c. Complex V or ATP synthase was determined 
as the oligomycin sensitive Mg-ATPase [2, 3]. For objective comparison between genotypes, 
complex activities were compared relative to amount of protein and based on the amount of CS.
Histology and mouse metabolic parameters 
Livers of Fibulin-4+/+ and Fibulin-4R/R mice were histologically examined for general pathology 
and metabolic state. Liver tissue from the same animals was either formalin fixated in 4% 
formalin or snap frozen in liquid nitrogen. Formalin-fixated tissue was embedded in paraffin wax, 
5 mm of paraffin sections were stained with Haematoxylin and Eosin (HE) for general pathology 
and Periodic Acid-Schiff (PAS) for glycogen storage. 5 mm of frozen sections were used for oil-
red-o (ORO) staining to determine the accumulation of neutral fats in the liver. ORO ratio was 
determined by measuring the ORO stained area, and dividing this by the total area measured. 
PAS ratio was determined by measuring the PAS stained area, and dividing this by the total 
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area measured. Blood glucose and β-ketone ketone levels were measured using a Freestyle 
mini blood glucose or the Freestyle Precision β-ketone measurement device (Abbott Diabetes 
Care), respectively, on a drop of freshly retrieved whole blood. Lactate levels were measured in 
a heparin coated capillary filled with 125 µl freshly retrieved whole blood, using the ABL800 FLEX 
analyzer (Radiometer Medical ApS).
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Thoracic aortic aneurysm is a potentially devastating disorder with a strong genetic predisposition. 
Despite the identification of multiple disease-causing genes in the past decade, still little is 
known about the exact underlying mechanisms that drive the pathological changes in the aortic 
wall. The aim of our study was to compare gene expression profiles of patients with syndromic 
and non-syndromic heritable thoracic aortic disease (HTAD), in order to identify the underlying 
molecular pathways that play a role in aneurysm formation.
Methods
We collected aortic wall samples from patients with FBN1-positive Marfan syndrome (MFS, n=6) 
and mutation-negative HTAD (n=15). Control samples were obtained from healthy donor hearts 
(n=5). mRNA expression levels were measured by RNA sequencing and compared between 
patients and controls.
Results
FBN1 mRNA expression levels were highly variable in MFS patients and not significantly different 
from HTAD and controls. Moreover, we did not identify a distinctive TGF-β gene expression 
signature in MFS patients. Interestingly, in both MFS and HTAD, differential gene expression 
analysis pointed toward inflammation and mitochondrial dysfunction. In HTAD, we also identified 
several pathways related to cell adhesion and motility.
Conclusions
Our findings suggest great overlap in the pathophysiological processes underlying MFS and 
HTAD. More importantly, our results reveal that mitochondrial and inflammatory pathways play 
important roles in the pathogenesis of HTAD, opening the possibilities for new therapeutic 
approaches.
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INTRODUCTION
Thoracic aortic aneurysms, typically involving the aortic root and/or proximal ascending aorta, 
are often asymptomatic. However, if left untreated, thoracic aortic aneurysms can result in aortic 
dissection, rupture or sudden death. Approximately 20% of individuals with thoracic aortic 
aneurysms and dissections have a positive family history [1], and thus may have a genetic 
predisposition, now generally referred to as heritable thoracic aortic disease (HTAD) [2]. 
A major breakthrough in our understanding of HTAD came in 1991, when Dietz et al. identified 
FBN1, encoding the extracellular matrix protein fibrillin-1, as the causal gene for Marfan syndrome 
(MFS) [3]. Though initially considered a mere structural disorder of the connective tissue caused 
by fibrillin-1 deficiency, dysregulation of the transforming growth factor-beta (TGF-β) signaling 
pathway has emerged as the key mechanism in the pathogenesis of MFS. In addition to aortic 
root dilatation, patients with MFS typically present with ectopia lentis and skeletal features. In 
over 90% of patients that meet the diagnostic criteria for MFS (Ghent nosology) a pathogenic 
variant in FBN1 can be identified [4, 5].
In the past decade, variants in genes encoding other components of the TGF-β signaling 
pathway and extracellular matrix have emerged as major drivers in the pathogenesis of other 
syndromic forms of HTAD, such as Loeys-Dietz syndrome and vascular Ehlers-Danlos syndrome 
[6]. Despite overlapping etiologies, these syndromes display important distinguishing features 
[7]. In addition, genes that encode components of the vascular smooth muscle cell (VSMC) 
contractility apparatus have been linked to non-syndromic forms of HTAD [8]. However, despite 
advancing knowledge and sequencing technologies, only ~30% of families with non-syndromic 
HTAD receive a molecular diagnosis [9]. The diagnostic yield decreases if sporadic cases are 
included [10], suggesting that other (genetic) factors remain to be identified in both familial 
and sporadic thoracic aortic disease. Finding a molecular cause enables predictive testing in 
relatives and contributes to personalized medical and surgical management [11]. 
Differential gene expression analysis may provide valuable information regarding the molecular 
mechanisms underlying thoracic aortic disease. Previous studies have mainly focused on patients 
with acute ascending aortic (Stanford type A) dissection, suggesting a key role for extracellular 
matrix assembly and maintenance, cell adhesion and signaling, inflammation and cytoskeleton 
proteins [12-16]. These studies were performed using microarrays, which rely on pre-designed 
complement sequence detection. RNA sequencing (RNA-seq), on the contrary, which was used 
in the present study, delivers unbiased information about the transcriptome, is more sensitive in 
detecting low abundant transcripts and has a broader dynamic range, allowing for the detection 
of a larger number of differentially expressed genes [17]. Here, we apply RNA-seq to investigate 
gene expression profiles in aortic tissue from patients with MFS and to compare these findings with 
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profiles from patients with mutation-negative HTAD. We hypothesize that (i) patients with MFS have a 
distinctive TGF-β specific gene expression signature, and (ii) patients without a molecular diagnosis 
will have a different gene expression signature compared to controls. Moreover, we expect that (iii) 
the expression signature of patients without a molecular diagnosis can be subdivided into specific 
clusters; either based on affected biological pathway (e.g. VSMC contractility, TGF-β signaling or 
other) or specific phenotypic features (e.g. aortic valve morphology, histological characteristics 
or gender). Characterizing the affected biological pathways and/or gene networks could aid in 
identifying the underlying genetic factors and may enhance the development of more effective 
therapies for thoracic aortic disease in individuals with a genetic predisposition.
MATERIALS AND METHODS
Study population
Patients with thoracic aortic disease undergoing elective ascending aortic replacement at 
the Erasmus University Medical Center between January 2015 and May 2018 were included 
in this study. Patients with acute aortic dissection and traumatic aortic injuries were excluded. 
Residual aortic tissue from healthy donor hearts, stored on ice and transported to our center for 
subsequent implantation, were collected as control samples. Full-thickness aortic wall samples 
were snap-frozen in liquid nitrogen immediately after surgical removal from the patient or donor 
heart, and stored at -80°C until further processing. 
All patients underwent structured clinical evaluation including medical and family history, 
physical examination, transthoracic echocardiography and preoperative computed tomography 
angiography of the thoracic aorta. Aortic diameters were determined at the level of the aortic 
annulus, sinuses of Valsalva, sinotubular junction, proximal and distal ascending aorta, aortic 
arch, and proximal and distal descending aorta. Aortic valve morphology and function were 
documented at surgery. Postoperatively, patients with thoracic aortic disease were offered 
standard genetic counseling and diagnostic testing (copy number analysis using SNP array 
and/or whole exome sequencing, see Supplemental Methods) at our outpatient clinic. We 
applied an exome-based virtual gene panel for targeted analysis of 34 known HTAD-related 
genes (Supplementary Table S1). Further analysis of selected candidate genes was based on 
individual characteristics. In patients with a strong suspicion of a specific disorder or known 
pathogenic variant in the family, we performed targeted analysis of the respective gene by 
Sanger sequencing. Variants in FBN1 were classified as dominant negative (DN; interference of 
mutant with non-mutant fibrillin-1 protein) or haploinsufficient (HI; production of only non-mutant 
fibrillin-1 protein) using the Alamut software, as described previously [18]. First-degree relatives 
were offered predictive genetic testing (if appropriate) and/or advised to undergo cardiovascular 
screening. Our study protocol was approved by the Erasmus MC Medical and Ethical Review 
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Committee (MEC 2014-579, MEC 2017-040 and MEC 2017-097). All participants provided 
written informed consent.
Sample selection
From the 61 patients included in the study, we selected 21 patients with either confirmed or 
suspected (i.e. age at diagnosis <40 years and/or positive family history) genetically triggered 
thoracic aortic disease: 6 patients with MFS, and 15 patients with non-syndromic HTAD without 
a pathogenic or likely pathogenic variant in any of the known HTAD-related genes (Table 1). In 
addition, we obtained 5 control samples from healthy donor hearts (HTx). Samples selected for 
genome-wide transcriptional analysis were derived from the anterior side of the ascending aorta. 
Statistical analyses were performed to compare the sample groups for significant differences 
in baseline characteristics. Data were expressed as mean ± standard deviation for continuous 
variables, and absolute numbers (percentage) for categorical variables. Comparisons were 
made using the Student’s t-test and Fisher’s exact test, respectively. All statistical tests were two-
sided. Differences between groups were considered statistically significant at p-values <0.05. 
Analyses were performed using Microsoft Excel or GraphPad Software.
Table 1. Demographics of the study population.
MFS (n=6) HTAD (n=15) controls (n=5)
Age at operation (years) 30.2 ± 11.8 † 53.2 ± 16.4 37.8 ± 18.1
Males (%) 4 (67%) 10 (67%) 1/4 (25%) ‡
Caucasian (%) 4 (67%) 15 (100%) N/A
Max. aortic diameter (mm) 51.5 ± 4.0 53.9 ± 5.7 N/A
Aortic z-score 7.03 ± 2.34 7.29 ± 2.44 N/A
Bicuspid aortic valve 0 (0%) 7 (47%) 0 (0%)
Positive family history 3 (50%) 9 (60%) N/A
Hypertension 1 (17%) 7 (47%) N/A
Hypercholesterolemia 0 (0%) 2 (13%) N/A
Diabetes mellitus 0 (0%) 1 (7%) N/A
Smoking 1 (17%) 2 (13%) N/A
HTAD, heritable thoracic aortic disease (without disease-causing variant in known genes); MFS, Marfan 
syndrome; N/A, not available.
† p<0.005 compared to HTAD, ‡ unknown gender in one control sample.
Histopathological examination
Available surgical aortic specimens were systematically examined for histopathologic findings 
of inflammatory and non-inflammatory aortic diseases according to current guidelines [19, 20]. 
All specimens were stained for hematoxylin-eosin, Verhoeff-van Gieson (elastin), Picrosirius red 
(collagen), and Alcian blue (proteoglycans). Additional stains were performed on indication.
188
CHAPTER 6
RNA sample preparation and sequencing
Frozen tissue samples were ground using a pre-chilled mortar and pestle, and subsequently 
disrupted and homogenized using a bead mill. Total RNA was extracted with the RNeasy Fibrous 
Tissue Mini Kit (QIAGEN). Residual genomic DNA was removed using the RNase-Free DNase 
Set (QIAGEN). RNA concentration, purity and integrity were assessed on the 2100 Bioanalyzer 
using the RNA 6000 Nano Kit (Agilent Technologies). Only samples with a RNA integrity number 
(RIN) >7 were eligible for RNA-seq. Libraries were prepared using the TruSeq Stranded mRNA 
Library Prep Kit (Illumina, San Diego, CA, USA). The resulting DNA libraries were sequenced 
according to the Illumina TruSeq Rapid v2 protocol on an Illumina HiSeq2500 machine. Paired-
end reads were generated of 100 base pairs in length.
Differential expression analysis
Raw RNA-seq data was processed in two ways: using (A) HISAT2 and htseq-count, and (B) CLC 
Genomics Workbench (see Supplemental Methods for further details). Subsequent normalization 
and differential expression analysis was performed using three different algorithms. After step 
A, normalization and differential expression analysis was performed on the public Galaxy 
server using either DESeq2 version 2.11.40.2 [21] or edgeR version 3.20.7.2 [22]. In approach 
B, further analysis was performed using the tools provided within CLC Genomics Workbench 
version 10.0.1 (QIAGEN Bioinformatics). Read counts were normalized for transcript length and 
total number of mapped reads (RPKM) [23]. Genes with a fold change (FC) ≥1.5 and a false 
discovery rate (FDR) adjusted p-value <0.05 were considered differentially expressed. Data 
were visualized using the Integrative Genomics Viewer (IGV).
Pathway analysis
Differentially expressed genes were uploaded into the Ingenuity Pathway Analysis (IPA) software, 
Summer Release 2018 (QIAGEN Bioinformatics). We performed a Core Analysis for each group, 
using default parameters, to predict effects on pathways and biological functions, and discover 
plausible upstream regulators and mechanistic networks [24]. Pathways with a negative log10(p-
value) greater than 1.3 were considered significant. In addition, gene lists were uploaded to 
ToppGene to perform gene set enrichment analysis [25].
RESULTS
Patient characteristics
Patients with MFS were significantly younger (mean age 30.2 ± 11.8 years) than those with 
mutation-negative HTAD (mean age 53.2 ± 16.4 years, p=0.0057) (Table 1). No significant age 
difference was found between the patient groups and controls. The majority of MFS and HTAD 
patients (67%) were male; whereas at least 3 out of 5 controls were female. The maximal aortic 
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diameters prior to surgical intervention and corresponding z-scores did not significantly differ 
between patients with MFS and HTAD. There were no significant differences in the presence 
or absence of cardiovascular risk factors (i.e. hypertension, hypercholesterolemia, diabetes 
mellitus and smoking) between these groups. The clinical and genetic features of patients with 
MFS are presented in Table 2.
Histopathological findings
Aortic wall specimens were available for histologic examination in 5/6 MFS patients and 12/15 
mutation-negative HTAD patients. Specimens from all MFS patients and five HTAD patients 
(mean age 36.5 ± 14.2 years) had histopathologic features of moderate to severe overall medial 
degeneration, i.e. disorganization and fragmentation of elastic fibers, smooth muscle cell nuclei 
loss, and mucoid extracellular matrix accumulation [20, 26]. Two of these HTAD specimens also 
showed atherosclerotic lesions with calcification, and (chronic) dissection of the medical layer. 
In three other HTAD patients (mean age 62.7 ± 6.7 years), aortic specimens showed moderate 
atherosclerosis. This was associated with inflammation in two patients. In the remaining four 
HTAD patients (mean age 52.0 ± 20.9 years), histological examination of aortic wall specimens 
revealed no abnormalities.
RNA-seq data alignment
We generated in excess of 34 million reads per sample (mean 43.5 ± 15.5 million reads). Of 
these reads, 92 to 99% aligned to the human reference genome. A total of 10,096 transcripts 
showed detectable expression (defined as mean expression of ≥2 reads per kilobase per million) 
in the ascending aorta of the control group. Twenty-six transcripts were highly expressed (≥1000 
reads per kilobase per million) (Supplemental Table S2), including the known HTAD genes ACTA2 
(aortic smooth muscle actin) [27] and BGN (biglycan) [28]. The list further includes several 
genes that code for calcium-binding and cytoskeletal proteins, such as MYL9 (myosin light 
chain 9), TAGLN (transgelin), S100A6 (S100 calcium binding protein A6) and TMSB4X (thymosin 
beta 4 X-linked), that represent good candidate genes for HTAD. Of note, we did not find rare, 
potentially deleterious variants in these four genes in our in-house cohort of 179 patients with 
unexplained thoracic aortic disease.
Correlation of transcriptome samples
Principal component analysis (PCA) of gene expression data in CLC Genomics Workbench 
showed wide scattering of the HTAD samples, which partially overlap with the clustering of 
MFS samples (Figure 1A). Unsupervised hierarchical clustering showed that the HTAD samples 
could be subdivided into three separate groups (Figure 1B). This clustering was not related to 
aortic valve morphology (i.e. bicuspid vs. tricuspid aortic valve) nor the presence or absence of 
atherosclerotic lesions at histologic examination. The HTAD subgroups will be investigated in 































































































































































































































































































































































































































































































































































































































































































































































































































Differential expression and pathway analysis
We used three algorithms (DESeq2, edgeR and CLC Genomics Workbench) to identify 
differentially expressed genes in pairwise comparisons between MFS, HTAD and controls. 
The number of differentially expressed genes per tool is shown in Figure 2 and Table 3. Lists 
of differentially expressed genes were uploaded into IPA and ToppGene for further analysis. 
The DESeq2 algorithm, which yielded the highest numbers of differentially expressed genes, 
was used for exploratory data analysis. The edgeR and CLC Genomics Workbench (CLC-GW) 
algorithms were used to confirm our findings. 
Figure 2. Venn diagrams showing the number and distribution of differentially expressed genes (fold change 
≥1.5, false discovery rate adjusted p-value <0.05) among the three algorithms used for differential expression 
analysis. 
A) Marfan syndrome (MFS) vs. controls, B) hereditary thoracic aortic disease (HTAD) vs. controls, C) MFS 
vs. HTAD.
Table 3. Number of differentially expressed genes in different comparisons
DESeq2 edgeR CLC-GW
Total Up Down Total Up Down Total Up Down
MFS vs. controls 1548 743 805 479 193 286 354 212 142
HTAD vs. controls 1776 888 888 1038 414 624 767 452 315
MFS vs. HTAD 67 42 25 0 0 0 7 7 0
HTAD, heritable thoracic aortic disease; MFS, Marfan syndrome.
Apparent lack of TGF-β signature in ascending aorta from MFS patients
The DESeq2 algorithm yielded a total of 1548 differentially expressed genes between MFS 
samples and controls: 743 genes were upregulated and 805 were downregulated (Figure 2A 
and Table 3). Sixty-four genes (4%) were also discovered by the edgeR and CLC-GW algorithms 
(Figure 2A and Supplemental Table S3). The top 10 up- en downregulated genes is displayed 
in Table 4. Four of the top dysregulated genes code for extracellular matrix proteins (indicated 
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by an asterisk). OGN (osteoglycin) and ASPN (asporin), that both encode members of the small 
leucine-rich proteoglycan family, have been reported to interact with the TGF-β signaling pathway 
[29, 30]. Pathway analysis identified 62 canonical pathways significantly enriched by genes that 
were differentially expressed between MFS and controls  (Supplemental Table S4). 
Table 4. Top 10 up- en downregulated genes in MFS compared with controls.
Symbol Description Location FC FDR
Upregulated genes
PRND Prion like protein doppel Plasma membrane 5.85 4.96E-07
LAMP5 Lysosomal associated membrane 
protein family member 5
Cytoplasm 4.98 4.63E-07
LINC00865 Long intergenic non-protein 
coding RNA 865
Other 3.42 2.24E-05
OGN* Osteoglycin Extracellular space 2.87 5.77E-07
ASPN* Asporin Extracellular space 2.69 1.10E-06
SCG5 Secretogranin V Extracellular space 2.66 5.22E-04
ECM2* Extracellular matrix protein 2 Extracellular space 2.54 8.68E-09
ANGPT2 Angiopoietin 2 Extracellular space 2.17 6.12E-05
PLD1 Phospholipidase D1 Cytoplasm 2.08 8.54E-17
PRSS35 Serine protease 35 Extracellular space 2.06 7.49E-04
Downregulated genes
PCSK1N Proprotein convertase subtilisin/
kexin type 1 inhibitor
Extracellular space -4.54 4.07E-05
RP11-124N14.3 [Undefined] Other -3.94 8.52E-05
RNF122 Ring finger protein 122 Other -3.91 3.14E-13
RP5-977B1.11 [Undefined] Other -3.86 4.58E-07
RP5-940J5.9 [Undefined] Other -3.46 2.71E-05
AC010761.8 [Undefined] Other -3.45 1.69E-03
ACTA2-AS1 ACTA2 antisense RNA 1 Other -3.10 5.44E-04
TPGS1 Tubulin polyglutamylase  
complex subunit 1
Cytoplasm -2.66 1.32E-04
CCDC85B Coiled-coil domain  
containing 85B
Cytoplasm -2.66 2.09E-05
FGFR2* Fibroblast growth factor  
receptor 2
Plasma membrane -2.59 4.69E-06
FC, fold change; FDR, false discovery rate (Benjamini-Hochberg procedure); MFS, Marfan syndrome.
Complete list of differentially expressed genes is provided in Supplemental Table S3. Genes marked with an 
asterisk (*) code for extracellular matrix proteins. 
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Surprisingly, the canonical TGF-β signaling pathway was not among them. The top 10 enriched 
pathways is displayed in Figure 3. Pathways indicative of inflammation and mitochondrial 
dysfunction were overrepresented. Targeted assessment of the canonical TGF-β signaling 
pathway revealed significantly increased expression of the ligand TGFB2 (fold change 2.3, FDR 
adjusted p-value 0.03). Expression of the TGF-β receptors and intracellular signaling molecules 
was not significantly altered. Top ranked network functions identified by IPA were associated 
with lipid metabolism and inflammatory response. Gene Ontology (GO) Enrichment Analysis 
revealed no statistically significant results.
Figure 3. Top 10 pathways enriched for differentially expressed genes (DESeq2) in MFS compared with 
controls.
FBN1 expression in highly variable and not significantly different from non-Marfan 
aortas
We subdivided the MFS patients in those with dominant negative (DN, n=3) and haploinsufficient 
(HI, n=3) FBN1 variants (Table 2). As expected, gene expression profiles of these subgroups 
did not differ substantially. FBN1 mRNA expression levels were lower in MFS patients with HI 
variants (mean 360 ± 74 counts per million) compared to MFS patients with DN variants (mean 
772 ± 351 counts per million) (Table 2). However, this difference was not statistically significant 
(p=0.1178). Inter-individual variability was high, with FBN1 mRNA levels ranging from 38% to 
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150% of the mean expression level in controls. The mean FBN1 mRNA levels in aortic tissue from 
patients with MFS did not significantly differ from patients with HTAD (p=0.7165) and controls 
(p=0.2963).
Figure 4. Top 10 pathways enriched for differentially expressed genes (DESeq2) in HTAD compared with 
controls.
No distinct clustering of gene expression profiles in HTAD
The DESeq2 algorithm yielded a total of 1776 genes differentially expressed between HTAD 
and controls: 888 genes were upregulated and 888 genes were downregulated (Figure 2B and 
Table 3). Two hundred ninety-seven genes (17%) were also discovered by edgeR and CLC-GW 
(Figure 2B and Supplemental Table S5). The top 10 up- en downregulated genes is displayed in 
Table 5. One of the top dysregulated genes, S100A12 (S100 calcium binding protein A12), has 
previously been associated with thoracic aortic aneurysm and dissection, albeit in an opposite 
direction [31]. Pathway analysis identified 79 canonical pathways significantly enriched by genes 
that were differentially expressed between HTAD and controls (Supplemental Table S6). The 
top 10 enriched pathways is displayed in Figure 3. Similar to the pairwise comparison between 
MFS and controls, pathways indicative of inflammation and mitochondrial dysfunction were 
overrepresented. In addition, we identified several pathways related to cell adhesion and motility, 
including integrin, paxillin and focal adhesion kinase (FAK) signaling and regulation of actin-
based motility by Rho family GTPases. This latter observation was supported by GO Enrichment 
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Analysis: the top enriched GO Biological Processes (Table 6) are mostly related to locomotion 
[GO:0040011] (7/25, 28%) and circulatory system development [GO:0072359] (5/25, 20%), 
both including factors involved in cytoskeletal organization and remodeling. The complete list 
of enriched GO Biological Processes can be found in Supplemental Table S7. Of the 269 genes 
assigned to a GO Cellular Component category, 42 (16%) are active in the extracellular space 
[GO:0005615].
Table 5. Top 10 up- en downregulated genes in HTAD compared with controls.
Symbol Description Location FC FDR
Upregulated genes
LINC00996 Long intergenic non-protein coding 
RNA 996
Other 3.82 3.96E-06
PRND Prion like protein doppel Plasma membrane 3.44 1.98E-04
DAPL1 Death associated protein like 1 Other 3.32 2.09E-05
WARS2-IT1 WARS intronic transcript 1 Other 3.15 2.31E-04
CCL17 C-C motif chemokine ligand 17 Extracellular space 3.05 7.23E-04
FRMD1 FERM domain containing 1 Other 2.99 1.41E-03
CD1C CD1c molecule Plasma membrane 2.86 4.70E-05
GPR82 G protein-coupled receptor 82 Plasma membrane 2.86 5.51E-04
MGAT4C MGAT4 family member C Cytoplasm 2.85 2.53E-04
ANO4 Anoctamin 4 Plasma membrane 2.82 8.88E-04
Downregulated genes
MCEMP1 Mast cell expressed membrane 
protein 1
Cytoplasm -6.91 1.64E-10
CBARP CACN beta subunit associated 
regulatory protein
Other -5.99 1.67E-12
LINC00473 Long intergenic non-protein coding 
RNA 473
Other -4.46 3.13E-06
S100A12 S100 calcium binding protein A12 Cytoplasm -4.36 4.13E-06
ERFE Erythroferrone Extracellular space -4.36 1.37E-07
AC010761.8 [Undefined] Other -4.31 4.16E-06
PROK2 Prokineticin 2 Extracellular space -4.26 7.25E-06
FOSL1 FOS like 1, AP-1 transcription  
factor subunit
Nucleus -4.24 2.58E-08
LILRA5 Leukocyte immunoglobulin like 
receptor 5
Plasma membrane -4.15 3.04E-06
RP11-124N14.3 [Undefined] Other -4.10 6.45E-07
FC, fold change; FDR, false discovery rate (Benjamini-Hochberg procedure); HTAD, hereditary thoracic 
aortic disease.
Complete list of differentially expressed genes is provided in Supplemental Table S5. 
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Table 6. Top 25 GO Biological Processes enriched in HTAD versus controls.
ID Name p-value FDR Molecules †
1 GO:0016477 cell migration 6.61E-08 1.46E-04 44 / 1300
2 GO:0040011 locomotion 7.11E-08 1.46E-04 53 / 1735
3 GO:0090130 tissue migration 4.54E-07 6.24E-04 16 / 244
4 GO:0048870 cell motility 8.99E-07 7.41E-04 44 / 1428
5 GO:0051674 localization of cell 8.99E-07 7.41E-04 44 / 1428
6 GO:0048646
anatomical structure formation involved 
in morphogenesis
1.22E-06 8.41E-04 41 / 1299
7 GO:0009967 positive regulation of signal transduction 2.68E-06 1.58E-03 44 / 1488
8 GO:0030198 extracellular matrix organization 3.46E-06 1.65E-03 18 / 354
9 GO:0043062 extracellular structure organization 3.60E-06 1.65E-03 18 / 355
10 GO:0090287
regulation of cellular response to growth 
factor stimulus
4.22E-06 1.72E-03 15 / 256
11 GO:0001944 vasculature development 4.60E-06 1.72E-03 26 / 677
12 GO:0001568 blood vessel development 7.09E-06 2.32E-03 25 / 651
13 GO:0010631 epithelial cell migration 7.31E-06 2.32E-03 14 / 235
14 GO:0030334 regulation of cell migration 8.03E-06 2.32E-03 27 / 742
15 GO:0090132 epithelium migration 8.45E-06 2.32E-03 14 / 238
16 GO:0048514 blood vessel morphogenesis 1.42E-05 3.65E-03 22 / 551
17 GO:0071363
cellular response to growth factor 
stimulus
1.74E-05 3.82E-03 24 / 643
18 GO:0040012 regulation of locomotion 1.76E-05 3.82E-03 29 / 866
19 GO:0072358 cardiovascular system development 1.92E-05 3.82E-03 33 / 1058
20 GO:0072359 circulatory system development 1.92E-05 3.82E-03 33 / 1058
21 GO:0034097 response to cytokine 1.95E-05 3.82E-03 28 / 825
22 GO:0006928
movement of cell or subcellular 
component
2.21E-05 4.14E-03 49 / 1882
23 GO:2000145 regulation of cell motility 2.61E-05 4.68E-03 27 / 793
24 GO:0071345 cellular response to cytokine stimulus 3.27E-05 5.61E-03 25 / 713
25 GO:0070848 response to growth factor 3.45E-05 5.63E-03 24 / 671
FDR, false discovery rate (Benjamini-Hochberg procedure); HTAD, hereditary thoracic aortic disease.
† Number of molecules in dataset / number of annotated molecules in genome. Complete list of enriched 
biological processes including hits in query list is provided in Supplemental Table S7.
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Aortic samples show similar gene expression profiles irrespective of their genetic 
make-up
The DESeq2 algorithm yielded only 67 differentially expressed genes between MFS and HTAD 
samples, indicating great overlap between the pathophysiological processes underlying these 
disorders (Figure 2C and Table 3), that may reflect a ‘final common pathway’. Indeed, the majority 
of genes differentially expressed between MFS and controls were also found in the pairwise 
comparison between HTAD and controls (Figure 5). Seven genes (10%) were also discovered 
by CLC-GW, including the collagen genes COL1A1, COL3A1 and COL4A1 (Supplementary Table 
S8); none were picked up by edgeR.
An overview of the main findings in our study is displayed in Table 7.
Figure 5. Venn diagrams showing the number of differentially expressed genes in common between Marfan 
syndrome (MFS) vs. controls and hereditary thoracic aortic disease (HTAD) vs. controls.
Table 7. Summary of the main results of this study.
MFS vs. controls HTAD vs. controls MFS vs. HTAD
# DEG ↑19 ↓45 ↑64 ↓233 0
# DEG in common ↑9 ↓37




Top downregulated genes FGFR2 S100A12
Top enriched pathways mitochondrial dysfunction and inflammation
Top enriched functions locomotion
Top enriched components extracellular space
DEG, differentially expressed genes; HTAD, hereditary thoracic aortic disease; MFS, Marfan syndrome.
† Genes detected using DESeq2 and CLC-GW algorithm (but not edgeR).
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DISCUSSION
In aortic samples from both MFS and HTAD patients, we identified a gene expression signature 
indicative of inflammation and mitochondrial dysfunction. Inflammation is a well-known 
contributor to atherosclerotic vascular disease, such as coronary artery disease [32]. In addition, 
chronic inflammation of the aortic wall is a typical histological feature of aneurysms located in the 
abdominal aorta [33]. Recent studies have demonstrated that inflammation is also involved in the 
pathogenesis of thoracic aortic disease, irrespective of genetic predisposition [34-36]. Though 
initially described as a non-inflammatory condition, these studies suggest that inflammatory 
cells, cytokines and metalloproteinases contribute to medial degeneration in both familial and 
sporadic thoracic aortic disease.
Mitochondrial dysfunction, leading to enhanced production of reactive oxygen species (ROS), 
reduced ATP production, and activation of cell death programs, has also been established as an 
important factor in various cardiovascular diseases [37]. The role of mitochondrial dysfunction 
in thoracic aortic disease, however, is less well studied. In VSMCs, ROS have been implicated 
in several physiological and pathophysiological processes such as growth, differentiation and 
migration [38], suggesting a direct link between the mitochondrial dysfunction and locomotion-
related gene expression signature that were observed in the  HTAD samples. Impaired 
mitochondrial function, reflected by decreased oxygen consumption and increased acidification 
rates, have recently been observed in aneurysmal aortas from Fibulin-4R/R mice [39]. These 
authors also demonstrated decreased oxygen consumption rates in VSMCs from Tgfbr1M318R/+ 
mice, a mouse model for Loeys-Dietz syndrome (LDS) [40], and skin fibroblasts from patients 
with MFS and LDS. Our findings support their concept that altered mitochondrial function plays 
a role in aneurysm formation. Further studies are pending to validate our findings and investigate 
the different components of the electron transport chain using patient-derived VSMCs. 
We observed high inter-individual variability in FBN1 mRNA expression levels in aortic tissue 
from MFS patients (Supplemental Table S2). In patients with FBN1 variants that are predicted 
to lead to haploinsuffiency, mutant FBN1 transcript was indeed absent or present at a very low 
level (0-6%), therefore excluding large variations in nonsense mediated mRNA decay as a cause 
of the variable expression in these patients. As suggested previously, variable expression of the 
normal allele likely contributes to the variability in FBN1 mRNA expression, and may depend on 
functional polymorphisms in the promotor region or trans-acting regulators [41, 42].
The top differentially expressed genes between MFS samples and controls encompassed several 
extracellular matrix genes. This might result from disorganization of extracellular matrix due to 
dysfunctional fibrillin-1, or reduced aortic wall strength due to reduced levels of normal fibrillin-1 
[43]. Surprisingly, we did not find a distinctive TGF-β gene expression signature in MFS patients. 
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This might be related to the advanced stage of disease, i.e. severe aortic dilatation requiring 
surgical intervention. Hence, our expression profiles likely reflect the effect rather than the cause 
of the disease. Alternatively, the use of full thickness aortic biopsies might have “diluted” the 
effect and masked relevant results. The use of VSMCs alone, however, would have excluded 
potentially important extracellular processes. Third, levels of mRNA may poorly correlate with 
the abundances of their corresponding proteins [44]. To distinguish between different scenarios, 
we will perform  further studies (e.g. immunohistochemical and functional analyses) of various 
components of the TGF-β pathway. 
Gene expression profiles may alter with disease progression and medical treatment [45]. As a 
consequence, we likely have missed relevant changes in gene expression that occurred early in 
the disease process. Our dataset does, however, provide important insight into the molecular 
mechanisms involved in disease progression. This knowledge may help to develop new 
therapeutic approaches to delay or prevent vascular complications and/or the need for surgical 
intervention. In fact, anti-inflammatory drugs may be effective in reducing aneurysm progression. 
Interestingly, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, commonly called 
statins, which are widely prescribed for their lipid-lowering effect, also possess anti-inflammatory 
properties [46]. A systematic review and meta-analysis involving more than 80,000 patients with 
abdominal aortic aneurysms (AAA) recently confirmed that statin therapy is associated with 
reduced AAA growth, rupture rate and elective perioperative mortality [47]. Ex vivo experiments 
in human AAA tissues suggest that statins inhibit of the Rac1/NF-κB pathway, with subsequent 
suppression of matrix metalloproteinase (MMP)-9 and cytokine secretion [48]. To date, only 
two studies have investigated the effect of statins in thoracic aortic aneurysms [49, 50]. Both 
studies suggested better outcomes (e.g. improved survival free from dissection and rupture or 
increased interval to surgery) among patients receiving statins. Our data support the idea that 
anti-inflammatory therapy should be considered as an additive treatment in patients with thoracic 
aortic disease. Future studies should investigate whether serologic markers for inflammation can 
help guide treatment decisions.
At present, there is no effective treatment for mitochondrial disorders. Therapeutic approaches 
mainly focus on maintaining optimal health, by preventing worsening of symptoms during illness 
and physiological stress (e.g. dehydration and prolonged fasting) and avoiding mitochondrial 
toxins. In general, measures aim to increase energy production and reduce reactive oxygen 
species. Scientific evidence that current interventions, such as the use of vitamins supplements, 
pharmacological agents and exercise therapy, do alleviate mitochondrial disease manifestations 
is limited [51, 52]. Nevertheless, as serious adverse events are uncommon, it would be interesting 
to investigate the effect of these interventions on the course of thoracic aortic disease. Such trials 
should be adequately designed and monitored to ascertain the efficacy of specific therapeutic 
agents in particular subtypes and stages of disease at a time.
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Technical limitations
RNA library preparation and sequencing procedures include a number of steps that might 
introduce biases in the resulting data [53]. The TruSeq Stranded mRNA Library Prep kit, for 
example, uses poly(A) selection for mRNA enrichment, which significantly reduces the proportion 
of unwanted ribosomal RNA, thereby improving the sequencing depth of mRNA. However, 
this procedure also removes other non-polyadenylated transcripts, including multiple histone-
encoding transcripts, which are therefore discarded from further analysis. Second, due to limited 
resources, we did not include technical replicates in our experimental design. Therefore, we 
could not control for technical variation. 
Biological limitations
Our control group contained more females than males, whereas the majority of MFS and HTAD 
patients was male. This might have had an effect on our study, considering the marked gender 
differences observed in thoracic aortic disease [54]. Principal component analysis, however, 
did not indicate a gender-dependent effect (Supplemental Figure 1). Second, HTAD exhibits 
extreme genetic heterogeneity. Therefore, we might not have been able to measure effects of 
individuals cases at the group level, and discriminate them from MFS and controls.
CONCLUSION
Our results indicate that different types of HTAD share common molecular pathways. Both 
inflammation and mitochondrial dysfunction seem to play important roles in the pathogenesis 
of MFS and mutation-negative HTAD. These pathways should be further explored as potential 
therapeutic targets for preventing disease progression.
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Cardiovascular diseases are one of the leading causes of mortality. They include aortic diseases 
such as aortic aneurysms, dilatations of the aorta that result in thinning of the aortic wall which 
eventually leads to aortic dissections or rupture of the aorta. Aortic aneurysms often remain 
asymptotic and are usually detected in late stages of the disease. Currently the only treatments 
are surgical repair of the aneurysm by placement of a stent or by placement of a stent that 
bridges the aneurysmal region. Aortic aneurysms can occur in different regions of the aorta; 
above the diaphragm they are categorized as thoracic aortic aneurysms (TAA) and below the 
diaphragm as abdominal aortic aneurysms (AAA). While multiple genetic causes have been 
identified for TAA, the genetic causes for AAA have not been very well established. Although 
genetic causes have been found for TAA, the availability of pharmaceutical treatments to prevent 
or delay aneurysm formation is still limited. Therefore, a better understanding of the molecular 
mechanisms that play a role in aneurysm development is needed to eventually develop new 
treatments for aortic aneurysms.
In this thesis, we aimed to characterize causative aneurysm genes and elucidate the molecular 
mechanisms that underlie aortic aneurysm formation. We aspired to create a better understanding 
of aneurysm formation and study the effect of different potential causative mutations on cellular 
function. The main findings of this thesis are summarized below.
In chapter 2 we characterized fibroblasts cell lines derived from aneurysm patients bearing 
ACTA2, MYH11, SMAD3 and FBN1 mutations and control fibroblasts. The cells were analyzed 
for transdifferentiation, TGFβ responsiveness and functional parameters such as migration and 
contractility to determine whether these features can be distinguished from controls. Our study 
showed that molecular phenotyping can distinguish aneurysm causing mutations from controls. 
Molecular phenotyping further proved to be an efficient method to investigate the functional 
consequences of identified variants of unknown significance. Additionally, in the future, these 
data can be used to select functional assays to identify the effects of potential novel aneurysm 
gene variants and thereby determine their pathogenicity.
A new SLC2A10 knockout mouse model is analyzed in chapter 3 to investigate whether this 
model is suitable to characterize the role of SLC2A10 in arterial tortuosity syndrome (ATS). 
Characterization of the Gulotm1mae/tm1mae;Slc2a10-/- (double knock-out) mice revealed only some 
mild cardiovascular phenotypic manifestations compared to controls. Interestingly, SLC2A10 
double knock-out VSMCs showed a reduced maximum oxygen consumption rate and aberrant 
extracellular matrix deposition compared to controls. Analysis of the TGFβ signaling pathway did 
not display any differences between Gulotm1mae/tm1mae;Slc2a10-/- and wild-type VSMCs. Although 
the mouse model did not show most of the typical ATS symptoms, e.g. arterial tortuosity and 
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aneurysm formation, the cellular phenotype did resemble the cellular findings of ATS patients, 
such as reduced maximum oxygen consumption rate and aberrant extracellular matrix deposition. 
This model could therefore be useful to further investigate the molecular mechanisms involved 
in ATS at the cellular level.
Chapter 4 evaluates two Fibulin-4 mouse models for cytoskeleton aberration, cellular movement 
and TGFβ signaling activity. During this study we aimed to determine the effects of reduced 
fibulin-4 (Fibulin-4R/R) and total ablation of fibulin-4 specifically in VSMCs (Fibulin-4f/-/SM22Cre+) 
on cellular function. Analysis of the cytoskeleton revealed that Fibulin-4f/-/SM22Cre+ VSMCs were 
unable to form smooth muscle actin (SMA) fibers, while Fibulin-4R/R VSMCs were able to form 
SMA fibers. However, both Fibulin-4 models showed decreased migration compared to their 
controls. Increased activation of the TGFβ signaling pathway was found in Fibulin-4R/R VSMCs. 
Yet, this increase was not present in Fibulin-4f/-/SM22Cre+ VSMCs. Since both mouse models 
show aneurysm formation, we concluded that not only dysregulation of the TGFβ signaling 
pathways, but also SMA cytoskeleton dynamics play a role in aneurysm formation.
In chapter 5 we aimed to identify novel pathways involved in aneurysm formation. Proteomics and 
genomics data revealed alterations in the mitochondrial protein composition in Fibulin-4R/R aortas. 
Functional analysis of Fibulin-4R/R VSMCs showed lower oxygen consumption rates. Additionally, 
reduced mitochondrial respiration was found in VSMCs of the Tgfbr-1M318R/+ Loeys-Dietz mouse 
model and fibroblasts of patients with Marfan (FBN1) and Loeys-Dietz syndrome (TGFBR2 and 
SMAD3). Furthermore, gene expression analysis revealed dysregulation of metabolic pathways 
and the predicted key regulator between mitochondrial function and metabolism, PGC1α, was 
found to be downregulated in Fibulin-4R/R VSMCs. Increased TGFβ levels led to a reduction 
of PGC1α, suggesting a link between TGFβ signaling and PGC1α regulation. We were able 
to restore PGC1α activity in Fibulin-4R/R VSMCs and improve the mitochondrial respiration by 
treatment with forskolin, a PGC1α activator. Our data uncovers a novel pathway that is involved 
in aneurysm formation and could serve as a potential new target for treatments of aneurysms.
Chapter 6 evaluates RNA expression of aortic tissue derived from Marfan and non-syndromic 
heritable thoracic aortic disease (HTAD) patients compared to control aortic tissue derived from 
healthy donors. Interestingly differential gene and protein expression analysis pointed towards 
mitochondrial dysfunction and increased inflammation in Marfan and HTAD patients, while 
lacking a distinct TGFβ gene expression signature. These findings show that inflammatory and 
mitochondrial pathways play an important role in the pathophysiological processes that underlie 
aortic aneurysmal disease. 
The results presented in this thesis illustrate that, although much research has been performed, 
novel pathways that are involved in aortic aneurysm formation are still identified. Our findings show 
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that not only defective TGFβ signaling is involved in aneurysm formation, but also cytoskeleton 
dysfunction, aberrant extracellular matrix deposition and altered mitochondrial respiration. 
Future perspectives
The presented functional assays and novel identified pathways in this thesis could be used for 
several advancements in the diagnosis and treatment of aneurysms in the future.
The described functional assays could in the future be used in a clinical setting. Functional 
outcomes that are determined for confirmed pathogenic variants and controls can be used to 
compare to functional outcomes of a variant of unknown significance (VUS). If the outcomes of 
the VUS suggest altered functionality this can indicate that the VUS is pathogenic. Reclassification 
of a VUS will lead to better diagnosis in families and provides them with clarity on the effects 
of the identified variant. Additionally these functional assays can be used to pinpoint potential 
new causative aneurysm genes. Dermal fibroblasts of aneurysm patients with an unknown 
variant can be transdifferentiated and compared to known pathogenic variants with regard to 
differentiation potential, migration and contractility. By comparing their outcomes, resemblances 
could be found that can suggest which processes are altered in the patient fibroblasts, pointing 
to a set of genes in which a variant might be present.
These two potential uses promote more accurate genetic diagnosis of aneurysm patients and 
family screening. To implement these functional assays, future research should include further 
analysis of pathogenic variants and their functional readouts in addition to analysis of VUS. The 
selection of these VUS would ideally be done in close collaboration with clinical geneticists to 
also link the clinical background of the patients to the functional readouts.
There is still a great need for a better understanding of the molecular mechanisms that are 
involved in aneurysm formation. This need is for instance illustrated by the minimal options for 
treatment for aneurysm patients. The novel pathways involved in aneurysm formation described 
in this thesis could give an impulse to the identification of therapeutic targets. These targets 
could lead to the development of medication that delays or prevents aneurysm formation. To 
ensure this development, future research should be focused on further identifying and specifying 
the pathways that are involved in aneurysm formation. By identifying the proteins and their 
interactors, the potential targets become further specified for drug development. Additionally, 
currently available medication that affects these novel pathways could be screened to determine 
if it positively affects the functionality of patient cells.
To take these next steps in the diagnosis and treatment of aneurysm formation it is important 
to have close collaboration between clinical geneticists, vascular surgeons, fundamental and 
translational scientists. A multidisciplinary approach will be essential in the diagnosis and 





Hart- en vaatziekten zijn een van de meest voorkomende doodsoorzaken, hieronder vallen ook 
aandoeningen aan de aorta zoals aorta aneurysmata. Aorta aneurysmata zijn verwijdingen van 
de aorta die leiden tot het dunner worden van de aortawand. Wanneer de aortawand te dun 
wordt kunnen aorta dissecties (scheuring van de binnenste laag van de aorta) ontstaan of de 
aorta wand kan helemaal scheuren, met fatale bloedingen tot gevolg. Aorta aneurysmata worden 
vaak per toeval ontdekt en patiënten ervaren vaak geen klachten vanwege het aneurysma totdat 
de ziekte al ver gevorderd is en het risico op scheuringen erg groot is geworden. Momenteel is 
het opereren van een aneurysma de enige behandelmogelijkheid. Tijdens deze operatie wordt 
een prothese geplaatst in de aorta waarna het aneurysma er strak om heen wordt gevouwen, 
of er wordt via de lies een opgevouwen prothese naar het aneurysma gebracht en die de 
verwijding afdekt. Aorta aneurysmata kunnen op verschillende plaatsen voorkomen; boven het 
diafragma noemen we deze thoracale aorta aneurysma (TAA) en onder het diafragma worden 
het abdominale aorta aneurysma (AAA) genoemd. Inmiddels zijn er verschillende genetische 
oorzaken gevonden voor TAA, terwijl voor AAA deze genetische oorzaken nog minder duidelijk 
zijn. Ondanks dat de genetische oorzaken voor TAA deels bekend zijn, zijn de behandelingen 
die aneurysmata kunnen voorkomen of kan zorgen dat ze minder snel groeien nog maar beperkt 
voorhanden. Om in de toekomst medicijnen te kunnen ontwikkelen voor de behandeling van 
een aneurysma is het belangrijk om te begrijpen wat er gebeurt tijdens aneurysmavorming op 
cellulair en moleculair niveau.
Het doel van dit proefschrift is om aneurysmavorming beter te begrijpen en dit doen we door 
het karakteriseren van de genetische oorzaken van aorta aneurysmata en het onderzoeken 
van processen op moleculair niveau in cellen uit de aorta. Ons onderzoek heeft meer inzicht 
gegeven in welke effecten genetische mutaties hebben op het functioneren van een cel en hoe 
dit bijdraagt aan aneurysma vorming. In dit hoofdstuk worden de belangrijkste bevindingen van 
dit proefschrift samengevat.
In hoofdstuk 2 karakteriseren we huidcellen afkomstig van aneurysma patiënten met mutaties 
in ACTA2, MYH11, SMAD3 en FBN1, en controle huidcellen. Het doel is om te bepalen of de 
patiëntcellen te onderscheiden zijn van de controle cellen aan de hand van transdifferentiatie, 
gevoeligheid voor TGFβ en functionele parameters, waaronder migratie en contractie. Ons 
onderzoek laat zien dat de patiëntcellen op verschillende manieren te onderscheiden zijn van de 
controle cellen. Onze resultaten laten ook zien dat de toegepaste testen effectieve methodes zijn 
om functionele consequenties van genetische mutaties te onderzoeken. In de toekomst zouden 
deze methodes gebruikt kunnen worden om de schadelijkheid van nieuw ontdekte mutaties te 
bepalen.
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Een nieuw ontwikkeld muismodel voor SLC2A10 wordt geanalyseerd in hoofdstuk 3 om te 
bepalen of dit model geschikt is om de rol van SLC2A10 in het arterial tortuosity syndroom (ATS) 
te onderzoeken. Karakterisering van de dubbel knock-out muizen (Gulotm1mae/tm1mae;Slc2a10-/-) 
onthulde een aantal milde cardiovasculaire afwijkingen in vergelijking met de controle muizen. 
Opmerkelijk was dat gladde spiercellen uit de aorta van de dubbel knock-out muizen een 
verlaagd maximaal zuurstofverbruik hadden in hun mitochondriën en dat deze cellen een 
afwijkende extracellulaire matrix produceerden in vergelijking met controle cellen. Analyse van 
de TGFβ signaleringsroute liet geen verschil zien tussen de dubbel knock-out en de controle 
cellen. Onze resultaten laten zien dat hoewel het nieuwe SLC2A10 muis model geen typische 
ATS symptomen zoals kronkeling van de arteriën en aneurysma vorming heeft, het fenotype van 
de cellen wel lijkt op dat van cellen van ATS patiënten. Daarom is dit model wel geschikt voor het 
onderzoek naar de rol van SLC2A10 in ATS op cellulair niveau.
Hoofdstuk 4 evalueert twee Fibuline-4 muis modellen aan de hand van cytoskelet afwijkingen, 
cellulaire beweging en TGFβ signalering. Het doel van dit onderzoek is om te bepalen wat de 
effecten zijn van verminderde hoeveelheden (Fibulin-4R/R) en totale afwezigheid (Fibulin-4f/-/
SM22Cre+) van fibuline-4 op het functioneren van een gladde spiercel uit de aorta. Analyse van 
het cytoskelet onthulde dat Fibulin-4f/-/SM22Cre+ gladde spiercellen geen gladde spiercel actine 
(SMA) vezels konden maken, terwijl Fibulin-4R/R gladde spiercellen dit wel konden. Echter lieten 
beide modellen verminderde migratie zien ten opzichte van de controles. In het Fibulin-4R/R model 
werd verhoogde activatie van de TGFβ signaaltransductie gevonden, terwijl dit niet aanwezig was 
in Fibulin-4f/-/SM22Cre+ gladde spiercellen. Aangezien beide muis modellen aneurysma vorming 
laten zien concludeerden wij dat niet alleen ontregeling van de TGFβ signaaltransductie, maar 
ook verstoring van de cytoskelet dynamiek een rol spelen in aneurysma vorming.
Het doel van hoofdstuk 5 was het identificeren van nieuwe signaleringsroutes die betrokken zijn 
bij aneurysmavorming. Eiwit (proteomics) en genexpressie analyse onthulden afwijkingen in de 
mitochondriële eiwitten in Fibulin-4R/R muizen aorta’s. Functionele analyse van Fibulin-4R/R gladde 
spiercellen liet een verlaagd zuurstofverbruik van de mitochondriën zien. Verlaagd zuurstofverbruik 
werd verder gevonden in gladde spiercellen van een Loeys-Dietz muis model (Tgfbr-1M318R/+) 
en in huidcellen van Marfan (FBN1) en Loeys-Dietz (TGFBR2 en SMAD3) syndroom patiënten. 
Analyse van genexpressie onthulde een ontregeling van het metabolisme in Fibulin-4R/R aorta’s 
en daarnaast werd gevonden dat de regelaar (PGC1α) tussen mitochondrieel functioneren en 
metabolisme verlaagd was. Verhoogde TGFβ niveaus leiden tot een verlaging van PGC1α en 
dit suggereert een link tussen de TGFβ signalering en PGC1α regulatie. In onze experimenten 
konden we de PGC1α activiteit in Fibulin-4R/R gladde spiercellen herstellen door middel van 
behandeling met forskolin, een PGC1α activator, en dit herstelde ook het mitochondriële 
zuurstofverbruik. Ons onderzoek legt een nieuwe signaleringsroute bloot die betrokken is bij 
aneurysma vorming en dit zou kunnen leiden tot nieuwe aangrijppunten voor medicijnen.
215
NEDERLANDSE SAMENVATTING
Hoofdstuk 6 evalueert de expressie van RNA in aorta weefsel van Marfan syndroom patiënten, 
aorta weefsel van niet-syndromale erfelijke aorta aneurysmata en aorta weefsel van gezonde 
donoren. Het doel van dit onderzoek was het ontrafelen van de moleculaire processen die ten 
grondslag liggen aan aneurysmavorming. Opmerkelijk genoeg duidde differentiële gen- en 
eiwitexpressie analyse op ontsteking en mitochondriële dysfunctie in zowel Marfan patiënten 
als niet-syndromale aneurysma patiënten. Verder viel op dat er geen dysregulatie van TGFβ 
genexpressie te vinden was in de aorta’s van Marfan patiënten niet-syndromale aneurysma 
patiënten. Deze resultaten laten zien dat ontsteking en mitochondriële signaleringsroutes een 
belangrijke rol spelen in de pathofysiologische processen die betrokken zijn bij aneurysmavorming.
De resultaten die gepresenteerd worden in dit proefschrift illustreren dat, hoewel er al veel 
onderzoek gedaan is, er nog steeds nieuwe signaleringsroutes geïdentificeerd worden die 
betrokken zijn bij aneurysmavorming. Onze bevindingen laten zien dat niet alleen afwijkingen 
in de TGFβ signaaltransductie betrokken zijn bij aneurysmavorming maar ook afwijkingen aan 
het cytoskelet, de extracellulaire matrix en mitochondrieel zuurstofverbruik. In de toekomst 
kunnen deze nieuw inzichten dienen als mogelijke aangrijpingspunten voor de ontwikkeling van 
medicijnen die aorta aneurysmavorming kunnen voorkomen of afremmen.
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AA   Aortic aneurysm
AA   Ascorbic acid (chapter 3)
AAA   Abdominal aortic aneurysms
ADP   Actin depolymerizing factor
ATP   Adenosine triphosphate
ATS   Arterial tortuosity syndrome
BAPN   β-aminopropionitrile monofumarate
BMPs   Bone morphogenetic proteins
CIMT   Carotid intima-media thickness
CTGF   Connective tissue growth factor
DHA   Dehydroascorbic acid
DKO   Double knock-out
DN   Dominant negative
ECAR   Extracellular acidification rate
ECM   Extracellular matrix
EDS   Ehlers-Danlos syndrome
EM   Electron microscopy
ER   Endoplasmic reticulum
EVAR   Endovascular aneurysm repair
F-actin   Filamentous actin
FC   Fold change
FCCP   Fluoro-carbonyl cyanide phenylhydrazone
FDR   False discovery rate
Fibulin-4-  Mouse with Fibulin-4 knock-out 
Fibulin-4+  Mouse carrying wildtype allele
Fibulin-4+/+  Wildtype mouse (wt)
Fibulin-4f  Mouse carrying floxed Fibulin-4 allele that can be deleted by Cre recombinase
Fibulin-4R  Mouse carrying Fibulin-4 mutant allele with reduced Fibulin-4 expression
Fibulin-4R/R  Mutant mouse with 4-fold reduction in the Fibulin-4 gene transcript
Fibulin-4SMKO   Wildtype mouse with Fibulin-4 deleted in vascular smooth muscle cells 
specifically
G-actin   Globular actin or monomeric actin
GDFs   Growth and differentiation factors
GO   Gene ontology
GWAS   Genome-wide association studies
HI   Haploinsufficient
HLA   Human leukocyte antigen
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HTAD   Heritable thoracic aortic disease
IPA   Ingenuity Pathway Analysis
KO   Knock-out
LAP   Latency associated peptide
LDS   Loeys-Dietz syndrome
LLC   Large latent complex
LOX   Lysyl oxidase
LTBPs   Latent TGFβ binding proteins
MAGPs   Microfibril-associated glycoproteins
MEF   Mouse embryonic fibroblast
MFS   Marfan syndrome
MMPs   Matrix metalloproteases
MYH11   Myosin heavy chain
MYLK   Myosin light chain kinase
OCR   Oxygen consumption rate
OXPHOS  Oxidative phosphorylation
PGC1   Peroxisome proliferator-activated receptor gamma, coactivator 1
PPAR   Peroxisome proliferator activated receptor
RAS   Renin-angiotensin system
ROS   Reactive oxygen species
SLC   Small latent complex
SM22 Cre+   Mouse expressing Cre recombinase under SM22 promoter, Smooth muscle 
cell specific
SMA   Smooth muscle actin
TAA   Thoracic aortic aneurysms
TCA   Tricarboxylic acid cycle
TEM   Transmission Electron Microscopy
TGFβ   Transforming growth factor β
VSMCs   Vascular smooth muscle cells
VUS   Variant of unknown significance
WES   Whole exome sequencing
WGS   Whole genome sequencing
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